U.S. patent application number 14/513486 was filed with the patent office on 2015-01-29 for imaging agents for detecting neurological dysfunction.
The applicant listed for this patent is Eli Lilly and Company. Invention is credited to Gang Chen, Kai Chen, Umesh B Gangadharmath, Dhanalakshmi Kasi, Hartmuth C Kolb, Changhui Liu, Vani P Mocharla, Peter J. H. Scott, Anjana Sinha, Anna Katrin Szardenings, Joseph C Walsh, Eric Wang, Chul Yu, Wei Zhang.
Application Number | 20150030540 14/513486 |
Document ID | / |
Family ID | 47219661 |
Filed Date | 2015-01-29 |
United States Patent
Application |
20150030540 |
Kind Code |
A1 |
Szardenings; Anna Katrin ;
et al. |
January 29, 2015 |
Imaging agents for detecting neurological dysfunction
Abstract
Disclosed here in are compounds and methods of diagnosing
Alzheimer's Disease or a predisposition thereto in a mammal, the
method comprising administering to the mammal a diagnostically
effective amount of a radiolabeled compound, wherein the compound
is selected from the group consisting of radiolabeled carbazoles
and derivatives thereof and triazoles derivatives, allowing the
compound to distribute into the brain tissue, and imaging the brain
tissue, wherein an increase in binding of the compound to the brain
tissue compared to a normal control level of binding indicates that
the mammal is suffering from or is at risk of developing
Alzheimer's Disease.
Inventors: |
Szardenings; Anna Katrin;
(Pacifica, CA) ; Kolb; Hartmuth C; (San Diego,
CA) ; Walsh; Joseph C; (Pacific Palisades, CA)
; Chen; Gang; (Rancho Palos Verdes, CA) ;
Gangadharmath; Umesh B; (Folsom, CA) ; Kasi;
Dhanalakshmi; (Silver Spring, MD) ; Liu;
Changhui; (Walnut, CA) ; Sinha; Anjana; (New
York, NY) ; Wang; Eric; (San Diego, CA) ; Yu;
Chul; (San Ramon, CA) ; Zhang; Wei; (San
Diego, CA) ; Chen; Kai; (San Gabriel, CA) ;
Mocharla; Vani P; (Sunnyvale, CA) ; Scott; Peter J.
H.; (Ypsilanti, MI) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Eli Lilly and Company |
Indianapolis |
IN |
US |
|
|
Family ID: |
47219661 |
Appl. No.: |
14/513486 |
Filed: |
October 14, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13477095 |
May 22, 2012 |
|
|
|
14513486 |
|
|
|
|
12372717 |
Feb 17, 2009 |
8318132 |
|
|
13477095 |
|
|
|
|
61489284 |
May 24, 2011 |
|
|
|
61066101 |
Feb 14, 2008 |
|
|
|
Current U.S.
Class: |
424/1.89 ;
546/82; 546/86; 548/444 |
Current CPC
Class: |
A61K 51/0446 20130101;
C07B 59/002 20130101; C07D 471/14 20130101; C07D 471/04 20130101;
A61K 51/0455 20130101 |
Class at
Publication: |
424/1.89 ;
546/86; 546/82; 548/444 |
International
Class: |
A61K 51/04 20060101
A61K051/04 |
Claims
1-43. (canceled)
44. A compound selected from the group consisting of:
N-(3-fluoropropyl)-3-methyl-5H-pyrido[3,2-b]indol-7-amine;
7-(2-fluoroethoxy)-1-methyl-9H-pyrido[3,4-b]indole;
7-(2-fluoroethoxy)-9H-pyrido[3,4-b]indole;
N-(3-fluoropropyl)-9H-pyrido[3,4-b]indol-7-amine;
7-(2-fluoroethoxy)-5H-pyrido[3,2-b]indole;
7-(2-fluoroethoxy)-2-methoxy-5H-pyrido[3,2-b]indole;
7-(2-fluoroethoxy)-3-methyl-5H-pyrido[3,2-b]indole;
N-(2-fluoroethyl)-N-methyl-9H-pyrido[3,4-b]indol-7-amine;
N-(2-fluoroethyl)-N-methyl-5H-pyrido[3,2-b]indol-7-amine;
N-(2-fluoroethyl)-N,3-dimethyl-5H-pyrido[3,2-b]indol-7-amine;
N-(2-fluoroethyl)-2-methoxy-N-methyl-5H-pyrido[3,2-b]indol-7-amine;
N-(3-fluoropropyl)-5H-pyrido[3,2-b]indol-7-amine;
N-(3-fluoropropyl)-3-methyl-5H-pyrido[3,2-b]indol-7-amine;
N-(3-fluoropropyl)-2-methoxy-5H-pyrido[3,2-b]indol-7-amine;
7-(2-(2-fluoroethoxy)ethoxy)-3-methyl-5H-pyrido[3,2-b]indole;
7-(4-(2-fluoroethoxy)phenyl)-5H-pyrido[3,2-b]indole;
7-(6-fluoropyridin-3-yl)-5H-pyrido[3,2-b]indole;
N-(2-fluoroethyl)-N-methyl-4-(3-methyl-5H-pyrido[3,2-b]indol-7-yl)aniline-
; 7-(4-fluoropiperidin-1-yl)-3-methyl-5H-pyrido[3,2-b]indole;
7-(3-fluoropropoxy)-5H-pyrido[4,3-b]indole;
4-(7-(3-fluoropropoxy)-5H-pyrido[3,2-b]indol-3-yl)aniline;
(E)-7-(3-fluoropropoxy)-3-(prop-1-enyl)-5H-pyrido[3,2-b]indole;
3-cyclopropyl-7-(3-fluoropropoxy)-5H-pyrido[3,2-b]indole;
7-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-5H-pyrido[4,3-b]indole;
7-(2-(2-fluoroethoxy)ethoxy)-5H-pyrido[4,3-b]indole;
7-((2-(2-fluoroethoxy)ethoxy)methyl)-5H-pyrido[4,3-b]indole;
7-(6-fluoropyridine-3-yl)-5-methyl-H-pyrido[4,3-b]indole;
8-fluoro-7-(2-fluoroethoxy)3-methyl-5H-pyrido[3,2-b]indole;
6-fluoro-7-(2fluoroethoxy)3-methyl-5H-pyrido[3,2-b]indole;
8-fluoro-7-methoxy-3-methyl-5H-pyrido[3,2-b]indole;
7-fluoro-3-methyl-5H-pyrrolo[2,3-b:4,5-b']dipyridine;
2-fluoro-7-methoxy-5H-pyrido[3,2-b]indole;
7-(2-(2-(2-Fluoroethoxy)ethoxy)ethoxy)-3-methyl-5H-pyrrolo[2,3b:4,5-b']di-
pyridine; 7-(3-fluoropropyl)-5H-pyrido[4,3-b]indole;
7-(3-fluoropropyl)-3-methyl-5H-pyrido[3,2-b]indole;
7-(2-fluoroethyl)-5H-pyrido[4,3-b]indole;
7-(2-(2-(2-fluoroethoxy)ethoxy)ethyl)-5H-pyrido[4,3-b]indole;
6-(2-fluoroethoxy)-5H-pyrido[3,2-b]indole;
8-(2-fluoroethoxy)-5H-pyrido[3,2-b]indole;
3-(6-fluoro-3-pyridyl)-5H-pyrido[3,2-b]indole;
3-[2-[2-(2-fluoroethoxy)ethoxy]ethoxy]-5H-pyrido[3,2-b]indole;
7-(3-fluoropropyl)-5H-pyrido[4,3-b]indole;
3-(6-fluoro-3-pyridyl)-5H-pyrido[3,2-b]indol-7-ol;
7-(3-fluoropropoxy)-3-methyl-5H-pyrido[3,2-b]indole;
2-(2-fluoroethoxy)-9H-carbazole;
2-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-9H-carbazole;
7-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-N-methyl-9H-carbazol-2-amine;
tert-butyl
2-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-9H-carbazole-9-carboxylate;
2-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-9-methyl-9H-carbazole;
7-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-N,N-dimethyl-9H-carbazol-2-amine;
7-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-N-methyl-9H-carbazol-3-amine;
N-(7-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-9H-carbazol-2-yl)acetamide;
N-(7-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-9H-carbazol-2-yl)formamide;
6-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-9-(methoxymethyl)-N,N-dimethyl-9H--
carbazol-3-amine; N-(7-(2-fluoroethoxy)-9H-carbazol-2-yl)formamide;
N-(2-fluoroethyl)-6-methoxy-9H-carbazol-3-amine;
7-((4-fluorobutyl)(methyl)amino)-9H-carbazol-2-ol;
7-((2-fluoroethyl)(methyl)amino)-9H-carbazol-2-ol;
7-(2-fluoroethylamino)-9H-carbazol-2-ol;
1-(2-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-9H-carbazol-9-yl)ethanone;
7-((2-(2-(2-fluoroethoxy)ethoxy)ethyl)(methyl)amino)-9H-carbazol-2-ol;
7-(2-fluoroethoxy)-N-methyl-9H-carbazol-2-amine;
(2-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-9H-carbazol-9-yl)(phenyl)methanon-
e; N-(7-(2-(2-fluoroethoxy)ethoxy)-9H-carbazol-2-yl)formamide;
7-(2-fluoroethoxy)-9H-carbazol-2-ol;
7-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-9H-carbazol-2-ol;
N-(4-(7-amino-9H-carbazol-2-yloxy)phenyl)-2-fluoropropanamide;
7-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-9H-pyrido[2,3-b]indole;
2-fluoro-N-(4-(7-(methylamino)-9H-carbazol-2-yloxy)phenyl)propanamide;
N-(7-(4-fluorobutoxy)-9H-carbazol-2-yl)formamide; tert-butyl
2-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-9H-pyrido[2,3-b]indol-7-ylcarbamat-
e;
2-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-9H-pyrido[2,3-b]indol-7-amine;
9-(2-fluoroethyl)-9H-carbazol-2-ol;
N-(2-fluoroethyl)-7-(2-(2-(2-methoxyethoxyl)ethoxy)ethoxy)-9H-carbazol-3--
amine; 7-(2-fluoroethoxy)-N,N-dimethyl-9H-carbazol-2-amine;
1-(3,6-diamino-9H-carbazol-9-yl)-3-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)pr-
opan-1-one;
N-(2-fluoroethyl)-2-hydroxy-11H-benzo[a]carbazole-3-carboxamide;
2-(6-chloro-9H-carbazol-2-yl)-N-(2-fluoroethyl)propanamide; and
2-(6-fluoro-9H-carbazol-2-yl)-N,N-dimethylpropanamide; or
pharmaceutically acceptable salts thereof, wherein fluoro is
optionally replaced with a radionuclide.
45. The compound of claim 44, wherein fluoro is .sup.18F.
46. A compound selected from the group consisting of:
7-(6-nitro-3-pyridyl)-5H-pyrido[4,3-b]indole;
7-(2-nitroethyl)-5H-pyrido[4,3-b]indole;
3-methyl-7-(2-nitroethoxy)-5H-pyrido[3,2-b]indole;
7-(3-nitropropyl)-5H-pyrido[4,3-b]indole; and
6'-fluoro-5-nitro-6-phenyl-3,3'-bipyridine; or pharmaceutically
acceptable salts thereof.
47. A method of diagnosing Alzheimer's disease or a predisposition
in a mammal comprising: a) administering to the mammal a
diagnostically effective amount of a radiolabeled compound of claim
45; b) allowing the compound to distribute to the brain tissue; and
c) imaging the brain tissue.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to provisional patent
application No. 61/489,284, filed on May 24, 2011; the entire
contents of which are incorporated by reference. This application
is a continuation-in-part of U.S. application Ser. No. 12/372,717,
filed Feb. 17, 2009; the entire contents of which are incorporated
by reference. U.S. Ser. No. 12/372,717 claims priority to
60/066,101, filed Feb. 14, 2008, which is also incorporated herein
by reference.
BACKGROUND
[0002] Alzheimer's disease (AD), a leading cause of dementia,
develops in one percent of the population between the ages 65 and
69, and increasing to 40-50% in those 95 years and older. AD
patients exhibit telltale clinical symptoms that include cognitive
impairment and deficits in memory function. In these patients,
heavy senile plaque burden found in the cerebral cortex, verified
by post mortem histopathological examination, confirms the presence
of AD. The mature senile plaques consist of intracellular
neurofibrillary tangles (NFT) derived from filaments of
hyperphosphorylated tau proteins, and extracellular .beta.-amyloid
peptides derived from enzymatic processing of amyloid precursor
protein. Interestingly, despite the development and presence of
senile plaques in elderly persons with normal cognitive function,
the severity of NFT and senile plaque deposition purportedly
correlates with a loss of cognitive function and neuronal circuitry
deterioration.
[0003] Neurological imaging of AD has seen the emergence of imaging
tracers that appear to confirm the presence of AD based on plaque
and fibril mediated tracer uptake and, subsequently, are currently
undergoing extensive clinical examination. Many of these tracers
contain chemotypes that derive from fluorescent dyes (Table 1).
[0004] The current array of AD imaging agents can only confirm the
well-established manifestation of AD and this late stage diagnosis
offers little defense against further disease progression past 36
months. Secondly, the detection of senile plaques and tangles may
not correlate to development of the early stages of AD. Recent data
suggests that the amyloid cascade model [Hardy, J. and D. Selkoe,
The Amyloid Hypothesis of Alzheimer's Disease: Progress and
Problems on the Road to Therapeutics. Science, 2002. 297: p.
353-356] does not accurately depict the primary factors leading to
cognitive decline in AD patients and that other contributing
factors, such as neuorotoxic soluble oligomers and aggregates may
play a contributory role in neurodegeneration. [Talaga, P.,
Inhibitors of beta-amyloid aggregation: still an issue of structure
and function? Drug Discovery Today: Therapeutic Strategies, 2004.
1: p. 7-12]. To date, FDDNP and PIB are not known to bind to
neurotoxic soluble oligomers and aggregates and thus are not
expected to differentiate accurately between the early stages of AD
from the advanced stages of AD in patients.
[0005] A number of medical diagnostic procedures, including PET and
SPECT utilize radiolabeled compounds. PET and SPECT are very
sensitive techniques and require small quantities of radiolabeled
compounds, called tracers. The labeled compounds are transported,
accumulated and converted in vivo in exactly the same way as the
corresponding non-radioactively compound. Tracers, or probes, can
be radiolabeled with a radionuclide useful for PET imaging, such as
.sup.11C, .sup.13N, .sup.15O, .sup.18F, .sup.64Cu and .sup.124I, or
with a radionuclide useful for SPECT imaging, such as .sup.99Tc,
.sup.77Br, .sup.61Cu, .sup.153Gd, .sup.123I, .sup.125I, .sup.131I
and .sup.32P.
[0006] PET creates images based on the distribution of molecular
imaging tracers carrying positron-emitting isotopes in the tissue
of the patient. The PET method has the potential to detect
malfunction on a cellular level in the investigated tissues or
organs. PET has been used in clinical oncology, such as for the
imaging of tumors and metastases, and has been used for diagnosis
of certain brain diseases, as well as mapping brain and heart
function. Similarly, SPECT can be used to complement any gamma
imaging study, where a true 3D representation can be helpful, for
example, imaging tumor, infection (leukocyte), thyroid or
bones.
BRIEF DESCRIPTION OF DRAWINGS
[0007] FIG. 1 shows Audoradiography of [18F]-T794.
[0008] FIG. 2 shows the correlation of [18F]-T794 with Tau and
Amyloid loads and KD (30 nM).
[0009] FIG. 3 shows [18F]-T794 PK in mice.
[0010] FIG. 4 shows Audoradiography of [18F]-T805.
[0011] FIG. 5 shows the correlation of [18F]-T805 with Tau and
Amyloid loads.
[0012] FIG. 6 shows [18F]-T805 PK in mice.
[0013] FIG. 7 shows Audoradiography of [18F]-T807.
[0014] FIG. 8 shows the correlation of [18F]-T807 with Tau and
Amyloid loads.
[0015] FIG. 9 shows [18F]-T807 PK in mice.
[0016] FIG. 10 shows double labeling of compound T687 and PHF-tau
IHC staining on human brain section.
[0017] FIG. 11 shows Double labeling of Compound T794 and total-tau
IHC Staining on Human Brain Section.
[0018] FIG. 12 shows 18F-T805: Brain uptake in mice.
[0019] FIG. 13 shows 18F-T807: Brain uptake in mice.
[0020] FIG. 14 shows 18F-T794 in WT and Tau mice.
SUMMARY
[0021] In one embodiment, there is provided a radiolabeled compound
of the Formula 7:
##STR00001##
and pharmaceutically acceptable salts and stereoisomers thereof,
wherein:
[0022] L is N or CR.sup.5;
[0023] M is N or CR.sup.6;
[0024] P is N or CR.sup.7; and
[0025] Q is N or CR.sup.8;
[0026] X is a bond or is C.sub.1-14alkyl, wherein at least one
carbon is optionally replaced by C(O), O, S, SO.sub.2, or NH,
NH--C.sub.1-8alkyl, and wherein at least one H of C.sub.1-8alkyl is
optionally replaced by halo, OH, C.sub.1-6alkyl;
[0027] R.sup.9 is H, a protecting group, a leaving group, an azide,
an alkyne, OH, halo, NH.sub.2, N(C.sub.1-8alkyl).sub.2, aryl or
heteroaryl, wherein at least one H of the aryl or heteroaryl is
optionally replaced by halo, SO.sub.2, NH.sub.2, or C.sub.1-6
alkyl, wherein at least one H of the C.sub.1-6 alkyl is optionally
replaced by halo, or C.sub.3-8cycloalkyl, wherein at least one H of
the C.sub.3-8cycloalkyl is optionally replaced by halo and wherein
at least one CH.sub.2 of the C.sub.3-8cycloalkyl is optionally
replaced with O, OH, S, SH, NH, N--C.sub.1-8alkyl;
[0028] R.sup.1-R.sup.8 are independently H, OH, halo, NH.sub.2,
CH.sub.3, SO.sub.2, NO.sub.2, a leaving group, a protecting group,
aryl, heteroaryl, NHR.sup.12, N(R.sup.12).sub.2
C.sub.3-8cycloalkyl, (--CH.sub.2).sub.1-12--R.sup.12, wherein
R.sup.12 is CH.sub.3, aryl, H or heteroaryl, wherein at least one H
of (--CH.sub.2).sub.1-12--R.sup.12, C.sub.3-8cycloalkyl, aryl, or
heteroaryl, is optionally replaced by halo, OH, NH.sub.2, a leaving
group, a protecting group and C.sub.1-8alkyl, wherein at least one
H of the C.sub.1-8alkyl is optionally replaced by halo, OH,
NH.sub.2, a leaving group, a protecting group, and
[0029] wherein at least one CH.sub.2 of
(--CH.sub.2).sub.1-12--R.sup.12 is optionally replaced with C(O),
O, S, SO.sub.2, or NH, NH--C.sub.1-8alkyl, N(C.sub.1-8alkyl).sub.2,
wherein at least one H of the C.sub.1-8alkyl is optionally replaced
by halo, OH, NH.sub.2, a leaving group, a protecting group,
[0030] and wherein at least one CH.sub.2 of the C.sub.3-8cycloalkyl
is optionally replaced by C(O), O, S or NH, N--C.sub.1-8alkyl,
wherein at least one H of the C.sub.1-8alkyl is optionally replaced
by halo, OH, a leaving group, a protecting group,
wherein at least one halo is optionally replaced with a
radionuclide or a fluorescent tag.
[0031] In another embodiment, the invention is a compound of the
Formula 7a:
##STR00002##
and pharmaceutically acceptable salts and stereoisomers thereof,
wherein:
[0032] L is N or CR.sup.5;
[0033] M is N or CR.sup.6;
[0034] X is a bond or is C.sub.1-14alkyl, wherein at least one
carbon is optionally replaced by C(O), O, S, SO.sub.2, or NH,
NH--C.sub.1-8alkyl, and wherein at least one H of C.sub.1-8alkyl is
optionally replaced by halo, OH, C.sub.1-6alkyl;
[0035] R.sup.9 is H, a protecting group, a leaving group, an azide,
an alkyne, OH, halo, NH.sub.2, N(C.sub.1-8alkyl).sub.2, aryl or
heteroaryl, wherein at least one H of the aryl or heteroaryl is
optionally replaced by halo, SO.sub.2, NH.sub.2, or C.sub.1-6 alkyl
or C.sub.1-6 alkyl, wherein at least one H of the C.sub.1-6 alkyl
is optionally replaced by halo, or C.sub.3-8cycloalkyl, wherein at
least one H of the C.sub.3-8cycloalkyl is optionally replaced by
halo and wherein at least one CH.sub.2 of the C.sub.3-8cycloalkyl
is optionally replaced with O, OH, S, SH, NH,
N--C.sub.1-8alkyl;
[0036] R.sup.2, R.sup.3, R.sup.7 and R.sup.8 are independently H,
OH, halo, NH.sub.2, CH.sub.3, SO.sub.2, NO.sub.2, a leaving group,
a protecting group, aryl, heteroaryl, NHR.sup.12, N(R.sup.12).sub.2
C.sub.3-8cycloalkyl, (--CH.sub.2).sub.1-12--R.sup.12, wherein
R.sup.12 is CH.sub.3, aryl, H or heteroaryl, [0037] wherein at
least one H of (--CH.sub.2).sub.1-12--R.sup.12,
C.sub.3-8cycloalkyl, aryl, or heteroaryl, is optionally replaced by
halo, OH, NH.sub.2, a leaving group, a protecting group and
C.sub.1-8alkyl, wherein at least one H of the C.sub.1-8alkyl is
optionally replaced by halo, OH, NH.sub.2, a leaving group, a
protecting group, and [0038] wherein at least one CH.sub.2 of
(--CH.sub.2).sub.1-12--R.sup.12 is optionally replaced with C(O),
O, S, SO.sub.2, or NH, NH--C.sub.1-8alkyl, N(C.sub.1-8alkyl).sub.2,
wherein at least one H of the C.sub.1-8alkyl is optionally replaced
by halo, OH, NH.sub.2, a leaving group, a protecting group, [0039]
and wherein at least one CH.sub.2 of the C.sub.3-8cycloalkyl is
optionally replaced by C(O), O, S or NH, N--C.sub.1-8alkyl, wherein
at least one H of the C.sub.1-8alkyl is optionally replaced by
halo, OH, a leaving group, a protecting group,
[0040] wherein at least one halo is optionally replaced with a
radionuclide or a fluorescent tag.
[0041] In another embodiment, the invention is a compound of the
Formula 8:
##STR00003##
and pharmaceutically acceptable salts and stereoisomers
thereof,
[0042] wherein: [0043] L is N or CR.sup.5; [0044] M is N or
CR.sup.6; [0045] X is a bond or is C.sub.1-14alkyl, wherein at
least one carbon is optionally replaced by C(O), O, S, SO.sub.2, or
NH, NH--C.sub.1-8alkyl, and wherein at least one H of
C.sub.1-8alkyl is optionally replaced by halo, OH, C.sub.1-6alkyl;
[0046] R.sup.9 is H, a protecting group, a leaving group, an azide,
an alkyne, OH, halo, NH.sub.2, N(C.sub.1-8alkyl).sub.2, aryl or
heteroaryl, wherein at least one H of the aryl or heteroaryl is
optionally replaced by halo, SO.sub.2, NH.sub.2, or C.sub.1-6 alkyl
or C.sub.1-6 alkyl, wherein at least one H of the C.sub.1-6 alkyl
is optionally replaced by halo, or C.sub.3-8cycloalkyl, wherein at
least one H of the C.sub.3-8cycloalkyl is optionally replaced by
halo and wherein at least one CH.sub.2 of the C.sub.3-8cycloalkyl
is optionally replaced with O, OH, S, SH, NH, N--C.sub.1-8alkyl;
[0047] R.sup.3 is a bond or is at least one of O, S, C(O),
SO.sub.2, NH, N--C.sub.1-8alkyl, (CH.sub.2).sub.1-12, wherein at
least one C of (CH.sub.2).sub.1-12 is optionally replaced by C(O),
O, S, SO.sub.2, NH, N--C.sub.1-8alkyl and wherein at least one H is
optionally replaced by C.sub.1-8alkyl or halo, [0048] R.sup.20 is
aryl or heteroaryl; [0049] R.sup.21 is H, OH, halo, NH.sub.2,
CH.sub.3, SO.sub.2, NO.sub.2, a leaving group, a protecting group,
(--CH.sub.2).sub.1-12--CH.sub.3, C.sub.3-8cycloalkyl, [0050]
wherein at least one H of the (--CH.sub.2).sub.1-12--CH.sub.3 or
the C.sub.3-8cycloalkyl is optionally replaced by halo, OH,
NH.sub.2, a leaving group, a protecting group and C.sub.1-8alkyl,
wherein at least one H of the C.sub.1-8alkyl is optionally replaced
by halo, OH, a leaving group, a protecting group, [0051] and
wherein at least one CH.sub.2 of the
(--CH.sub.2).sub.1-12--CH.sub.3 is optionally replaced with C(O),
O, S, SO.sub.2, or NH, NH--C.sub.1-8alkyl, N(C.sub.1-8alkyl).sub.2,
wherein at least one H of the C.sub.1-8alkyl is optionally replaced
by halo, OH, NH.sub.2, a leaving group, a protecting group, [0052]
and wherein at least one CH.sub.2 of the C.sub.3-8cycloalkyl is
optionally replaced by C(O), O, S, SO.sub.2, or NH,
N--C.sub.1-8alkyl, wherein at least one H of the C.sub.1-8alkyl is
optionally replaced by halo, OH, NH.sub.2, a leaving group, a
protecting group, [0053] wherein at least one halo is optionally
replaced with a radionuclide or a fluorescent tag.
[0054] In another embodiment, the invention is a compound of the
Formula 7b:
##STR00004##
and pharmaceutically acceptable salts and stereoisomers thereof,
wherein:
[0055] L is N or CR.sup.5;
[0056] M is N or CR.sup.6;
[0057] R.sup.9 is H, a protecting group, a leaving group, halo, or
CH.sub.3;
[0058] R.sup.2, R.sup.3, R.sup.5 and R.sup.6 are independently H,
OH, halo, NH.sub.2, CH.sub.3, SO.sub.2, NO.sub.2, a leaving group,
a protecting group, aryl, heteroaryl, NHR.sup.12, N(R.sup.12).sub.2
C.sub.3-8cycloalkyl, (--CH.sub.2).sub.1-12--R.sup.12, wherein
R.sup.12 is CH.sub.3, aryl, H or heteroaryl, [0059] wherein at
least one H of (--CH.sub.2).sub.1-12--R.sup.12,
C.sub.3-8cycloalkyl, aryl, or heteroaryl, is optionally replaced by
halo, OH, NH.sub.2, a leaving group, a protecting group and
C.sub.1-8alkyl, wherein at least one H of the C.sub.1-8alkyl is
optionally replaced by halo, OH, NH.sub.2, a leaving group, a
protecting group, and [0060] wherein at least one CH.sub.2 of
(--CH.sub.2).sub.1-12--R.sup.12 is optionally replaced with C(O),
O, S, SO.sub.2, or NH, NH--C.sub.1-8alkyl, N(C.sub.1-8alkyl).sub.2,
wherein at least one H of the C.sub.1-8alkyl is optionally replaced
by halo, OH, NH.sub.2, a leaving group, a protecting group,
[0061] and wherein at least one CH.sub.2 of the C.sub.3-8cycloalkyl
is optionally replaced by C(O), O, S or NH, N--C.sub.1-8alkyl,
wherein at least one H of the C.sub.1-8alkyl is optionally replaced
by halo, OH, a leaving group, a protecting group,
[0062] wherein at least one halo is optionally replaced with a
radionuclide or a fluorescent tag.
[0063] In another embodiment, the invention is a compound of the
Formula 7c:
##STR00005##
and pharmaceutically acceptable salts and stereoisomers thereof,
wherein:
[0064] L is N or CR.sup.5;
[0065] M is N or CR.sup.6;
[0066] P is N or CR.sup.7; and
[0067] Q is N or CR.sup.8;
[0068] X is a bond or is C.sub.1-14alkyl, wherein at least one
carbon is optionally replaced by C(O), O, S, SO.sub.2, or NH,
NH--C.sub.1-8alkyl, and wherein at least one H of C.sub.1-8alkyl is
optionally replaced by halo, OH, C.sub.1-6alkyl;
[0069] R.sup.9 is H, a protecting group, a leaving group, OH,
NH.sub.2, N(C.sub.1-8alkyl).sub.2, aryl or heteroaryl, wherein at
least one H of the aryl or heteroaryl is optionally replaced by
SO.sub.2, NH.sub.2, or C.sub.1-6 alkyl, wherein at least one H of
the C.sub.1-6 alkyl is optionally replaced by C.sub.3-8cycloalkyl,
wherein at least one CH.sub.2 of the C.sub.3-8cycloalkyl is
optionally replaced with O, OH, S, SH, NH, N--C.sub.1-8alkyl;
[0070] R.sup.3 and R.sup.5-R.sup.8 are independently H or
(--CH.sub.2).sub.1-12--R.sup.13, wherein R.sup.13 is an azide or an
alkyne, [0071] wherein at least one H of
(--CH.sub.2).sub.1-12--R.sup.13 is optionally replaced by OH,
NH.sub.2, and C.sub.1-8alkyl, wherein at least one H of the
C.sub.1-8alkyl is optionally replaced by OH, NH.sub.2, and wherein
at least one CH.sub.2 of (--CH.sub.2).sub.1-12--R.sup.13 is
optionally replaced with C(O), O, S, SO.sub.2, or NH,
NH--C.sub.1-8alkyl, N(C.sub.1-8alkyl).sub.2, wherein at least one H
of the C.sub.1-8alkyl is optionally replaced by OH, NH.sub.2.
[0072] In another embodiment, the invention is a pharmaceutical
composition for in vivo imaging of amyloid deposits and tau
tangles, comprising (a) the compound of any of the Formulas herein
and/or shown in Claims 1-43 and (b) a pharmaceutically acceptable
carrier.
[0073] In another embodiment, the invention is a method of
diagnosing Alzheimer's Disease or a predisposition thereto in a
mammal, the method comprising: a) administering to the mammal a
diagnostically effective amount of a radiolabeled compound of any
of the Formulas herein, wherein the compound passes the blood-brain
barrier and preferentially binds to amyloid plaques and/or tau
tangles in a brain tissue and wherein the compound is selected from
the group consisting of radiolabeled compounds of formula 7, for
example; b) allowing the compound to distribute into the brain
tissue; and c) imaging the brain tissue, wherein an increase in
binding of the compound to the brain tissue compared to a normal
control level of binding indicates that the mammal is suffering
from or is at risk of developing Alzheimer's Disease.
[0074] In another embodiment, the invention is a method of
diagnosing Alzheimer's Disease or a predisposition thereto in a
mammal, the method comprising: a) administering to the mammal a
diagnostically effective amount of a radiolabeled compound of any
of Claims 1-43, wherein the compound passes the blood-brain barrier
and preferentially binds to amyloid plaques and/or tau tangles in a
brain tissue and wherein the compound is selected from the group
consisting of radiolabeled compounds of formula 1; b) allowing the
compound to distribute into the brain tissue; and c) imaging the
brain tissue, wherein an increase in binding of the compound to the
brain tissue compared to a normal control level of binding
indicates that the mammal is suffering from or is at risk of
developing Alzheimer's Disease.
DETAILED DESCRIPTION
[0075] "Halogen" or "halo" means F, Cl, Br and I.
[0076] "Alkyl" means a saturated monovalent hydrocarbon radical
having straight or branched moieties. Examples of alkyl groups
include, but are not limited to, methyl, ethyl, n-propyl, isopropyl
and t-butyl.
[0077] "Alkenyl" means an alkyl moieties having at least one
carbon-carbon double bond wherein alkyl is as defined above.
Examples of alkenyl include, but are not limited to, ethenyl and
propenyl.
[0078] "Alkynyl" means alkyl moieties having at least one
carbon-carbon triple bond wherein alkyl is as defined above.
Examples of alkynyl groups include, but are not limited to, ethynyl
and 2-propynyl.
[0079] "Alkylene" or "alkenylenyl" means a saturated, divalent
hydrocarbon radicals i.e., generally present as a bridging or
linking group between two other groups, having straight or branched
moieties. Examples of alkylene groups include
--CH.sub.2-(methylene); --CH.sub.2CH.sub.2-(ethylene);
--CH.sub.2CH.sub.2CH.sub.2-(propylene),
--CH(CH.sub.3)CH.sub.2-(isopropylene) etc.
[0080] "Amino" means a nitrogen moiety having two further
substituents where a hydrogen or carbon atom is attached to the
nitrogen. For example, representative amino groups include
--NH.sub.2, --NHCH.sub.3, --N(CH.sub.3).sub.2, --NHC.sub.2-3-alkyl,
--N(C.sub.2-3-alkyl).sub.2 and the like. Unless indicated
otherwise, the compounds of the invention containing amino moieties
may include protected derivatives thereof. Suitable protecting
groups for amino moieties include acetyl, tert-butoxycarbonyl,
benzyloxycarbonyl and the like.
[0081] "Aryl" means an organic radical derived from an aromatic
hydrocarbon by removal of one hydrogen, such as phenyl, naphthyl,
indenyl, indanyl and fluorenyl. "Aryl" encompasses fused ring
groups wherein at least one ring is aromatic.
[0082] "Cycloalkyl" means non-aromatic saturated cyclic alkyl
moieties consisting of one or more rings, wherein said rings (if
more than one) share at least one carbon atom, wherein alkyl is as
defined above. Examples of cycloalkyl include, but are not limited
to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,
bicyclo-[3.1.0]-hexyl, bicyclo-[2.2.1]-hept-1-yl, norbornyl,
spiro[4.5]decyl, spiro[4.4]nonyl, spiro[4.3]octyl, spiro[4.2]heptyl
and adamantanyl.
[0083] "HaloC.sub.1-6alkyl" means a C.sub.1-6alkyl group that is
substituted with at least one halogen atom on a carbon atom of the
alkyl group. Non-exclusive, representative examples of such
haloC.sub.1-6alkyl include F--CH.sub.2--, F--CH.sub.2CH.sub.2--,
F--CH.sub.2CH.sub.2CH.sub.2--, CHF.sub.2--, CHF.sub.2CH.sub.2--,
CHF.sub.2CH.sub.2CH.sub.2--, Br--CH.sub.2--,
Br--CH.sub.2CH.sub.2--, Br--CH.sub.2CH.sub.2CH.sub.2--,
CHBr.sub.2--, CHBr.sub.2CH.sub.2--, CHBr.sub.2CH.sub.2CH.sub.2--
and the like.
[0084] "Heterocyclic" or "heterocycloalkyl" means a non-aromatic
cyclic groups consisting of one or more rings, wherein the rings
(if more than one) share one or two atoms and each ring contains up
to four heteroatoms (i.e. from zero to four heteroatoms, provided
that at least one ring contains at least one heteroatom). The
heterocyclic groups of this invention can also include ring systems
substituted with one or more O, S(O).sub.0-2, and/or N--R.sup.10 as
heteroatoms, wherein R.sup.10 is as defined herein, and wherein the
subscript "0-2" of S(O).sub.0-2 represents an integer of 0, 1 or 2.
Thus, S(O).sub.2 represents the group consisting of S, S(.dbd.O),
and S(O).sub.2. Examples of non-aromatic heterocyclic groups are
aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, azepinyl,
piperazinyl, 1,2,3,6-tetrahydropyridinyl, oxiranyl, oxetanyl,
tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl,
tetrahydrothiopyranyl, morpholino, thiomorpholino, thioxanyl,
pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl,
1,3-dioxolanyl, pyrazolinyl, dihydropyranyl, dihydrothienyl,
dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl,
3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl,
quinolizinyl, quinuclidinyl, 1,4-dioxaspiro[4.5]decyl,
1,4-dioxaspiro[4.4]nonyl, 1,4-dioxaspiro[4.3]octyl and
1,4-dioxaspiro[4.2]heptyl.
[0085] "Heteroaryl" means an aromatic group containing one or more
heteroatoms (O, S, or N), preferably from one to four heteroatoms.
A heteroaryl may be a monocyclic or a polycyclic group. Examples of
heteroaryl groups are pyridinyl, pyridazinyl, imidazolyl,
pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, quinolyl,
isoquinolyl, 1,2,3,4-tetrahydroguinolyl, tetrazolyl, furyl,
thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl,
indolyl, benzimidazolyl, benzofuranyl, indazolyl, indolizinyl,
phthalazinyl, triazinyl, 1,3,5-triazinyl, isoindolyl, purinyl,
oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl,
benzothiophenyl, benzotriazolyl, benzothiazolyl, benzoxazolyl,
quinazolinyl, quinoxalinyl, naphthyridinyl, dihydroquinolyl,
tetrahydroquinolyl, dihydroisoquinolyl, tetrahydroisoquinolyl,
benzofuryl, furopyridinyl, pyrolopyrimidinyl and azaindolyl. In
certain aspects of the present application, the heteroaryl is a
4-substituted-1H-1,2-3-triazol-1-yl.
[0086] As used herein, where a divalent group, such as a linker for
example, is represented by a structure -A-B-, as shown below, it is
intended to also represent a group that may be attached in both
possible permutations, as noted in the two structures below.
##STR00006##
[0087] For example, when a divalent group such as the group
"--N(R.sup.10)C(O)--" is provided, for example, the group is
intended to also include both the divalent group
--N(R.sup.10)C(O)-- and also the divalent group
--C(O)N(R.sup.10)--.
[0088] The substituents or the groups C.sub.1-6alkyl,
C.sub.3-6cycloalkyl, C.sub.3-12cycloalkylC.sub.1-5alkyl,
C.sub.6-14aryl, C.sub.6-14aryloxy, C.sub.6-10arylC.sub.1-4 alkyl,
heteroaryl, heteroaryloxy etc. . . . of the variables R.sup.1,
R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8,
R.sup.9 and R.sup.10 are also optionally further substituted by
substituents selected from the group consisting of amino, halo,
cyano, nitro, hydroxyl, --SH, --SC.sub.1-6alkyl, --C(O)NH.sub.2,
--C(S)NH.sub.2, haloC.sub.1-6alkyl, perhaloC.sub.1-6alkyl,
C.sub.1-6alkyl, C.sub.3-6cycloalkyl, C.sub.3-12cycloalkyl,
C.sub.6-14aryl and heteroaryl.
[0089] For example, in certain aspect of the present application,
the heteroaryl substituent is a
4-substituted-1H-1,2-3-triazol-1-yl. In the radiolabeled compounds
of the present application, a radionuclide may be attached to an
aryl group of the compound of Formula I, as in a
2-.sup.18F-'carbazole derivative such as the compound represented
as:
##STR00007##
or a 2-(.sup.18F-fluoroethyl)-'carbazole,
2-(.sup.18F-fluoromethyl)-'carbazole, a .sup.11C-methoxy-group, for
example, and/or the radionuclide may be attached to any one or more
of the variables R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5,
R.sup.6, R.sup.7, R.sup.8, R.sup.9 and R.sup.10 by way of a
.sup.18F-fluoroethyl-group, a .sup.18F-fluoromethyl-group, a
.sup.11C-methoxy-group,
4-[(.sup.18F-fluoroethyl)-1H-1,2-3-triazol-1-yl]-ethoxy-group,
4-[(.sup.18F-fluoroethyl)-1H-1,2-3-triazol-1-yl]-propyloxy-group, a
.sup.123I, a .sup.124I, a .sup.125I or a .sup.131I group, and the
like. Unless otherwise noted, a compound represented as being
substituted by an atom, such as the generic representation by the
atom fluorine in F--CH.sub.2CH.sub.2-(`carbazole) or
F--CH.sub.2CH.sub.2O-(`carbazole), for example, is intended to
cover both the naturally occurring element .sup.19F (fluorine-19)
as well as the .sup.18F (fluorine-18) isotope(s) of the element
itself.
[0090] The term "optionally substituted" or "substituted" refers to
the specific substituents or groups wherein one to four hydrogen
atoms in the group may be replaced by one to four substituents, for
example, independently selected from the substituents amino, halo,
cyano, nitro, hydroxyl, --SH, --SC.sub.1-6alkyl, --C(O)NH.sub.2,
--C(S)NH.sub.2, haloC.sub.1-6alkyl, perhaloC.sub.1-6alkyl,
C.sub.1-6alkyl, C.sub.3-6cycloalkyl, C.sub.342cycloalkyl,
C.sub.6-14aryl and heteroaryl, or as specifically disclosed herein.
In addition, the substituents may also include alkyl, aryl,
alkylene-aryl, hydroxy, alkoxy, aryloxy, perhaloalkoxy,
heterocyclyl, azido, amino, guanidino, amidino, halo, alkylthio,
oxo, acylalkyl, carboxy esters, carboxyl, carboxamido, acyloxy,
aminoalkyl, alkylaminoaryl, alkylaminoalkyl, alkoxyaryl, arylamino,
phosphono, sulfonyl, carboxamidoaryl, hydroxyalkyl, haloalkyl,
alkoxyalkyl and perhaloalkyl. In addition, the term "optionally
substituted" or "substituted" in reference to the variables
R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7,
R.sup.8, R.sup.9 and R.sup.10, includes groups substituted by one
to four substituents, as identified above, that further comprise a
positron or gamma emitter. Such positron emitters include, but are
not limited to, and .sup.11C, .sup.13N, .sup.15O, .sup.18F,
.sup.123I, .sup.124I, .sup.125I, .sup.131I and .sup.77Br.
[0091] The term "radiolabeled compound" as used herein refers to
compounds having an atom or group that may provide a radiolabel or
may be converted to a radiolabel, such as from a non-radioactive
atom to a radionuclide that is active, such as for example,
.sup.11C, .sup.13N, .sup.15O, .sup.18F, .sup.123I, .sup.124I,
.sup.125I, .sup.131I and .sup.77Br. In addition, for the purpose of
the present application, such "radiolabeled compound" may also
refer to an atom or a group, that comprises a non-active nuclide,
such as a halogen, such as .sup.19F for example, wherein the
compound may be used and administered in a therapeutically
effective amount.
[0092] Compounds of the Formulas disclosed herein may have optical
centers and therefore may occur in different enantiomeric and
diastereomeric configurations. The present invention includes all
enantiomers, diastereomers, and other stereoisomers of such
compounds of the Formulas disclosed herein, as well as racemic
compounds and racemic mixtures and other mixtures of stereoisomers
thereof. Pharmaceutically acceptable salts of the compounds of the
Formulas disclosed herein include the acid addition and base salts
thereof. Suitable acid addition salts are formed from acids which
form non-toxic salts. Examples include, but are not limited to, the
acetate, adipate, aspartate, benzoate, besylate,
bicarbonate/carbonate, bisulphate/sulphate, borate, citrate,
formate, fumarate, gluconate, glucuronate, hydrochloride/chloride,
hydrobromide/bromide, hydroiodide/iodide, lactate, malate, maleate,
malonate, mesylate, methylsulphate, naphthylate, oxalate,
palmitate, phosphate/hydrogen phosphate/dihydrogen phosphate,
pyroglutamate, salicylate, stearate, succinate, sulfonate,
tartrate, tosylate and trifluoroacetate salts. Suitable base salts
are formed from bases which form non-toxic salts. Examples include,
but are not limited to, the aluminum, arginine, benzathine,
calcium, choline, diethylamine, diolamine, glycine, lysine,
magnesium, potassium, sodium, tromethamine and zinc salts.
Hemisalts of acids and bases may also be formed, for example,
hemisulphate and hemicalcium salts. For a review on suitable salts,
see Handbook of Pharmaceutical Salts: Properties, Selection, and
Use by Stahl and Wermuth (Wiley-VCH, 2002). Pharmaceutically
acceptable salts of compounds of the Formulas disclosed herein may
be prepared by one or more of three methods: (i) by reacting the
compound of the Formulas disclosed herein with the desired acid or
base; (ii) by removing an acid- or base-labile protecting group
from a suitable precursor of the compound of the Formulas disclosed
herein; or (iii) by converting one salt of the compound of the
Formulas disclosed herein to another salt by the reaction with an
appropriate acid or base or by means of a suitable ion exchange
column.
[0093] In another embodiment, the imaging is by employing a
fluorescence imaging technique or a nuclear imaging technique
selected from the group consisting of positron emission tomography
(PET) and single photon emission computed tomography (SPECT), the
fluorescence imaging technique and/or nuclear imaging technique for
monitoring or visualizing a distribution of the radiolabeled or
tagged compound within the brain or within a portion thereof.
[0094] In another embodiment, the invention is a method for
treating a disease or condition, in a mammal in need thereof,
selected from the group consisting of anxiety, depression,
schizophrenia, Alzheimer's Disease, stress-related disease, panic,
a phobia, obsessive compulsive disorder, obesity, post-traumatic
stress syndrome, or epilepsy comprising administering to the mammal
a therapeutically effective amount of the compound of formulas
7-8.
[0095] In one embodiment, there is provided a radiolabeled compound
of the formula:
##STR00008##
and pharmaceutically acceptable salts and stereoisomers thereof,
wherein:
[0096] L is N or CR.sup.5;
[0097] M is N or CR.sup.6;
[0098] P is N or CR.sup.7; and
[0099] Q is N or CR.sup.8;
[0100] X is a bond or is C.sub.1-14alkyl, wherein at least one
carbon is optionally replaced by C(O), O, S, SO.sub.2, or NH,
NH--C.sub.1-8alkyl, and wherein at least one H of C.sub.1-8alkyl is
optionally replaced by halo, OH, C.sub.1-6alkyl;
[0101] R.sup.9 is H, a protecting group, a leaving group, an azide,
an alkyne, OH, halo, NH.sub.2, N(C.sub.1-8alkyl).sub.2, aryl or
heteroaryl, wherein at least one H of the aryl or heteroaryl is
optionally replaced by halo, SO.sub.2, NH.sub.2, or C.sub.1-6
alkyl, wherein at least one H of the C.sub.1-6 alkyl is optionally
replaced by halo, or C.sub.3-8cycloalkyl, wherein at least one H of
the C.sub.3-8cycloalkyl is optionally replaced by halo and wherein
at least one CH.sub.2 of the C.sub.3-8cycloalkyl is optionally
replaced with O, OH, S, SH, NH, N--C.sub.1-8alkyl;
[0102] R.sup.1-R.sup.8 are independently H, OH, halo, NH.sub.2,
CH.sub.3, SO.sub.2, a leaving group, a protecting group, aryl,
heteroaryl, NHR.sup.12, N(R.sup.12).sub.2 C.sub.3-8cycloalkyl,
(--CH.sub.2).sub.1-12--R.sup.12, wherein R.sup.12 is CH.sub.3,
aryl, H or heteroaryl, [0103] wherein at least one H of
(--CH.sub.2).sub.1-12--R.sup.12, C.sub.3-8cycloalkyl, aryl, or
heteroaryl, is optionally replaced by halo, OH, NH.sub.2, a leaving
group, a protecting group and C.sub.1-8alkyl, wherein at least one
H of the C.sub.1-8alkyl is optionally replaced by halo, OH,
NH.sub.2, a leaving group, a protecting group, and [0104] wherein
at least one CH.sub.2 of (--CH.sub.2).sub.1-12--R.sup.12 is
optionally replaced with C(O), O, S, SO.sub.2, or NH,
NH--C.sub.1-8alkyl, N(C.sub.1-8alkyl).sub.2, wherein at least one H
of the C.sub.1-8alkyl is optionally replaced by halo, OH, NH.sub.2,
a leaving group, a protecting group, [0105] and wherein at least
one CH.sub.2 of the C.sub.3-8cycloalkyl is optionally replaced by
C(O), O, S or NH, N--C.sub.1-8alkyl, wherein at least one H of the
C.sub.1-8alkyl is optionally replaced by halo, OH, a leaving group,
a protecting group,
[0106] wherein at least one halo is optionally replaced with a
radionuclide or a fluorescent tag.
[0107] In another embodiment, the invention is a compound of the
formula:
##STR00009##
and pharmaceutically acceptable salts and stereoisomers thereof,
wherein:
[0108] L is N or CR.sup.5;
[0109] M is N or CR.sup.6;
[0110] X is a bond or is C.sub.1-14alkyl, wherein at least one
carbon is optionally replaced by C(O), O, S, SO.sub.2, or NH,
NH--C.sub.1-8alkyl, and wherein at least one H of C.sub.1-8alkyl is
optionally replaced by halo, OH, C.sub.1-6alkyl;
[0111] R.sup.9 is H, a protecting group, a leaving group, an azide,
an alkyne, OH, halo, NH.sub.2, N(C.sub.1-8alkyl).sub.2, aryl or
heteroaryl, wherein at least one H of the aryl or heteroaryl is
optionally replaced by halo, SO.sub.2, NH.sub.2, or C.sub.1-6 alkyl
or C.sub.1-6 alkyl, wherein at least one H of the C.sub.1-6 alkyl
is optionally replaced by halo, or C.sub.3-8cycloalkyl, wherein at
least one H of the C.sub.3-8cycloalkyl is optionally replaced by
halo and wherein at least one CH.sub.2 of the C.sub.3-8cycloalkyl
is optionally replaced with O, OH, S, SH, NH,
N--C.sub.1-8alkyl;
[0112] R.sup.2, R.sup.3, R.sup.7 and R.sup.8 are independently H,
OH, halo, NH.sub.2, CH.sub.3, SO.sub.2, a leaving group, a
protecting group, aryl, heteroaryl, NHR.sup.12, N(R.sup.12).sub.2
C.sub.3-8cycloalkyl, (--CH.sub.2).sub.1-12--R.sup.12, wherein
R.sup.12 is CH.sub.3, aryl, H or heteroaryl, [0113] wherein at
least one H of (--CH.sub.2).sub.1-12--R.sup.12,
C.sub.3-8cycloalkyl, aryl, or heteroaryl, is optionally replaced by
halo, OH, NH.sub.2, a leaving group, a protecting group and
C.sub.1-8alkyl, wherein at least one H of the C.sub.1-8alkyl is
optionally replaced by halo, OH, NH.sub.2, a leaving group, a
protecting group, and [0114] wherein at least one CH.sub.2 of
(--CH.sub.2).sub.1-12--R.sup.12 is optionally replaced with C(O),
O, S, SO.sub.2, or NH, NH--C.sub.1-8alkyl, N(C.sub.1-8alkyl).sub.2,
wherein at least one H of the C.sub.1-8alkyl is optionally replaced
by halo, OH, NH.sub.2, a leaving group, a protecting group, [0115]
and wherein at least one CH.sub.2 of the C.sub.3-8cycloalkyl is
optionally replaced by C(O), O, S or NH, N--C.sub.1-8alkyl, wherein
at least one H of the C.sub.1-8alkyl is optionally replaced by
halo, OH, a leaving group, a protecting group,
[0116] wherein at least one halo is optionally replaced with a
radionuclide or a fluorescent tag.
[0117] In another embodiment, the invention is a compound of the
formula:
##STR00010##
and pharmaceutically acceptable salts and stereoisomers
thereof,
[0118] wherein: [0119] L is N or CR.sup.5; [0120] M is N or
CR.sup.6; [0121] X is a bond or is C.sub.1-14alkyl, wherein at
least one carbon is optionally replaced by C(O), O, S, SO.sub.2, or
NH, NH--C.sub.1-8alkyl, and wherein at least one H of
C.sub.1-8alkyl is optionally replaced by halo, OH, C.sub.1-6alkyl;
[0122] R.sup.9 is H, a protecting group, a leaving group, an azide,
an alkyne, OH, halo, NH.sub.2, N(C.sub.1-8alkyl).sub.2, aryl or
heteroaryl, wherein at least one H of the aryl or heteroaryl is
optionally replaced by halo, SO.sub.2, NH.sub.2, or C.sub.1-6 alkyl
or C.sub.1-6 alkyl, wherein at least one H of the C.sub.1-6 alkyl
is optionally replaced by halo, or C.sub.3-8cycloalkyl, wherein at
least one H of the C.sub.3-8cycloalkyl is optionally replaced by
halo and wherein at least one CH.sub.2 of the C.sub.3-8cycloalkyl
is optionally replaced with O, OH, S, SH, NH, N--C.sub.1-8alkyl;
[0123] R.sup.3 is a bond or is at least one of O, S, C(O),
SO.sub.2, NH, N--C.sub.1-8alkyl, (CH.sub.2).sub.1-12, wherein at
least one C of (CH.sub.2).sub.1-12 is optionally replaced by C(O),
O, S, SO.sub.2, NH, N--C.sub.1-8alkyl and wherein at least one H is
optionally replaced by C.sub.1-8alkyl or halo, [0124] R.sup.20 is
aryl or heteroaryl; [0125] R.sup.21 is H, OH, halo, NH.sub.2,
CH.sub.3, SO.sub.2, a leaving group, a protecting group,
(--CH.sub.2).sub.1-12--CH.sub.3, C.sub.3-8cycloalkyl, [0126]
wherein at least one H of the (--CH.sub.2).sub.1-12--CH.sub.3 or
the C.sub.3-8cycloalkyl is optionally replaced by halo, OH,
NH.sub.2, a leaving group, a protecting group and C.sub.1-8alkyl,
wherein at least one H of the C.sub.1-8alkyl is optionally replaced
by halo, OH, a leaving group, a protecting group, [0127] and
wherein at least one CH.sub.2 of the
(--CH.sub.2).sub.1-12--CH.sub.3 is optionally replaced with C(O),
O, S, SO.sub.2, or NH, NH--C.sub.1-8alkyl, N(C.sub.1-8alkyl).sub.2,
wherein at least one H of the C.sub.1-8alkyl is optionally replaced
by halo, OH, NH.sub.2, a leaving group, a protecting group, [0128]
and wherein at least one CH.sub.2 of the C.sub.3-8cycloalkyl is
optionally replaced by C(O), O, S, SO.sub.2, or NH,
N--C.sub.1-8alkyl, wherein at least one H of the C.sub.1-8alkyl is
optionally replaced by halo, OH, NH.sub.2, a leaving group, a
protecting group,
[0129] wherein at least one halo is optionally replaced with a
radionuclide or a fluorescent tag.
[0130] In another embodiment, the invention is a compound of the
formula:
##STR00011##
and pharmaceutically acceptable salts and stereoisomers thereof,
wherein:
[0131] L is N or CR.sup.5;
[0132] M is N or CR.sup.6;
[0133] R.sup.9 is H, a protecting group, a leaving group, halo, or
CH.sub.3;
[0134] R.sup.2, R.sup.3, R.sup.5 and R.sup.6 are independently H,
OH, halo, NH.sub.2, CH.sub.3, SO.sub.2, a leaving group, a
protecting group, aryl, heteroaryl, NHR.sup.12, N(R.sup.12).sub.2
C.sub.3-8cycloalkyl, (--CH.sub.2).sub.1-12--R.sup.12, wherein
R.sup.12 is CH.sub.3, aryl, H or heteroaryl, [0135] wherein at
least one H of (--CH.sub.2).sub.1-12--R.sup.12,
C.sub.3-8cycloalkyl, aryl, or heteroaryl, is optionally replaced by
halo, OH, NH.sub.2, a leaving group, a protecting group and
C.sub.1-8alkyl, wherein at least one H of the C.sub.1-8alkyl is
optionally replaced by halo, OH, NH.sub.2, a leaving group, a
protecting group, and [0136] wherein at least one CH.sub.2 of
(--CH.sub.2).sub.1-12--R.sup.12 is optionally replaced with C(O),
O, S, SO.sub.2, or NH, NH--C.sub.1-8alkyl, N(C.sub.1-8alkyl).sub.2,
wherein at least one H of the C.sub.1-8alkyl is optionally replaced
by halo, OH, NH.sub.2, a leaving group, a protecting group,
[0137] and wherein at least one CH.sub.2 of the C.sub.3-8cycloalkyl
is optionally replaced by C(O), O, S or NH, N--C.sub.1-8alkyl,
wherein at least one H of the C.sub.1-8alkyl is optionally replaced
by halo, OH, a leaving group, a protecting group,
[0138] wherein at least one halo is optionally replaced with a
radionuclide or a fluorescent tag.
[0139] In another embodiment, the invention is a compound of the
formula:
##STR00012##
and pharmaceutically acceptable salts and stereoisomers thereof,
wherein:
[0140] L is N or CR.sup.5;
[0141] M is N or CR.sup.6;
[0142] P is N or CR.sup.7; and
[0143] Q is N or CR.sup.8;
[0144] X is a bond or is C.sub.1-14alkyl, wherein at least one
carbon is optionally replaced by C(O), O, S, SO.sub.2, or NH,
NH--C.sub.1-8alkyl, and wherein at least one H of C.sub.1-8alkyl is
optionally replaced by halo, OH, C.sub.1-6alkyl;
[0145] R.sup.9 is H, a protecting group, a leaving group, OH,
NH.sub.2, N(C.sub.1-8alkyl).sub.2, aryl or heteroaryl, wherein at
least one H of the aryl or heteroaryl is optionally replaced by
SO.sub.2, NH.sub.2, or C.sub.1-6 alkyl, wherein at least one H of
the C.sub.1-6 alkyl is optionally replaced by C.sub.3-8cycloalkyl,
wherein at least one CH.sub.2 of the C.sub.3-8cycloalkyl is
optionally replaced with O, OH, S, SH, NH, N--C.sub.1-8alkyl;
[0146] R.sup.3 and R.sup.5-R.sup.8 are independently H or
(--CH.sub.2).sub.1-12--R.sup.13, wherein R.sup.13 is an azide or an
alkyne, [0147] wherein at least one H of
(--CH.sub.2).sub.1-12--R.sup.13 is optionally replaced by OH,
NH.sub.2, and C.sub.1-8alkyl, wherein at least one H of the
C.sub.1-8alkyl is optionally replaced by OH, NH.sub.2, and wherein
at least one CH.sub.2 of (--CH.sub.2).sub.1-12--R.sup.13 is
optionally replaced with C(O), O, S, SO.sub.2, or NH,
NH--C.sub.1-8alkyl, N(C.sub.1-8alkyl).sub.2, wherein at least one H
of the C.sub.1-8alkyl is optionally replaced by OH, NH.sub.2.
[0148] In another embodiment, the invention is a pharmaceutical
composition for in vivo imaging of amyloid deposits and tau
tangles, comprising (a) the compound of any of the Formulas above
or shown in Claims 1-43 and (b) a pharmaceutically acceptable
carrier.
[0149] In another embodiment, the invention is a method of
diagnosing Alzheimer's Disease or a predisposition thereto in a
mammal, the method comprising: a) administering to the mammal a
diagnostically effective amount of a radiolabeled compound, wherein
the compound passes the blood-brain barrier and preferentially
binds to amyloid plaques and/or tau tangles in a brain tissue and
wherein the compound is selected from the group consisting of
radiolabeled compounds of formula 7, for example; b) allowing the
compound to distribute into the brain tissue; and c) imaging the
brain tissue, wherein an increase in binding of the compound to the
brain tissue compared to a normal control level of binding
indicates that the mammal is suffering from or is at risk of
developing Alzheimer's Disease.
[0150] In another embodiment, the invention is a method of
diagnosing Alzheimer's Disease or a predisposition thereto in a
mammal, the method comprising: a) administering to the mammal a
diagnostically effective amount of a radiolabeled compound of any
of Claims 1-43, provided below, wherein the compound passes the
blood-brain barrier and preferentially binds to amyloid plaques
and/or tau tangles in a brain tissue and wherein the compound is
selected from the group consisting of radiolabeled compounds of
formula 7, for example; b) allowing the compound to distribute into
the brain tissue; and c) imaging the brain tissue, wherein an
increase in binding of the compound to the brain tissue compared to
a normal control level of binding indicates that the mammal is
suffering from or is at risk of developing Alzheimer's Disease.
[0151] In another embodiment, the present invention is a method for
imaging and detection of senile plaques and/or neurofibrillary
tangles in a brain tissue, the method comprising treating the
tissue with a compound of formulas 7-8 for detection of
neurological disorders.
[0152] The neurological disorder may be detected by measuring the
affinity of compounds of formulas 7-8 for tau aggrerates.
[0153] In one embodiment, the detection may be by gamma imaging
with PET or SPECT.
TABLE-US-00001 TABLE 1 Known AD positive fluorescent dyes and
imaging agents Binding Name Compound and Reference Target Affinity
Congo Red ##STR00013## Anal. Biochem. 2006, 356, 265-272; J. Biol.
Chem. 2005, 280, 5892-5901 A.beta. monomer IC.sub.50: 2-10 uM
Curcumin ##STR00014## Anal. Biochem. 2006, 356, 265-272; J. Biol.
Chem. 2005, 280, 5892-5901 A.beta. monomer IC.sub.50: 10-20 uM ANS
##STR00015## Anal. Biochem. 2006, 356, 265-272 A.beta. monomer
IC.sub.50: >100 uM Thioflavin T ##STR00016## Anal. Biochem.
2006, 356, 265-272 A.beta. monomer IC.sub.50: >500 uM Iodinated
Flavone ##STR00017## R = NHMe, NMe.sub.2, OMe, OH J. Med. Chem.
2005, 48, 7253-7260 A.beta.40 aggregates Ki = 13 nM (--NMe2) to 72
nM (--OH) Pyridyl Styrene ##STR00018## R = NHMe, NMe.sub.2 J. Med.
Chem. 2007, 50, 2157-2165 A.beta. fibrils Kd = 7.5-9 nM Diaryl
acetylenes ##STR00019## R= --OH,
--OCH.sub.2CH.sub.2--O--CH.sub.2CH.sub.2F Bioorg. Med. Chem. 2007,
17, 3581- 3584 A.beta. plaques Kd = ~10 nM Thiophene chalcones
##STR00020## R,R' = H, Me Bioorg. Med. Chem. 2007, 15, 6802- 6809
A.beta. 1-42 aggregates Ki = 3.9-14 nM Aurones ##STR00021##
Biochem. Biophys. Res. Commun. 2007, 361, 116-121 A.beta. 1-42
aggregates Ki = 1.24 nM Benzofuran ##STR00022## J. Med. Chem. 2006,
49, 2725-2730 A.beta. fibrils Ki = 2.8 nM
TABLE-US-00002 TABLE 2 Examples of compounds useful for detecting
AD biomarkers in vivo. These compounds may be radiolabeled or be
"cold". Chemical Name Structure Formula MW Code 2-(2-
fluoroethoxy)- 9H-carbazole ##STR00023## C.sub.14H.sub.12FNO 229.25
CB-001 9-(2- fluoroethyl)- 9H-carbazol-2- ol ##STR00024##
C.sub.14H.sub.12FNO 229.25 N-(2- fluoroethyl)-7- (2-(2-(2-
methoxyethoxy) ethoxy)ethoxy)- 9H-carbazol- 3-amine ##STR00025##
C.sub.21H.sub.27FN.sub.2O.sub.4 390.45 7-(2- fluoroethoxy)-
N,N-dimethyl- 9H-carbazol-2- amine ##STR00026##
C.sub.16H.sub.17FN.sub.2O 272.32 7-(2-(2-(2- fluoroethoxy)
ethoxy)ethoxy)- N-methyl-9H- carbazol-3- amine ##STR00027##
C.sub.19H.sub.23FN.sub.2O.sub.3 346.40 CB-008 1-(3,6- diamino-9H-
carbazol-9-yl)- 3-(2-(2-(2- fluoroethoxy) ethoxy)ethoxy)
propan-l-one ##STR00028## C.sub.21H.sub.26FN.sub.3O.sub.4 403.45
N-(2- fluoroethyl)-2- hydroxy-11H- benzo[a] carbazole-
3-carboxamide ##STR00029## C.sub.19H.sub.15FN.sub.2O.sub.2 322.33
2-(6-chloro- 9H-carbazol-2- yl)-N-(2- fluoroethyl) propanamide
##STR00030## C.sub.17H.sub.16ClFN.sub.2O 318.77 2-(6-fluoro-
9H-carbazol-2- yl)-N,N- dimethylpropa- namide ##STR00031##
C.sub.17H.sub.17FN.sub.2O 284.33 2-methoxy-9H- carbazole
##STR00032## C.sub.13H.sub.11NO 197.23 6-iodo-2- methoxy-9H-
carbazole ##STR00033## C.sub.13H.sub.10INO 323.13 7-(2-
fluoroethoxy)- N,N-dimethyl- 9H-carbazol-2- amine ##STR00034##
C.sub.16H.sub.17FN.sub.2O 272.32 tert-butyl 2-(2- (2-(2-
fluoroethoxy) ethoxy)ethoxy)- 9H-carbazole- 9-carboxylate
##STR00035## C.sub.23H.sub.28FNO.sub.5 417.47 CB-005 2-(2-(2-(2-
fluoroethoxy) ethoxy)ethoxy)- 9-methyl-9H- carbazole ##STR00036##
C.sub.19H.sub.22FNO.sub.3 331.38 CB-006 7-(2-(2-(2- fluoroethoxy)
ethoxy)ethoxy)- N,N-dimethyl- 9H-carbazol-2- amine ##STR00037##
C.sub.20H.sub.25FN.sub.2O.sub.3 360.42 CB-007 N-(7-(2-(2-(2-
fluoroethoxy) ethoxy)ethoxy)- 9H-carbazol-2- yl)acetamide
##STR00038## C.sub.20H.sub.23FN.sub.2O.sub.4 374.41 CB-009
7-(2-(2-(2- fluoroethoxy) ethoxy)ethoxy)- 9H-pyrido[2,3- b]indole
##STR00039## C.sub.17H.sub.19FN.sub.2O.sub.3 318.34 CB-028
2-(2-(2-(2- fluoroethoxy) ethoxy)ethoxy)- 9H-carbazole ##STR00040##
C.sub.18H.sub.20FNO.sub.3 317.35 CB-003 7-(2-(2-(2- fluoroethoxy)
ethoxy)ethoxy)- N-methyl-9H- carbazol-2- amine ##STR00041##
C.sub.19H.sub.23FN.sub.2O.sub.3 346.40 CB-004 N-(7-(2-(2-(2-
fluoroethoxy) ethoxy)ethoxy)- 9H-carbazol-2- yl)formamide
##STR00042## C.sub.19H.sub.21FN.sub.2O.sub.4 360.38 CB-010
6-(2-(2-(2- fluoroethoxy) ethoxy)ethoxy)- 9- (methoxymethyl)- N,N-
dimethyl-9H- carbazol-3- amine ##STR00043##
C.sub.22H.sub.29FN.sub.2O.sub.4 404.48 CB-011 N-(7-(2-
fluoroethoxy)- 9H-carbazol-2- yl)formamide ##STR00044##
C.sub.15H.sub.13FN.sub.2O.sub.2 272.27 CB-012 N-(7-(2-(2-
fluoroethoxy) ethoxy)-9H- carbazol-2- yl)formamide ##STR00045##
C.sub.17H.sub.17FN.sub.2O.sub.3 316.33 CB-024 N-(2- fluoroethyl)-6-
methoxy-9H- carbazol-3- amine ##STR00046##
C.sub.15H.sub.15FN.sub.2O 258.29 CB-013 7-((4- fluorobutyl)
(methyl)amino)- 9H-carbazol-2- ol ##STR00047##
C.sub.17H.sub.19FN.sub.2O 286.34 CB-014 7-((2 - fluoroethyl)
(methyl)amino)- 9H-carbazol-2- ol ##STR00048##
C.sub.15H.sub.15FN.sub.2O 258.29 CB-015 7-(2 - fluoroethyl-
amino)-9H- carbazol-2-ol ##STR00049## C.sub.14H.sub.13FN.sub.2O
244.26 CB-016 7-((2-(2-(2- fluoroethoxy) ethoxy)ethyl)
(methyl)amino)- 9H-carbazol-2- ol ##STR00050##
C.sub.19H.sub.23FN.sub.2O.sub.3 346.40 CB-019 7-(2- fluoroethoxy)-
N-methyl-9H- carbazol-2- amine ##STR00051##
C.sub.15H.sub.15FN.sub.2O 258.29 CB-020 7-(2- fluoroethoxy)-
9H-carbazol-2- ol ##STR00052## C.sub.14H.sub.12FNO.sub.2 245.25
CB-025 7-(2-(2-(2- fluoroethoxy) ethoxy)ethoxy)- 9H-carbazol-2-
##STR00053## C.sub.18H.sub.20FNO.sub.4 333.35 CB-026 N-(4-(7-amino-
9H-carbazol-2- yloxy)phenyl)- 2- fluoropropan- amide ##STR00054##
C.sub.21H.sub.18FN.sub.3O.sub.2 363.38 CB-027 1-(2-(2-(2-(2 -
fluoroethoxy) ethoxy)ethoxy)- 9H-carbazol-9- yl)ethanone
##STR00055## C.sub.20H.sub.22FNO.sub.4 359.39 CB-017 (2-(2-(2-(2 -
fluoroethoxy) ethoxy)ethoxy)- 9H-carbazol-9- yl)(phenyl)- methanone
##STR00056## C.sub.25H.sub.24FNO.sub.4 421.46 CB-021 2-fluoro-N-(4-
(7- (methylamino)- 9H-carbazol-2- yloxy)phenyl) propanamide
##STR00057## C.sub.22H.sub.20FN.sub.3O.sub.2 377.41 CB-029 N-(7-(4-
fluorobutoxy)- 9H-carbazol-2- yl)formamide ##STR00058##
C.sub.17H.sub.17FN.sub.2O.sub.2 300.33 CB-030 tert-butyl 2-(2-
(2-(2- fluoroethoxy) ethoxy)ethoxy)- 9H-pyrido[2,3- b]indol-7-
ylcarbamate ##STR00059## C.sub.22H.sub.28FN.sub.3O.sub.5 433.47
CB-031 2-(2-(2-(2- fluoroethoxy) ethoxy)ethoxy)- 9H-pyrido[2,3-
b]indol-7- amine ##STR00060## C.sub.17H.sub.20FN.sub.3O.sub.3
333.36 CB-032 7-(benzyloxy)- N-(2- fluoroethyl)-N- methyl-9H-
carbazol-2- amine ##STR00061## C.sub.22H.sub.21FN.sub.2O 348.41
CB-033 2-(2-(2-(2- fluoroethoxy) ethoxy)ethoxy)- N-methyl-9H-
pyrido[2,3- b]indol-7- amine ##STR00062##
C.sub.18H.sub.22FN.sub.3O.sub.3 347.38 CB-034 6-bromo-9H-
carbazol-2-ol ##STR00063## C.sub.12H.sub.8BrNO 262.10 6-(2-
fluoroethoxy)- 3-hydroxy-2- phenylquinolin- 4(1H)-one ##STR00064##
C.sub.17H.sub.14FNO.sub.3 299.30
[0154] Other embodiments of the present invention include the
following Table 3:
TABLE-US-00003 ID T807 T805 T703 T794 ##STR00065## ##STR00066##
##STR00067## ##STR00068## MW 360.3 214.2 244.3 228.3 CLogP 3.2 2.8
3.6 3.4 KD (tau) 15 nM 32 nM 30 nM selectivity 29x 14x 16x 17x
(tau/Ab) GM Intensity 28% 8% 6% 14% (comp. with W372) background 61
49 15 97 (normal brain 32566) PSL/mm2 Tx/tau/amyloid yes yes
correlation Brain uptake yes (3 rats, 3 mice) yes (2 rats, 2 mice)
Yes yes (4 rats, 4 mice) in vivo 15, 30 min 15 min Yes 5, 15,30 min
metabolism in vivo metabolism: one day human somewhat stable stable
hepatocytes (less polar metabolite) PK yes yes yes yes 45 brain
panel done done double staining yes AchE activity 6 uM <50% at
10 uM 5 uM (IC50) MAO 0% (1 uM) MAO-A 0% (1 uM) MAO-A 16% (1 .mu.M)
MAO-A 19% (1 uM) MAO-A inhibition 0% (1 uM) MAO-B 0% (1 uM) MAO-B
0% (1 .mu.M) MAO-B 0% (1 uM) MAO-B CNS selectivity NET, .sigma.l 1
uM panel Norepinephrine transp.(49%) Dopamine transp.(34%)
Glutamate, NMDA (44%) Monoamine transp. (41%) Serotonin 5-HT2c
(33%) MDS SDL-20, #22673 SDL-18, #22639-1 SDL/quote # (5 targets at
2 more concentrations)
[0155] Other embodiments of the present invention include the
following Table 4:
TABLE-US-00004 compound dbl staining KD KD ID Stucture MW CLogP
(100 uM) (tau) (amyloid) T734 ##STR00069## 257.31 3.5 blue/green.
Tau+. Other- T733 ##STR00070## 243.3 3.0 blue/green. Tau-. Other-
T728 ##STR00071## 257.3 3.8 green/blue. Tau+. Other- T726
##STR00072## 243.3 3.3 green/blue. Tau+++. Other- T687 ##STR00073##
243.3 2.8 blue. Tau++++. Ab++ T686 ##STR00074## 230.2 2.9 blue.
Tau+. Other+ T660 ##STR00075## 244.3 3.4 Tau-. Ab+
[0156] It will be understood that the halogen of these
carbazole-based compounds, for example, F, may be radioactive or it
may be "cold." In particular, it may be .sup.18F. Other suitable
radioactive atoms may include .sup.11C, .sup.13N, .sup.15O,
.sup.18F, .sup.61Cu, .sup.62Cu, .sup.64Cu, .sup.67Cu, .sup.68Ga,
.sup.124I, .sup.125I, .sup.131I, .sup.99Tc, .sup.75Br, .sup.153Gd
and .sup.32P.
[0157] For example, radiolabeled compounds may include:
##STR00076##
[0158] Compounds of the Present Invention May Also be
Precursors:
##STR00077##
Other precursors may include:
##STR00078##
[0159] Compounds of the present invention may also be:
##STR00079##
wherein R.sub.13 is halo or a radionuclide.
[0160] When injected intravenously into mice, the Carbazole based
compounds; in particular T807, T805 and T794 have shown excellent
brain uptake. These compounds also display high binding affinity to
tau fibrils. Autoradiography using the present compounds
demonstrated labeling of NFTs in AD brain sections. Fluorescence
assay data shows the binding ability of these agents to tau
aggregates and A.beta. fibrils. In neuropathological staining,
compounds of the present invention stained amyloid plaques and/or
tau aggregates.
[0161] In another embodiment, the present invention relates to
compounds and compositions which comprise the formulae as disclosed
herein, wherein the compound is an amyloid and/or tau protein
binding compound. An amyloid and/or tau protein binding compound of
the invention may be administered to a patient in amounts suitable
for in vivo imaging of amyloid deposits and/or NTFs, and
distinguish between neurological tissue with amyloid deposits
and/or NTfs and normal neurological tissue.
[0162] A.beta. compounds are typically evaluated in a competitive
binding assay using synthetic A.beta.1-42 fibrils (IC.sub.50s). The
situation is more complicated for tau, because there are 6 isoforms
of tau potentially present in AD brains as products of alternate
splicing of a single tau gene. Most reports in the literature rely
therefore on only one recombinant isoform, Tau-441. To add more
complexity, the various tau isoforms are hyperphosphorylated in
vivo, something that is difficult to mimic in vitro. Furthermore,
structural information on these tau fibrils is lacking, making an
interpretation of binding of compounds difficult.
[0163] Native forms of tau (various isoforms, hyperphosphorylated)
and amyloid aggregates are present in brain sections and therefore
preferred for compound testing. Using the self-fluorescence of a
test compound can give an indication of whether the compound binds
to tau tangles/PHFs and/or amyloid plaques. This is further
confirmed by immunostaining with A.beta. and tau antibodies and
overlaying the images. The drawback is that the fluorescent signals
cannot be used for quantitation as some compounds might exhibit a
stronge fluorescent signal than others and the coexistence of
A.beta. plaques and tau tangles in AD brains. However, it is
possible to "rate" the signal strength qualitatively and
distinguish compounds that show binding to these aggregates.
[0164] Furthermore, the selectivity can be evaluated in brains
containing only A.beta. plaques/no tau aggregates, A.beta.
plaques/and tau aggregates, and control brains. Unfortunately,
there are no AD brains with only tau and no A.beta. present. By
testing radiolabeled tracers in these brain sections, one can more
quantitative evaluate the relative binding strength (signal
strength) and selectivity of various test compounds as they all
contain the same radioactive tracer. For examples, if a test tracer
binds only to tau, and not amyloid, it should show no signal in the
A.beta. plaques only brain sections. If a compound binds only to
amyloid, it should show uptake in both types of brains. The
difficulty of identifying and further quantifying selective
compounds lies in the relative abundance of amyloid vs. tau, which
is difficult to measure.
[0165] Amyloid and/or tau protein probes of the invention may be
used to detect and quantitate amyloid deposits and/or NTFs in
diseases including, but not limited to Mediterranean fever,
MuckleWells syndrome, idiopathetic myeloma, amyloid polyneuropathy,
amyloid cardiomyopathy, systemic senile myloidosis, amyloid
polyneuropathy, hereditary cerebral hemorrhage with amyloidosis,
Down's syndrome, Scrapie, Creutzfeldt-Jacob disease, Kuru,
Gerstamnn-Straussler-Scheinker syndrome, medullary carcinoma of the
thyroid, Isolated atrial amyloid, .beta..sub.2-microglobulin
amyloid in dialysis patients, inclusionbody myositis,
.beta..sub.2-amyloiddeposits in muscle wasting disease, chronic
traumatic encephalopathy (CTE), and Islets of Langerhans diabetes
Type II insulinoma.
[0166] In other embodiments of the invention, the labeled compound
is introduced into a patient in a detectable quantity and after
sufficient time has passed for the compound to become associated
with amyloid deposits and/or tau proteins, the labeled compound is
detected noninvasively. In another embodiment of the invention, a
labeled compound of the Formulas disclosed herein is introduced
into a patient, sufficient time is allowed for the compound to
become associated with amyloid deposits, and then a sample of
tissue from the patient is removed and the labeled compound in the
tissue is detected apart from the patient. In another embodiment of
the invention, a tissue sample is removed from a patient and a
labeled compound of Formula 7, for example, is introduced into the
tissue sample. After a sufficient amount of time for the compound
to become bound to amyloid deposits and/or tau proteins, the
compound is detected.
Synthesis of Ligands and their Labeling Precursors
Halogenation and Radiohalogenation:
[0167] As disclosed herein, for a number of different AD ligands,
such as flavones, coumarins, carbazoles, quinolinones, chromenones,
trisubstituted imidazoles and their derivatives as disclosed
herein, the radiolabeled atom, such as a halogen atom, for example,
may be readily introduced into the ligand using a number of
different methods well known in the art. Accordingly, the
radiolabeled compounds of the Formulas 7-8 may be prepared using
standard methods known in the art for preparing such radiolabeled
compounds having a particular substituent, wherein the compound may
be incorporated with a particular radionuclide selected from the
group consisting of .sup.11C, .sup.13N, .sup.15O, .sup.18F,
.sup.123I, .sup.124I, .sup.125I, .sup.131I and .sup.77Br.
[0168] In one particular example, the halogen may be introduced by
a method using a tin for halogen exchange process. For example, a
non-radioactive halogen such as iodine, may be replaced by an
organo tin compound via a metal, such as a palladium composition,
to form the radiolabeling tin precursor, as represented below. This
precursor is then subjected to radioactive halogenation via
displacement with Na.sup.125I source, for example, to afford the
radioactive ligand.
##STR00080##
[0169] Alternatively, the radio labeled halogen may be readily
introduced via direct halogenation. For example, for a ligand
comprising an aromatic ring as part of the scaffold, or an aromatic
substituent of a ligand, the aromatic ring may be directly
iodinated using well-established radioiodination procedure. One
such example is represented below using a carbazole ligand.
##STR00081##
[0170] For .sup.11C-labeled compounds, the labeled compound may be
prepared by the alkylation or methylation of a hydroxyl group, such
as with [.sup.11C]CH.sub.3I to provide the corresponding C-11
labeled methoxy derivative. For example, such a process is
represented by the reaction of the flavone derivative shown
below.
##STR00082##
[0171] Other methods of preparing radiolabeled ligands are well
known in the art. Example of such methods are disclosed in, for
example: 1) Jewett, D. M. (1992) A Simple Synthesis of
[.sup.11C]Methyl Triflate Appl. Radiat. Isot. 43, 1383-1385; 2)
Crouzel, C. Langstrom, B., Pike, V. W., and Coenen, H. H. (1987)
Recommendations for a practical production of [.sup.11C]methyl
iodide Appl. Radiat. Isot. Int. J. Appl. Instrum. Part A 38,
601-603; Dannals, R. F., Ravert, H. T.; 3) Wilson, A. A. (1990)
Radiochemistry of Tracers for Neurotransmitter Receptor Studies.
In: Quantitative Imaging: Neuroreceptors, Neurotransmitters, and
Enzymes. (Edited by Frost, J. J. Wagner Jr., H. N. pp. 19-35, Raven
Press, New York; 4) Jewett, D. M., Manger, T. J., and Watkins, G.
L. (1991) Captive Solvent Methods for Fast Simple Carbon-11
Radioalkylations. In: New Trends in Radiopharmaceutical Synthesis,
Quality Assurance and Regulatory Control (Edited by Emran, A. M.)
pp. 387-391. Plenum Press, New York; 5) Marazano, C., Maziere, M.,
Berger, G., and Comar, D. (1977) Synthesis of methyl
iodide-.sup.11C and formaldehyde-.sup.11C Appl. Radiat. Isot. 28,
49-52; 6) Watkins, G., Jewett, D., Mulholland, G., Kitbourn, M.,
and Toorongian, S. (1988) A Captive Solvent Method for Rapid
N-[.sup.11C]Methylation of Secondary Amides: Application to the
Benzodiazepine, 4'-Chlorodiazepam (RO5-4864) Appl. Radiat. Isot.
39, 441-444; and 7) Wilson, A. A., DaSilva, J. N., and Houle, S.
(1996) In vivo evaluation of [.sup.11C] and [.sup.15F]-labelled
cocaine analogues as potential dopamine transporter ligands for
positron emission tomography Nucl. Med. Biol. 23, 141-146. The
subject matter of all references cited herein are incorporated
herein by reference in their entirety.
Synthesis of AD-CB-WZ01013
##STR00083##
[0173] To hydroxycarbazole (73 mg, 0.4 mmol) in 1 mL of NMP was
added Cs.sub.2CO.sub.3 (130 mg, 0.4 mmol) and bromofluoroethane (51
mg, 0.4 mmol). The mixture was stirred at rt for 15 h and diluted
with Et.sub.2O (50 mL). It was washed with 1 M HCl (30 mL) and
water (2.times.40 mL), dried over MgSO.sub.4 and concentrated. The
crude product was purified with silica chromatography (4% EtOAc in
hexane to 25%) to afford the desired product (36 mg) as an
off-white solid.
[0174] .sup.1H NMR (400 MHz, CDCl.sub.3/acetone-d.sub.6) .delta.
9.98 (s, 1H), 7.95 (t, J=8.8 Hz, 2H), 7.40 (d, J=8.0 Hz, 1H), 7.28
(t, J=8 Hz, 1H), 7.13 (t, J=8.0 Hz, 1H), 7.00 (d, J=2 Hz, 1H), 6.83
(dd, J=8.8, 2.0 Hz, 1H), 4.85 (t, J=4 Hz, 1H), 4.73 (t, J=4 Hz,
1H), 4.35 (t, J=4 Hz, 1H), 4.28 (t, J=4 Hz, 1H); MS (ESI) m/z 230
(M+H.sup.+).
Synthesis of AD-C-WZ01011
##STR00084##
[0176] To hydroxycarbazole (183 mg, 1 mmol) in 4 mL of NMP was
added Cs.sub.2CO.sub.3 (326 mg, 1 mmol) and ethylenedi-tosylate
(370 mg, 1 mmol). The mixture was stirred at rt for 15 h and
diluted with Et.sub.2O (80 mL). It was washed with 1 M HCl (50 mL)
and water (2.times.50 mL), dried over MgSO.sub.4 and concentrated.
The crude product was purified with silica chromatography (50% DCM
in hexane to 100% DCM) to afford the desired product (75 mg) as an
off-white solid.
[0177] .sup.1H NMR (400 MHz, acetone-d.sub.6) .delta. 10.21 (s,
1H), 8.00 (d, J=8.0 Hz, 1H), 7.95 (d, J=8.4 Hz, 1H), 7.84 (d, J=8.4
Hz, 2H), 7.45 (m, 3H), 7.30 (t, J=8.0 Hz, 1H), 7.13 (t, J=8.0 Hz,
1H),); 6.98 (s, 1H), 6.73 (d, J=8.4 Hz, 1H), 4.44 (t, J=4.0 Hz,
2H), 4.30 (t, J=4.0 Hz, 2H), 2.42 (s, 3H); MS (ESI) m/z 382
(M+H.sup.+), 404 (M+Na.sup.+).
Synthesis of 18F-Labeled AD-CB-001P-WZ-01019
([.sup.18F]2-(2-Fluoro-ethoxy)-9H-carbazole)
##STR00085##
[0179] [.sup.18F]Fluoride (600-900 mCi) as an enriched solution in
H.sub.2.sup.18O was delivered to the synthesis module. The
[.sup.18F]fluoride was trapped on an ion-exchange column and then
eluted into the reaction vessel using aqueous potassium carbonate
(3.0 mg in 0.4 mL H.sub.2O). Kryptofix-2.2.2 phase transfer reagent
was added (20.0 mg in 1.0 mL MeCN) and the water-acetonitrile
azeotrope was evaporated to dryness. Toluene-4-sulfonic acid
2-(9H-carbazol-2-yloxy)-ethyl ester precursor (4 mg in 0.9 mL
MeCN/0.1 mL DMSO) was added to the reactor and then the
fluorination reaction was heated at 115.degree. C. for 10 min. The
crude reaction mixture was then purified by semi-preparative HPLC
(Column: Phenomenex Luna C-18, 250 mm.times.10 mm; Mobile-Phase
Gradient 95:5 H.sub.20 (+0.05% TFA): MeCN (+0.05% TFA) to 100% MeCN
(+0.05% TFA); Flow rate: 5 mL/min).
[0180] The peak corresponding to
[.sup.18F]2-(2-fluoro-ethoxy)-9H-carbazole was collected and
simultaneously diluted with sterile water (10 mL). The resulting
mixture was passed over a C-18 Sep-Pak so that the product was
trapped and residual acetonitrile was washed away with further
water (10 mL). [.sup.18F]2-(2-Fluoro-ethoxy)-9H-carbazole was then
eluted into the product vial with USP grade ethanol (0.5 mL) and
diluted with sterile water (9.5 mL) to provide a final formulation
(19-34 mCi in 10 mL) suitable for injection (7.5% decay corrected
yield, 100% radiochemical purity).
[0181] Purity was determined by analytical HPLC equipped with a
radioactivity detector and identity was confirmed by comparison
with HPLC data for the corresponding unlabeled reference standard
(FIG. 3A and FIG. 3B of U.S. Ser. No. 12/372,717).
Synthesis of AD-CB-002P-WZ01031
##STR00086##
[0183] To hydroxycarbazole (92 mg, 0.5 mmol) in 2 mL of NMP was
added Cs.sub.2CO.sub.3 (163 mg, 0.5 mmol) and azido ethyltosylate
(121 mg, 0.5 mmol). The mixture was stirred at rt for 15 h and
diluted with Et.sub.2O (50 mL). It was washed with 0.5 M HCl (50
mL) and water (2.times.50 mL), dried over MgSO.sub.4 and
concentrated. The crude product was purified with silica
chromatography (80% DCM in hexane to 100% DCM) to afford the
desired product (76 mg) as a white solid.
[0184] .sup.1H NMR (400 MHz, CDCl.sub.3/acetone-d.sub.6) .delta.
9.98 (s, 1H), 7.95 (m, 2H), 7.41 (d, J=8.4 Hz, 1H), 7.29 (t, J=8.0
Hz, 1H), 7.14 (t, J=8.0 Hz, 1H),); 7.01 (s, 1H), 6.84 (d, J=8.4 Hz,
1H), 4.28 (t, J=4.8 Hz, 2H), 3.67 (t, J=4.8 Hz, 2H); MS (ESI) m/z
253 (M+H.sup.+).
Synthesis of AD-CB-0025-WZ01033
##STR00087##
[0186] To azido carbazole (32 mg, 0.127 mmol) in 0.5 mL of DMF was
added CuI (7.6 mg, 0.04 mmol), DIPEA (16.4 mg, 0.127 mmol), and
fluoropentyne (16.4 mg, 0.19 mmol). The reaction mixture was
vigorously stirred for 1 h and diluted with EtOAc (30 mL). It was
washed with water (50 mL), 0.5 M HCl (30 mL), water (2.times.50
mL), dried over MgSO.sub.4 and concentrated. The crude product was
pre-absorbed on silica (3 g) and loaded on a 4 g silica column and
eluted with 30% EtOAc in hexane to 50% to afford the desired
compound (20 mg).
[0187] .sup.1H NMR (400 MHz, CDCl.sub.3/CD.sub.3OD) .delta. 7.95
(d, J=7.6 Hz, 1H), 7.91 (d, J=8.4 Hz, 1H), 7.76 (s, 1H), 7.40 (d,
J=8.0 Hz, 1H), 7.31 (t, J=7.6 Hz, 1H), 7.14 (t, J=7.6 Hz, 1H), 6.94
(d, J=2.4 Hz, 1H), 6.78 (dd, J=8.8, 2.4 Hz, 1H), 4.83-4.78 (m, 2H),
4.53-4.48 (m, 3H), 4.40 (t, J=6.0 Hz, 1H), 2.85 (t, J=7.6 Hz, 2H),
2.10-1.99 (m, 2H); MS (ESI) m/z 339 (M+H.sup.+).
Synthesis of 18F-Labeled AD-CB-0025-WZ01033
Preparation of [.sup.18F] 5-Fluoro-pent-1-yne
##STR00088##
[0189] [.sup.18F]Fluoride (600-900 mCi) as an enriched solution in
H.sub.2.sup.18O is delivered to the synthesis module. The
[.sup.18F]fluoride is trapped on an ion-exchange column and then
eluted into the reaction vessel using aqueous potassium carbonate
(3.0 mg in 0.4 mL H.sub.2O). Kryptofix-2.2.2 phase transfer reagent
is added (20.0 mg in 1.0 mL MeCN) and the water-acetonitrile
azeotrope is evaporated to dryness.
[0190] Toluene-4-sulfonic acid pent-4-ynyl ester (20 mg in 0.8 mL
MeCN) is added to the reactor and the fluorination reaction is
heated at 110.degree. C. for 5 min. Following fluorination, the
crude reaction mixture is purified by distillation and yields
[.sup.18F] 5-fluoro-pent-1-yne as a solution in acetonitrile
(trapped at -78.degree. C. due to the volatility of the
product).
Preparation of Triazole
##STR00089##
[0192] A mixture of azide precursor (5 mg), sodium ascorbate (40
mg), tris-(benzyltriazolylmethyl)amine (TBTA, 25 mg) and aqueous
copper sulfate solution (0.1 M, 0.25 mL) in DMF (0.4 mL) and water
(0.1 mL) is added to the cooled pentyne solution described above.
The reaction mixture is then warmed to rt and stirred for 30 min.
After this time, the reaction is purified by semi-preparative HPLC.
The peak corresponding to the product is collected and
simultaneously diluted with sterile water (10 mL). The resulting
mixture is passed over a C-18 Sep-Pak and residual acetonitrile is
washed away with additional water (10 mL). The product is eluted
into the product vial with USP grade ethanol (0.5 mL) and diluted
with sterile water (9.5 mL) providing a final formulation suitable
for injection.
[0193] Purity is determined by analytical HPLC equipped with a
radioactivity detector and identity is confirmed by comparison with
HPLC data for the corresponding unlabeled reference standard.
Synthesis of .sup.18F-labeled CB-003
##STR00090##
[0195] [.sup.18F]Fluoride (600-900 mCi) as an enriched solution in
H.sub.2.sup.18O is delivered to the synthesis module. The
[.sup.18F]fluoride is trapped on an ion-exchange column and then
eluted into the reaction vessel using aqueous potassium carbonate
(3.0 mg in 0.4 mL H.sub.2O). Kryptofix-2.2.2 phase transfer reagent
is added (20.0 mg in 1.0 mL MeCN) and the water-acetonitrile
azeotrope is evaporated to dryness. The precursor (4 mg in 0.9 mL
MeCN/0.1 mL DMSO) is added to the reactor and the fluorination
reaction is heated at 115.degree. C. for 10 min. The mixture was
cooled to 55.degree. C. and most of the acetonitrile was evaporated
under vacuum and a stream of argon as before. To the crude
Boc-protected product was added aqueous hydrochloric acid (1.0 M,
1.0 mL), and the mixture was heated to 105.degree. C. for 3
minutes. After cooling to 35.degree. C., aqueous sodium acetate
(2.0 M, 0.5 mL) was added with stirring. The crude reaction mixture
is then purified by semi-preparative HPLC (Column: Phenomenex Luna
C-18, 250 mm.times.10 mm; Mobile-Phase Gradient 95:5 H.sub.2O
(+0.05% TFA): MeCN (+0.05% TFA) to 100% MeCN (+0.05% TFA); Flow
rate: 5 mL/min; time=25 min). The peak corresponding to the final
product is collected and simultaneously diluted with sterile water
(10 mL). The resulting mixture is passed over a C-18 Sep-Pak so
that the product is trapped and residual acetonitrile is washed
away with further water (10 mL). The product is then eluted into
the product vial with USP grade ethanol (0.5 mL) and diluted with
sterile water (9.5 mL) providing a final formulation suitable for
injection (31% decay uncorrected yield, 100% radiochemical purity).
Purity was determined by analytical HPLC equipped with a
radioactivity detector and identity was confirmed by comparison
with HPLC data for the corresponding unlabeled reference
standard.
Synthesis of .sup.18F-Labeled CB-004
##STR00091##
[0197] [.sup.18F]Fluoride (600-900 mCi) as an enriched solution in
H.sub.2.sup.18O is delivered to the synthesis module. The
[.sup.18F]fluoride is trapped on an ion-exchange column and then
eluted into the reaction vessel using aqueous potassium carbonate
(3.0 mg in 0.4 mL H.sub.2O). Kryptofix-2.2.2 phase transfer reagent
is added (20.0 mg in 1.0 mL MeCN) and the water-acetonitrile
azeotrope is evaporated to dryness. The precursor (4 mg in 0.9 mL
MeCN/0.1 mL DMSO) is added to the reactor and the fluorination
reaction is heated at 115.degree. C. for 10 min. The mixture was
cooled to 55.degree. C. and most of the acetonitrile was evaporated
under vacuum and a stream of argon as before. To the crude
Boc-protected product was added aqueous hydrochloric acid (1.0 M,
1.0 mL), and the mixture was heated to 105.degree. C. for 3
minutes. After cooling to 35.degree. C., aqueous sodium acetate
(2.0 M, 0.5 mL) was added with stirring. The crude reaction mixture
is then purified by semi-preparative HPLC (Column: Phenomenex Luna
C-18, 250 mm.times.10 mm; Mobile-Phase Gradient 95:5 H.sub.2O
(+0.05% TFA): MeCN (+0.05% TFA) to 100% MeCN (+0.05% TFA); Flow
rate: 5 mL/min; time=25 min). The peak corresponding to the final
product is collected and simultaneously diluted with sterile water
(10 mL). The resulting mixture is passed over a C-18 Sep-Pak so
that the product is trapped and residual acetonitrile is washed
away with further water (10 mL). The product is then eluted into
the product vial with USP grade ethanol (0.5 mL) and diluted with
sterile water (9.5 mL) providing a final formulation suitable for
injection (3% decay uncorrected yield, 100% radiochemical purity).
Purity was determined by analytical HPLC equipped with a
radioactivity detector and identity was confirmed by comparison
with HPLC data for the corresponding unlabeled reference
standard.
Synthesis of .sup.18F-Labeled CB-007
##STR00092##
[0199] [.sup.18F]Fluoride (600-900 mCi) as an enriched solution in
H.sub.2.sup.18O is delivered to the synthesis module. The
[.sup.18F]fluoride is trapped on an ion-exchange column and then
eluted into the reaction vessel using aqueous potassium carbonate
(3.0 mg in 0.4 mL H.sub.2O). Kryptofix-2.2.2 phase transfer reagent
is added (20.0 mg in 1.0 mL MeCN) and the water-acetonitrile
azeotrope is evaporated to dryness. The precursor (4 mg in 0.9 mL
MeCN/0.1 mL DMSO) is added to the reactor and the fluorination
reaction is heated at 115.degree. C. for 10 min. The mixture was
cooled to 55.degree. C. and most of the acetonitrile was evaporated
under vacuum and a stream of argon as before. To the crude
Boc-protected product was added aqueous hydrochloric acid (1.0 M,
1.0 mL), and the mixture was heated to 105.degree. C. for 3
minutes. After cooling to 35.degree. C., aqueous sodium acetate
(2.0 M, 0.5 mL) was added with stirring. The crude reaction mixture
is then purified by semi-preparative HPLC (Column: Phenomenex Luna
C-18, 250 mm.times.10 mm; Mobile-Phase Gradient 95:5 H.sub.2O
(+0.05% TFA): MeCN (+0.05% TFA) to 100% MeCN (+0.05% TFA); Flow
rate: 5 mL/min; time=25 min). The peak corresponding to the final
product is collected and simultaneously diluted with sterile water
(10 mL). The resulting mixture is passed over a C-18 Sep-Pak so
that the product is trapped and residual acetonitrile is washed
away with further water (10 mL). The product is then eluted into
the product vial with USP grade ethanol (0.5 mL) and diluted with
sterile water (9.5 mL) providing a final formulation suitable for
injection (1.2% decay uncorrected yield, 100% radiochemical
purity). Purity was determined by analytical HPLC equipped with a
radioactivity detector and identity was confirmed by comparison
with HPLC data for the corresponding unlabeled reference
standard.
Synthesis of .sup.18F-Labeled CB-012
##STR00093##
[0201] [.sup.18F]Fluoride (600-900 mCi) as an enriched solution in
H.sub.2.sup.18O was delivered to the synthesis module. The
[.sup.18F]fluoride was trapped on an ion-exchange column and then
eluted into the reaction vessel using aqueous potassium carbonate
(3.0 mg in 0.4 mL H.sub.2O). Kryptofix-2.2.2 phase transfer reagent
was added (20.0 mg in 1.0 mL MeCN) and the water-acetonitrile
azeotrope was evaporated to dryness. Toluene-4-sulfonic acid
2-(9H-carbazol-2-yloxy)-ethyl ester precursor (4 mg in 0.9 mL
MeCN/0.1 mL DMSO) was added to the reactor and then the
fluorination reaction was heated at 115.degree. C. for 10 min. The
crude reaction mixture was then purified by semi-preparative HPLC
(Column: Phenomenex Luna C-18, 250 mm.times.10 mm; Mobile-Phase
Gradient 95:5 H.sub.2O (+0.05% TFA): MeCN (+0.05% TFA) to 100% MeCN
(+0.05% TFA); Flow rate: 5 mL/min). The peak corresponding to the
product was collected and simultaneously diluted with sterile water
(10 mL). The resulting mixture was passed over a C-18 Sep-Pak so
that the product was trapped and residual acetonitrile was washed
away with further water (10 mL).
[.sup.18F]2-(2-Fluoro-ethoxy)-9H-carbazole was then eluted into the
product vial with USP grade ethanol (0.5 mL) and diluted with
sterile water (9.5 mL) to provide a final formulation (19-34 mCi in
10 mL) suitable for injection (2% decay uncorrected yield, 100%
radiochemical purity). Purity was determined by analytical HPLC
equipped with a radioactivity detector and identity was confirmed
by comparison with HPLC data for the corresponding unlabeled
reference standard.
Assays of Carbazole Derivatives:
[0202] From the Biacore assay, two carbazole derivatives displayed
promising binding affinities to oligomers/polymers and fibrils
(Table 4). The beta-carboline Harmol, a member of the harmala
alkaloids, is the urinary metabolite of harmine. The harmala
alkaloids are MAO inhibitors and are commonly found in Syrian rue,
Peganum harmala, and the South American vine Banisteriopsis caapi,
both of which are purported to possess strong hallucinogenic
effects. The beta-carbolenes have a varied effect on the central
nervous system including binding to the 5-HT.sub.2, 5-HT.sub.1a,
glutamate NMDA and imidazoline receptors; inhibiting MAO-A enzyme
and interfering with dopaminergic transmission. And while
beta-carbolines are thought to be cytotoxic, they also maintain
neuroprotective properties supposedly offering neuroprotection
against dopamine and glutamate and, additionally, by scavenging
reactive oxygen species. A recent report demonstrated that
beta-carboline alkyloids induce a facilitation of short and long
term memory in object recognition tasks in mice, although the means
by which the alkyloids are exerting their effect is unclear. Moura,
D. J., et al., Effects of b-carboline alkaloids in the object
recognition task in mice. Life Sciences, 2006, 79: p.
2099-2104.
[0203] The second active carbazole discovered in the assay is
2-hydroxycarbazole. 2-Hydroxycarbazole has been recently shown to
release Ca.sup.2+ ion from skeletal and cardiac muscle through a
distinct pharmacological pathway. The generic carbazole scaffold
exists in several therapeutics including the non-steroidal
anti-inflammatory carprofen, carazolol (a beta-blocker) and
YM-53601 (a squalene synthase inhibitor). Recent work has shown
that carbazole derivatives can act as .gamma.-secretase modulators.
[Narlawar, R., et al., N-Substituted carbazolyloxyacetic acids
modulate Alzheimer associated g-secretas. Bioorganic &
Medicinal Chemistry Letters, 2007, 17: p. 176-182] In another AD
related project, Howlett discovered highly elaborated carbazoles,
such as carvedilol, inhibit fibril formation, albeit the binding
affinities to the fibrils were not determined. [Howlett, D. R., et
al., Common Structural Features Determine the Effectiveness of
Carvedilol, Daunomycin and Rotiletracycline as Inhibitors of
Alzheimer b-Amyloid Fibril Formation. Biochemical Journal, 1999,
343: p. 419-423] Interestingly, an article intending to determine
the practicality of using carbazoles as fibril inhibitors based on
cell permeability suggests that carbazoles are unlikely to cross
the blood brain barrier, as they are PGP substrates, precluding
their use as therapeutics for fibril inhibition. [Saengkhae, C., et
al., Ability of Carbazole Salts, Inhibitors of Alzheimer b-Amyloid
Fibril Formation, to Cross Cellular Membranes. European Journal of
Pharmacology, 2007, 559: p. 124-131]
[0204] By using an appropriate imaging modality, a tracer's
biodistribution pattern becomes instantly visible and accessible.
For example, by using .sup.18F-labeled tracers one can easily
quantify a tracer's uptake into, and washout from, the brain using
positron emission tomography (PET). Tracers with high uptake and
slow washout in normal brains generate low signal to noise ratios.
Tracers with high uptake and fast washout in normal brains have
high signal to noise rations and are considered ideal.
.sup.18F-labeled carbazoles possess ideal brain imaging properties.
For example, an .sup.18F-labeled carbazole was prepared and
administered to a normal, white Sprague-Dawley rat (FIG. 6 of U.S.
Ser. No. 12/372,717). Within minutes, the tracer entered into the
brain and washed out over several minutes.
[0205] The non-radioactive carbazole also successfully competes off
both Thioflavin T and FDDNP in brain tissue sections suggesting
that the tracer binds to similar binding sites (FIGS. 4 and 5 of
U.S. Ser. No. 12/372,717).
TABLE-US-00005 TABLE 4 Carbazole-based hits from the Biacore assay.
A "+" sign represents a hit and the increase in "+" signs relates
to increasing binding affinity. A "-"sign represents no binding.
Binding to Binding oligomers/polymers to fibrils (A.beta.1-42)
(A.beta.1-42) #54: Harmol ++ + ##STR00094## #55: 2-Hydroxycarbazole
+++ + ##STR00095## #73: 7,8-Dihydroxy-4- phenylcoumarin
[0206] A list of examples of carbazole-based imaging agents are
shown in Table 5. Many of the compounds are either .sup.18F- or
.sup.11C-labeled.
TABLE-US-00006 TABLE 5 Examples of carbazole-based imaging agents.
Any of these may include a halogen and/or a radionuclide or may be
"cold." The halogen may be replaced with a radionuclide such as
.sup.18F. Mol. Compound Name Structure Formula Weight
2-(2-fluoroethoxy)-9H- carbazole ##STR00096## C.sub.14H.sub.12FNO
229.25 9-(2-fluoroethyl)-9H- carbazol-2-ol ##STR00097##
C.sub.14H.sub.12FNO 229.25 N-(2-fluoroethyl)-7-(2-(2-(2-
methoxyethoxy)ethoxy)- ethoxy)-9H-carbazol-3-amine ##STR00098##
C.sub.21H.sub.27FN.sub.2O.sub.4 390.45 7-(2-fluoroethoxy)-N,N-
dimethyl-9H-carbazol-2- amine ##STR00099##
C.sub.16H.sub.17FN.sub.2O 272.32 7-(2-(2-(2-
fluoroethoxy)ethoxy)ethoxy)- N-methyl-9H-carbazol-3- amine
##STR00100## C.sub.19H.sub.23FN.sub.2O.sub.3 346.40
1-(3,6-diamino-9H-carbazol- 9-yl)-3-(2-(2-(2-
fluoroethoxy)ethoxy)ethoxy)- propan-l-one ##STR00101##
C.sub.21H.sub.26FN.sub.3O.sub.4 403.45 N-(2-fluoroethyl)-2-hydroxy-
11H-benzo[a]carbazole-3- carboxamide ##STR00102##
C.sub.19H.sub.15FN.sub.2O.sub.2 322.33 2-(6-chloro-9H-carbazol-2-
yl)-N-(2- fluoroethyl)propanamide ##STR00103##
C.sub.17H.sub.16ClFN.sub.2O 318.77 2-(6-fluoro-9H-carbazol-2-
yl)-N,N-dimethylpropanamide ##STR00104## C.sub.17H.sub.17FN.sub.2O
284.33 2-methoxy-9H-carbazole ##STR00105## C.sub.13H.sub.11NO
197.23 6-iodo-2-methoxy-9H- carbazole ##STR00106##
C.sub.13H.sub.10INO 323.13
Detailed Biacore Assay Protocol:
[0207] .beta.-Amyloid (A.beta.42) Soluble Aggregates
(Oligomers/Soluble Polymers).
[0208] Biotin-LC-A.beta.42 was mixed with A.beta.42 at a ratio of
3:2. After dissolving in 1% NH.sub.4OH and dH.sub.2O, the mixture
(40 uM concentration) was incubated in 1.times.PBS (pH 7.4) buffer
at RT for 6-hours to form oligomers/soluble polymers. The free
monomer of A.beta.42 in the sample was removed using a Microcon
centrifugal filter tube with a 10 KDa of MW cutoff. The
Biotin-LC-A.beta.42 oligomers/polymers were immobilized onto SA
chip by streptavidin-biotin capture.
[0209] .beta.-Amyloid (A.beta.42) Insoluble Aggregates
(Fibrils).
[0210] Fibrils were prepared according to methods published
previously (Agdeppa E D et al. 2001). Briefly, 0.5 mg of A.beta.42
(Biotin-LC-A.beta.42:A.beta.42=1:1) was dissolved in 1 ml of PBS,
pH 7.4, and mixed with a magnetic stir bar for 3 d at 37.degree.
C., resulting in a visibly cloudy solution. The fibril pellet was
collected by centrifugation. The Biotin-LC-A.beta.42 fibrils were
immobilized onto SA chip by streptavidin-biotin capture.
[0211] Screening of Amyloid Binding Compounds with Biacore (Surface
Plasmon Resonance Analysis).
[0212] A.beta.42 oligomers/soluble polymers or fibrils were
immobilized on Flow Cell 2 (Fc2) or Flow Cell 3 (Fc3) of the Sensor
Chip, with Fc1 serving as the control. Screening compounds at 10 uM
concentration was flown through Fc1, Fc2, and Fc3 for 2 minutes at
a flow rate of 30 ul/minute. The Flow Cells were then washed with
running buffer (1.times.PBS) for 2 minute, and regenerated with 50
mM of NaOH for 30 seconds. The real time interaction between the
screening compound and the amyloid aggregates immobilized on the
chip surface was recorded in the sensorgram.
[0213] Immunostaining of Brain Sections with Thioflavin T.
[0214] Brain samples from donors with Alzheimer disease were
paraffin wax infiltrated after fixation. Paraffin blocks with
embedded brain samples were mounted onto microtome and sectioned.
Sections were then deparaffinized and hydrated, followed by
incubation with or without AD-CB-001S-WZ01013. Staining was carried
out with 1 uM Thioflavin T. Images were obtained with a
fluorescence microscope (FIG. 4 of U.S. Ser. No. 12/372,717).
[0215] Immunostaining of Brain Sections with FDDNP.
[0216] Brain samples from donors with Alzheimer disease were
paraffin wax infiltrated after fixation. Paraffin blocks with
embedded brain samples were mounted onto microtome and sectioned.
Sections were then deparaffinized and hydrated, followed by
incubation with or without AD-CB-001S-WZ01013. Staining was carried
out with 1 uM FDDNP. Images were obtained with a fluorescence
microscope (FIG. 5 of U.S. Ser. No. 12/372,717).
Imaging Results of AD-CB-001
[0217] A white Sprague-Dawley rat was injected via tail vein with
.about.850 uCi AD-CB-001, formulated in 10% EtOH:water. A dynamic
scan was conducted for 30 min on a R4 microPET scanner. The data
was reconstructed using 1 min framing. Within minutes, the tracer
entered the rat brain and quickly washed out (FIG. 6 of U.S. Ser.
No. 12/372,717).
Synthesis of AD-CB-002P-WZ01031
##STR00107##
[0219] To hydroxycarbazole (92 mg, 0.5 mmol) in 2 mL of NMP was
added Cs.sub.2CO.sub.3 (163 mg, 0.5 mmol) and ethylazido tosylate
(121 mg, 0.5 mmol). The mixture was stirred at rt for 15 h and
diluted with Et.sub.2O (50 mL). It was washed with 0.5 M HCl (50
mL) and water (2.times.50 mL), dried over MgSO.sub.4 and
concentrated. The crude product was purified with silica
chromatography (80% DCM in hexane to 100% DCM) to afford the
desired product (76 mg) as a white solid.
[0220] .sup.1H NMR (400 MHz, CDCl.sub.3/acetone-d6) .delta. 9.98
(s, 1H), 7.95 (m, 2H), 7.41 (d, J=8.4 Hz, 1H), 7.29 (t, J=8.0 Hz,
1H), 7.14 (t, J=8.0 Hz, 1H),); 7.01 (s, 1H), 6.84 (d, J=8.4 Hz,
1H), 4.28 (t, J=4.8 Hz, 2H), 3.67 (t, J=4.8 Hz, 2H); MS (ESI) m/z
253 (M+H.sup.+).
Synthesis of AD-CB-002S-WZ01033
##STR00108##
[0222] To ethylazido carbazole (32 mg, 0.127 mmol) in 0.5 mL of DMF
was added CuI (7.6 mg, 0.04 mmol), DIPEA (16.4 mg, 0.127 mmol), and
fluoropentyne (16.4 mg, 0.19 mmol). The reaction mixture was
vigorously stirred for 1 h and diluted with EtOAc (30 mL). It was
washed with water (50 mL), 0.5 M HCl (30 mL), water (2.times.50
mL), dried over MgSO.sub.4 and concentrated. The crude product was
pre-absorbed on silica (3 g) and loaded on a 4 g silica column and
eluted with 30% EtOAc in hexane to 50% to afford the desired
compound (20 mg).
[0223] .sup.1H NMR (400 MHz, CDCl.sub.3/CD.sub.3OD) .delta. 7.95
(d, J=7.6 Hz, 1H), 7.91 (d, J=8.4 Hz, 1H), 7.76 (s, 1H), 7.40 (d,
J=8.0 Hz, 1H), 7.31 (t, J=7.6 Hz, 1H), 7.14 (t, J=7.6 Hz, 1H); 6.94
(d, J=2.4 Hz, 1H), 6.78 (dd, J=8.8, 2.4 Hz, 1H), 4.83-4.78 (m, 2H),
4.53-4.48 (m, 3H), 4.40 (t, J=6.0 Hz, 1H), 2.85 (t, J=7.6 Hz, 2H),
2.10-1.99 (m, 2H); MS (ESI) m/z 339 (M+H.sup.+).
Synthesis of 18F-Labeled AD-CB-0025-WZ01033
Preparation of Triazole
##STR00109##
[0225] A mixture of azide precursor (5 mg), sodium ascorbate (40
mg), tris-(benzyltriazolylmethyl)amine (TBTA, 25 mg) and aqueous
copper sulfate solution (0.1 M, 0.25 mL) in DMF (0.4 mL) and water
(0.1 mL) is added to the cooled pentyne solution described above.
The reaction mixture is then warmed to rt and stirs for 30 min.
After this time, the reaction is purified by semi-preparative HPLC.
The peak corresponding to the product is collected and
simultaneously diluted with sterile water (10 mL). The resulting
mixture is passed over a C-18 Sep-Pak and residual acetonitrile is
washed away with additional water (10 mL). The product is eluted
into the product vial with USP grade ethanol (0.5 mL) and diluted
with sterile water (9.5 mL) providing a final formulation suitable
for injection.
[0226] Purity is determined by analytical HPLC equipped with a
radioactivity detector and identity is confirmed by comparison with
HPLC data for the corresponding unlabeled reference standard.
General Procedure for Carbazole N-Boc Protection:
[0227] To a round bottomed flask equipped with a magnetic stir bar,
rubber septum, and argon inlet containing THF (40 vol) was placed
carbazole (1.0 equiv). To this solution was added NaH (60%
dispersion in oil, 3 equiv) at 0.degree. C. and the reaction was
allowed to stir at 0.degree. C. for 30 min. To this reaction was
added (Boc).sub.2O (1.2 equiv) at 0.degree. C. and the reaction was
allowed to stir for 1 h. After the reaction was complete by LCMS,
poured into water (25 vol) and extracted into EtOAc (3.times.20
vol). The combined organic extracts were washed with water
(2.times.25 vol), dried (Na.sub.2SO.sub.4) and concentrated in
vacuo. The residue was purified over silica gel using Hexanes:EtOAc
as an eluent to afford the final product.
General Procedure for Carbazole N-Methylation:
[0228] To a round bottomed flask equipped with a magnetic stir bar,
rubber septum, and argon inlet containing THF (50 vol) was placed
carbazole (1.0 equiv). To this solution was added NaH (60%
dispersion in oil, 3 equiv) at 0.degree. C. and the reaction was
allowed to stir at 0.degree. C. for 30 min. To this reaction was
added MeOTf (1.0 equiv) at 0.degree. C. and the reaction was
allowed to stir for 1 h. After the reaction was complete by LCMS,
poured into water (25 vol) and extracted into EtOAc (3.times.20
vol). The combined organic extracts were washed with water
(2.times.25 vol), dried (Na.sub.2SO.sub.4) and concentrated in
vacuo. The residue was purified over silica gel using Hexanes:EtOAc
as an eluent to afford the final product.
General Experimental Procedure for Phenolic Alkylation:
[0229] To a round bottomed flask equipped with a magnetic stir bar
containing DMF (20 vol) was placed phenol (1 equiv). To this
solution was added alkylating agent (1.0 equiv), Cs.sub.2CO.sub.3
(1.2 equiv) and the reaction was allowed to stir at 60.degree. C.
for 16 h. The reaction was then poured into water (25 vol) and
extracted into EtOAc (3.times.20 vol). The combined organic
extracts were washed with water (2.times.25 vol), dried
(Na.sub.2SO.sub.4) and concentrated in vacuo. The residue was
purified over silica gel using Hexanes:EtOAc as an eluent to afford
the final product.
General Experimental Procedure for Suzuki Coupling Reaction:
[0230] To a round bottomed flask equipped with a magnetic stir bar
rubber septum, and argon inlet containing toluene:H.sub.2O (1:1, 40
vol) was placed chloro compound (1 equiv). To this solution was
added boronic acid (1.5 equiv), Pd(PPh.sub.3).sub.4 (0.02 equiv),
K.sub.2CO.sub.3 and the reaction was allowed to stir at 110.degree.
C. for 16 h. The reaction was then poured into water (25 vol) and
extracted into EtOAc (3.times.20 vol). The combined organic
extracts were washed with water (2.times.25 vol), dried
(Na.sub.2SO.sub.4) and concentrated in vacuo. The residue was
purified over silica gel using Hexanes:EtOAc as an eluent to afford
the final product.
General Experimental Procedure for Carbazole Formation Using
P(OEt).sub.3
[0231] To a round bottomed flask equipped with a magnetic stir bar
containing P(OEt).sub.3 (25 vol) was placed biaryl (1 equiv). The
reaction was allowed to stir at 150.degree. C. for 16 h. After the
reaction was complete, P(OEt).sub.3 was removed in vacuo. The
residue was purified over silica gel using Hexanes:EtOAc as the
eluent to afford the final compound.
Synthesis of CB1-Nosylate Precursor
##STR00110##
[0232] Preparation of ethane-1,2-diyl bis(2-nitrobenzenesulfonate)
(DHK-4-14)
[0233] To a 50 mL round bottomed flask equipped with a magnetic
stir bar containing DCM (10 mL) was placed 1,2-ethanediol (0.25 g,
4.0 mmol). To this solution was added nosyl chloride (1.9 g, 8.5
mmol) and Et.sub.3N (0.90 g, 8.9 mmol) at 0.degree. C. and the
reaction was allowed to stir at room temperature for 16 h. After
the reaction was complete, the white solid was filtered, washed
with DCM (100 mL) and dried in vacuo to afford DHK-4-14 (1.3 g,
75%) as a colorless solid.
[0234] MS: [M+Na].sup.+: 455.0
Preparation of 2-(9H-carbazol-2-yloxy)ethyl 2-nitrobenzenesulfonate
(DHK-4-15)
[0235] To a 25 mL round bottomed flask equipped with a magnetic
stir bar containing DMF (5 vol) was placed carbazole (0.2 g, 1.1
mmol). To this solution was added the DHK-4-14 (0.52 g, 1.2 mmol),
Cs.sub.2CO.sub.3 (0.43 g, 1.3 mmol) and the reaction was allowed to
stir at room temperature for 16 h. The reaction was then poured
into water (25 mL) and extracted into EtOAc (4.times.50 mL). The
combined organic extracts were dried (Na.sub.2SO.sub.4) and
concentrated in vacuo. The crude residue was purified by flash
chromatography using Hexanes:EtOAc (50:50) on a Combiflash
purification system to yield DHK-4-15 as a white solid (0.28 g,
62%). MS: [M+Na].sup.+: 435.0
Synthesis of CB-5
##STR00111##
[0236] Preparation of tert-butyl
2-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-9H-carbazole-9-carboxylate:
CB-5: DHK-4-27
[0237] General experimental procedure for carbazole N-Boc
protection was followed. Reaction was performed on a 0.03 g scale.
Product eluted out in 30-35% EtOAc:Hexanes mixture in a gradient
elution on a Combiflash purification system. Isolated 0.03 g (74%)
of CB-5 as a colorless oil. MS: [M+H].sup.+: 418.0
Synthesis of CB-6: DHK-4-28
##STR00112##
[0238] Preparation of
2-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-9-methyl-9H-carbazole:
CB-6
[0239] General experimental procedure for carbazole N-methylation
was followed. Reaction was performed on a 0.05 g scale. Product
eluted out in 40-45% EtOAc:Hexanes mixture in a gradient elution on
a Combiflash purification system. Isolated 0.04 g (78%) of CB-6 as
a white solid. MS: [M+H].sup.+: 332.1.
Synthesis of N-Boc-Protected CB-3 Precursor
##STR00113##
[0240] Preparation of tert-butyl
2-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethoxy)-9H-carbazole-9-carboxylate:
DHK-4-32
[0241] General experimental procedure for carbazole N-Boc
protection was followed. Reaction was performed on a 0.07 g scale.
Product eluted out in 40% EtOAc:Hexanes mixture in a gradient
elution on a Combiflash purification system. Isolated 0.07 g (82%)
of DHK-4-32 as white solid. MS: [M+Na].sup.+: 592.
Synthesis of N-Methyl CB-3 Precursor
##STR00114##
[0242] Preparation of
2-(2-(2-(9-methyl-9H-carbazol-2-yloxy)ethoxy)ethoxy)ethyl
4-methylbenzenesulfonate: DHK-4-30
[0243] General experimental procedure for carbazole N-methylation
was followed. Reaction was performed on a 0.075 g scale. Product
eluted out in 40% EtOAc:Hexanes mixture in a gradient elution on a
Combiflash purification system. Isolated 0.07 g (91%) of DHK-4-30
as a white solid. MS: [M+H].sup.+: 484.2
Synthesis of CB-7 Std
##STR00115##
[0244] Preparation of
1-chloro-4-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-2-nitrobenzene:
DHK-4-51
[0245] General experimental procedure for phenolic alkylation was
followed. Reaction was performed on a 0.25 g scale. Product eluted
out in 20-30% EtOAc:Hexanes mixture in a gradient elution on a
Combiflash purification system. Isolated 0.44 g (99%) of DHK-4-51
as yellow oil. MS: [M+H].sup.+: 308.0.
Preparation of
4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-N,N-dimethyl-2'-nitrobiphenyl-4-a-
mine: DHK-4-26
[0246] General experimental procedure for Suzuki coupling reaction
was followed. Reaction was performed on a 0.11 g scale. Product
eluted out in 50-60% EtOAc:Hexanes mixture in a gradient elution on
a Combiflash purification system. Isolated 0.06 g (43%) of DHK-4-26
as yellow oil. MS: [M+H].sup.+: 393.1
Preparation of
7-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-N,N-dimethyl-9H-carbazol-2-amine:
DHK-4-29: CB-7
[0247] General experimental procedure for carbazole formation using
P(OEt).sub.3 was followed. Reaction was performed on a 0.06 g
scale. Product eluted out in 70-80% EtOAc:Hexanes mixture in a
gradient elution on a Combiflash purification system. Isolated 0.03
g (49%) of DHK-4-29 CB-7 as white solid. MS: [M+H].sup.+:
361.1.
Synthesis of CB-9 Std
##STR00116##
[0248] Preparation of
1-chloro-4-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-2-nitrobenzene:
DHK-4-51
[0249] General experimental procedure for phenolic alkylation was
followed. Reaction was performed on a 0.25 g scale. Product eluted
out in 20-30% EtOAc:Hexanes mixture in a gradient elution on a
Combiflash purification system. Isolated 0.44 g (99%) of DHK-4-51
as yellow oil. MS: [M+H].sup.+: 308.0.
Preparation of
N-(4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-2'-nitrobiphenyl-4-yl)acetamid-
e: DHK-4-31
[0250] General experimental procedure for Suzuki coupling reaction
was followed. Reaction was performed on a 0.11 g scale. Product
eluted out in 80-90% EtOAc:Hexanes mixture in a gradient elution on
a Combiflash purification system. Isolated 0.14 g (100%) of
DHK-4-31 as yellow oil. MS: [M+H].sup.+: 407.0.
Preparation of
N-(7-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-9H-carbazol-2-yl)acetamide:
DHK-4-33: CB-9
[0251] General experimental procedure for carbazole formation using
P(OEt).sub.3 was followed. Reaction was performed on a 0.15 g
scale. Product eluted out in 90% EtOAc:Hexanes mixture in a
gradient elution on a Combiflash purification system. Isolated 0.03
g (49%) of CB-9 as white solid. MS: [M+H].sup.+: 375.1.
Synthesis of CB-28 Std
##STR00117##
[0252] Preparation of
1-chloro-4-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-2-nitrobenzene:
DHK-4-51
[0253] General experimental procedure for phenolic alkylation was
followed. Reaction was performed on a 0.25 g scale. Product eluted
out in 20-30% EtOAc:Hexanes mixture in a gradient elution on a
Combiflash purification system. Isolated 0.44 g (99%) of DHK-4-51
as yellow oil. MS: [M+H].sup.+: 308.0.
Preparation of
3-(4-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-2-nitrophenyl)pyridine:
DHK-4-56
[0254] General experimental procedure for Suzuki coupling reaction
was followed. Reaction was performed on a 0.095 g scale. Product
eluted out in 40-50% EtOAc:Hexanes mixture in a gradient elution on
a Combiflash purification system. Isolated 0.01 g (9%) of DHK-4-56
as yellow oil. MS: [M+H].sup.+: 351.1.
Preparation of
7-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-9H-pyrido[2,3-b]indole
DHK-4-58: CB-28
[0255] General experimental procedure for carbazole formation using
P(OEt).sub.3 was followed. Reaction was performed on a 0.01 g
scale. Product eluted out in 50% EtOAc:Hexanes mixture in a
gradient elution on a Combiflash purification system. Isolated
0.002 g (22%) of CB-28 as white solid. MS: [M+H].sup.+: 319
Synthesis of CB-7-Precursor
##STR00118##
[0256] Preparation of 4-(benzyloxy)-1-chloro-2-nitrobenzene:
DHK-4-63
[0257] General experimental procedure for phenolic alkylation was
followed. Reaction was performed on a 1 g scale. K.sub.2CO.sub.3
was used as a base and acetone was used as the solvent. Reaction
time was 4 h. Product eluted out in 20-30% EtOAc:Hexanes mixture in
a gradient elution on a Combiflash purification system. Isolated
1.45 g (95%) of DHK-4-63 as white crystalline solid. MS:
[M+H].sup.+: 264.0
Preparation of 3
4'-(benzyloxy)-N,N-dimethyl-2'-nitrobiphenyl-4-amine: DHK-4-66
[0258] General experimental procedure for Suzuki coupling reaction
was followed. Reaction was performed on a 0.47 g scale. Product
eluted out in 20-30% EtOAc:Hexanes mixture in a gradient elution on
a Combiflash purification system. Isolated 0.21 g (34%) of DHK-4-66
as orange solid. MS: [M+H].sup.+: 349.1
Preparation of 7-(benzyloxy)-N,N-dimethyl-9H-carbazol-2-amine
DHK-4-68
[0259] General experimental procedure for carbazole formation using
P(OEt).sub.3 was followed. Reaction was performed on a 0.21 g
scale. Product eluted out in 20-30% EtOAc:Hexanes mixture in a
gradient elution on a Combiflash purification system. Isolated 0.13
g (68%) of DHK-4-68 as white solid. MS: [M+H].sup.+: 317.1
Preparation of tert-butyl
2-(benzyloxy)-7-(dimethylamino)-9H-carbazole-9-carboxylate:
DHK-4-69
[0260] General experimental procedure for carbazole N-Boc
protection was followed. Reaction was performed on a 0.13 g scale.
Reaction temperature was carried at room temperature for 16 h.
Product eluted out in 10% EtOAc:Hexanes mixture in a gradient
elution on a Combiflash purification system. Isolated 0.12 g (70%)
of DHK-4-69 as white solid. MS: [M+H].sup.+: 417.2.
Preparation of tert-butyl
2-(dimethylamino)-7-hydroxy-9H-carbazole-9-carboxylate:
DHK-4-71
[0261] To a 50 mL round bottomed flask equipped with a magnetic
stir bar containing EtOAc (50 mL) was placed DHK-4-69 (0.11 g, 0.19
mmol). To this solution was added Pd/C (10%, 20 mg) and the
reaction was allowed to stir under H.sub.2 (1 atm) at RT for 16 h.
After the reaction was complete, the reaction mixture was filtered
through celite and the volatiles were removed in vacuo to afford
DHK-4-71 (0.09 g, 100%) as white solid.
Preparation of tert-butyl
2-(dimethylamino)-7-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethoxy)-9H-carbazole-
-9-carboxylate: DHK-4-72: CB-7 precursor
[0262] General experimental procedure for phenolic alkylation was
followed. Reaction was performed on a 0.09 g scale. Product eluted
out in 45% EtOAc:Hexanes mixture in a gradient elution on a
Combiflash purification system. Isolated 0.07 g (41%) of CB-7
precursor as white solid. MS: [M+H].sup.+: 613.2.
Synthesis of AD-CB-003S-WZ0129
##STR00119##
[0264] To
2,2'-(ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl)bis(4-methylbe-
nzenesulfonate) (8.7 g, 19 mmol) was added TBAF (22.8 mL, 1.0 M THF
solution, 22.8 mmol). The mixture was heated to reflux for 1 h
under Ar atmosphere and cooled to rt and concentrated under reduced
pressure. The crude material was purified with silica
chromatography (5% to 40% THF in hexane) to afford
2-(2-(2-fluoroethoxy)ethoxy)ethyl 4-methylbenzenesulfonate as a
clear oil (2.5 g, 43%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.
7.80 (d, J=8.4 Hz, 2H), 7.34 (d, J=8.4 Hz, 2H), 4.61 (m, 1H), 4.49
(m, 1H), 4.16 (m, 2H), 3.75 (m, 1H), 3.71-3.67 (m, 3H), 3.62 (m,
4H); MS (ESI) m/z 307 (M+H.sup.+).
[0265] To 2-hydroxycarbazole (45 mg, 0.25 mmol) and
2-(2-(2-fluoroethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (82 mg,
0.27 mmol) in 0.5 mL NMP was added Cs.sub.2CO.sub.3 (82 mg, 0.25
mmol). The mixture was stirred at rt for 15 h under Ar atmosphere
and diluted with Et.sub.2O (50 mL). It was washed with water
(3.times.50 mL) and dried over MgSO.sub.4. Solvent was removed
under reduced pressure and the crude product was purified with
silica chromatography (5% to 50% EtOAc in hexane) to afford the
desired product as white solid (37 mg, 47%). .sup.1H NMR (400 MHz,
CDCl3) .delta. 8.02 (s, 1H), 7.96 (d, J=7.2 Hz, 1H), 7.91 (d, J=8.4
Hz, 1H), 7.38-7.33 (m, 2H), 7.20 (m, 1H), 6.91 (d, J=2.4 Hz, 1H),
6.86 (dd, J=8.8, 2.4 Hz, 1H), 4.63 (m, 1H), 4.51 (m, 1H), 4.21 (m,
2H), 3.90 (m, 2H), 3.80-3.76 (m, 3H), 3.74-3.71 (m, 3H); MS (ESI)
m/z 318 (M+H.sup.+).
Synthesis of AD-CB-003P-WZ0141
##STR00120##
[0267] To 2-hydroxycarbazole (183 mg, 1 mmol) and
2-(2-(2-fluoroethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (687 mg,
1.5 mmol) in 5 mL NMP was added Cs.sub.2CO.sub.3 (326 mg, 1 mmol).
The mixture was stirred at rt for 15 h under Ar atmosphere and
diluted with Et.sub.2O (100 mL). It was washed with water
(3.times.100 mL) and dried over MgSO.sub.4. Solvent was removed
under reduced pressure and the crude product was purified with
silica chromatography (5% to 60% EtOAc in hexane) to afford the
desired product as white solid (165 mg, 35%). .sup.1H NMR (400 MHz,
CDCl3) .delta. 8.21 (s, 1H), 7.95 (d, J=7.2 Hz, 1H), 7.91 (d, J=8.4
Hz, 1H), 7.77-7.75 (m, 2H), 7.37-7.30 (m, 2H), 7.28 (s, 1H), 7.25
(m, 1H), (td, J=7.6, 1.2 Hz, 1H), 6.92 (d, J=2.4 Hz, 1H), 6.83 (dd,
J=8.8, 2.4 Hz, 1H), 4.15 (m, 4H), 3.84 (m, 2H), 3.69-3.65 (m, 4H),
3.62-3.59 (m, 2H), 2.38 (s, 3H); MS (ESI) m/z 470 (M+H.sup.+), 492
(M+Na.sup.+).
AD-CB-004S-WZ01165
##STR00121##
[0269] To 4-chloro-3-nitrophenol (1.74 g, 10 mmol) and benzyl
bromide (2.05 g, 12 mmol) in 25 mL of acetone was added
K.sub.2CO.sub.3 (2.76 g, 20 mmol). The mixture was heated at
60.degree. C. for 4 h under Ar atmosphere and cooled to rt. It was
filtered and the solid was washed with ether (80 mL) and the
combined filtrate was concentrated and chromatographed (EtOAc in
hexane, 3% to 30% gradient) to afford
4-(benzyloxy)-1-chloro-2-nitrobenzene as a light-yellow solid (2.5
g, 95%). .sup.1H NMR (400 MHz, CDCl3) .delta. 7.46 (d, J=2.8 Hz,
1H), 7.42-7.34 (m, 5H), 7.11 (dd, J=8.8, 2.8 Hz, 1H), 5.08 (s, 2H);
MS (ESI) m/z 264 (M+H.sup.+).
[0270] To 4-(benzyloxy)-1-chloro-2-nitrobenzene (526 mg, 2 mmol)
and tert-butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylcarbamate (670
mg, 2.1 mmol) in 12 mL dioxane was added 4 mL of a 1 M
Na.sub.2CO.sub.3 (aq) solution and
Tetrakis(triphenylphosphine)palladium (69 mg, 0.06 mmol). The
suspension was heated at reflux for 15 h under Ar atmosphere and
cooled to rt. It was added EtOAc (100 mL) and washed with brine (80
mL), water (80 mL), and dried over MgSO.sub.4. After solvent
removal, the residue was chromatographed (hexane/EtOAc) to afford
tert-butyl 4'-(benzyloxy)-2'-nitrobiphenyl-4-ylcarbamate as a
yellow solid (740 mg, 88%). .sup.1H NMR (400 MHz, CDCl.sub.3)
.delta. 7.44-7.34 (m, 8H), (d, J=8.4 Hz, 1H), 7.20-7.16 (m, 3H),
6.50 (s, 1H), 5.12 (s, 2H), 1.51 (s, 9H); MS (ESI) m/z 443
(M+Na.sup.+).
[0271] A suspension of tert-butyl
4'-(benzyloxy)-2'-nitrobiphenyl-4-ylcarbamate (740 mg, 1.67 mmol)
in 2 mL of triethyl phosphite was heated at 145.degree. C. for 15 h
under Ar atmosphere and cooled to rt. It was added 10 mL of hexane
and let sit for 10 min. Solid was collected via filtration and
washed with ether/hexane (v:v 1/1, 10 mL) and dried under high
vacuum to afford tert-butyl 7-(benzyloxy)-9H-carbazol-2-ylcarbamate
as a off-white solid (480 mg, 74%). .sup.1H NMR (400 MHz, CDCl3)
.delta. 7.89 (s, 1H), 7.83-7.78 (m, 3H), 7.46 (d, J=7.2 Hz, 2H),
7.38 (m, 2H), 7.32 (d, J=7.2 Hz, 1H), 6.94 (d, J=2.0 Hz, 1H), 6.88
(dd, J=8.8, 2.4 Hz, 1H), 6.83 (dd, J=8.4, 2.0 Hz, 1H), 6.60 (s,
1H), 5.15 (s, 2H), 1.52 (s, 9H); MS (ESI) m/z 389 (M+H.sup.+).
[0272] To tert-butyl 7-(benzyloxy)-9H-carbazol-2-ylcarbamate (220
mg, 0.56 mmol) in 50 mL MeOH was added Palladium on activated
carbon (80 mg). The mixture was stirred at rt under H2 atmosphere
for 3 h. Solid was filtered off and the filtrate was concentrated
to afford tert-butyl 7-hydroxy-9H-carbazol-2-ylcarbamate as a brown
solid (165 mg, 100%). This material was used directly for the next
reaction without purification. MS (ESI) m/z 619 (2M+Na.sup.+).
[0273] To tert-butyl 7-hydroxy-9H-carbazol-2-ylcarbamate (165 mg,
0.55 mmol) and 2-(2-(2-fluoroethoxy)ethoxy)ethyl
4-methylbenzenesulfonate (202 mg, 0.66 mmol) in 2 mL of NMP was
added Cs.sub.2CO.sub.3 (179 mg, 0.55 mmol). The mixture was stirred
at rt for 15 h under Ar atmosphere and diluted with EtOAc (50 mL).
It was washed with water (3.times.50 mL) and dried over MgSO.sub.4.
After solvent removal, the residue was chromatographed
(hexane/EtOAc) to afford tert-butyl
7-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-9H-carbazol-2-ylcarbamate as
a white solid (130 mg, 55%). .sup.1H NMR (400 MHz, CDCl3) .delta.
7.94 (s, 1H), 7.83-7.79 (m, 3H), 6.91 (d, J=2.0 Hz, 1H), 6.86 (dd,
J=8.4, 2.0 Hz, 1H), 6.83 (dd, J=8.8, 2.4 Hz, 1H), 6.63 (s, 1H),
4.64 (m, 1H), 4.51 (m, 1H), 4.21 (m, 2H), 3.91 (m, 2H), 3.81-3.71
(m, 6H), 1.55 (s, 9H); MS (ESI) m/z 433 (M+H.sup.+).
[0274] To tert-butyl
7-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-9H-carbazol-2-ylcarbamate
(130 mg, 0.3 mmol) was added 10 mL of a 4 M HCl in dioxane
solution. The mixture was stirred at rt for 5 h and concentrated
under reduced pressure. The residue was washed with ether (15 mL)
and suspended in EtOAc (50 mL). To this suspension was added 10 mL
of a NaHCO.sub.3 (sat.) and the mixture was stirred for 5 min. The
organic layer was dried over MgSO.sub.4 and concentrated to afford
7-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-9H-carbazol-2-amine as a
brown solid (95 mg, 95%). MS (ESI) m/z 333 (M+H.sup.+).
[0275] A mixture of
7-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-9H-carbazol-2-amine (95 mg,
0.28 mmol), paraformaldehyde (43 mg, 1.43 mmol), and NaOMe (492 mg,
25% MeOH solution, 2.3 mmol) in 8 mL of MeOH was heated at reflux
for 1.5 h under Ar atmosphere and cooled to rt. To this mixture was
added NaBH.sub.4 (54 mg, 1.43 mmol) and the mixture was heated at
reflux for 2 h. After cooling to rt, the mixture was quenched onto
ice. It was extracted with ether (3.times.30 mL) and the combined
organic phase was dried over MgSO.sub.4 and concentrated. The crude
product was purified with chromatography (hexane/EtOAc) to afford
7-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-N-methyl-9H-carbazol-2-amine
(AD-CB-003P-WZ0141) as a light-brown solid (55 mg, 56%). .sup.1H
NMR (400 MHz, CDCl3) .delta. 7.76 (s, 1H), 7.77 (t, J=8.8 Hz, 2H),
6.78 (dd, J=8.0, 2.0 Hz, 1H), 6.77 (s, 1H), 6.53 (dd, J=8.4, 2.0
Hz, 1H), 6.46 (s, 1H), 4.62 9 m, 1H), 4.50 (m, 1H), 4.13 (t, J=5.2
Hz, 2H), 3.85 (t, J=5.2 Hz, 2H), 3.83 (s, 1H), 3.79-3.67 (m, 6H),
2.87 (s, 3H); MS (ESI) m/z 347 (M+H.sup.+).
AD-CB-004Pa-WZ01179
##STR00122##
[0277] To tert-butyl 7-(benzyloxy)-9H-carbazol-2-ylcarbamate (200
mg, 0.51 mmol) was added 10 mL of a 4 M HCl in dioxane solution.
The mixture was stirred at rt for 4 h and concentrated under
reduced pressure. The residue was washed with ether (15 mL) and
suspended in EtOAc (50 mL). To this suspension was added 10 mL of a
NaHCO.sub.3 (sat.) and the mixture was stirred for 5 min. The
organic layer was dried over MgSO.sub.4 and concentrated to afford
7-(benzyloxy)-9H-carbazol-2-amine as a brown solid (150 mg, 100%).
.sup.1H NMR (400 MHz, DMSO-d6) .delta. 11.33 (s, 1H), 7.99 (d,
J=8.4 Hz, 1H), 7.92 (d, J=8.8 Hz, 1H), 7.42 (d, J=6.8 Hz, 2H),
7.34-7.21 (m, 3H), 7.27-7.23 (m, 1H), 7.00-6.97 (m, 2H), 6.81 (dd,
J=8.8, 2.4 Hz, 1H), 5.12 (s, 2H); MS (ESI) m/z 289 (M+H.sup.+).
[0278] A mixture of 7-(benzyloxy)-9H-carbazol-2-amine (150 mg, 0.52
mmol), paraformaldehyde (78 mg, 2.6 mmol), and NaOMe (900 mg, 25%
MeOH solution, 4.16 mmol) in 15 mL of MeOH was heated at reflux for
2 h under Ar atmosphere and cooled to rt. To this mixture was added
NaBH.sub.4 (98 mg, 2.6 mmol) and the mixture was heated at reflux
for 2 h. After cooling to rt, the mixture was quenched onto ice (30
g). It was extracted with EtOAc (3.times.50 mL) and the combined
organic phase was dried over MgSO.sub.4 and concentrated. The crude
product was purified with chromatography (hexane/EtOAc) to afford
7-(benzyloxy)-N-methyl-9H-carbazol-2-amine as a light-brown solid
(130 mg, 82%). .sup.1H NMR (400 MHz, acetone-d6) .delta. 9.78 (s,
1H), 7.72 (d, J=8.4 Hz, 1H), 7.66 (d, J=8.8 Hz, 1H), 7.49 (d, J=7.2
Hz, 2H), 7.37 (m, 2H), 7.32-7.28 (m, 1H), 6.98 (d, J=2.4 Hz, 1H),
6.78 (dd, J=8.4, 2.4 Hz, 1H), 6.56 (d, J=2.0 Hz, 1H), 6.49 (dd,
J=8.4, 2.4 Hz, 1H), 5.13 (s, 2H), 4.96 (s, 1H), 2.82 (s, 3H); MS
(ESI) m/z 303 (M+H.sup.+).
[0279] To 7-(benzyloxy)-N-methyl-9H-carbazol-2-amine (120 mg, 0.4
mmol), formic acid (55 mg, 1.2 mmol) and DMAP (5 mg, 0.04 mmol) in
3 mL of pyridine was added portionwise EDC (230 mg, 1.2 mmol). The
mixture was stirred at rt for 3 h under Ar atmosphere and
concentrated under reduced pressure. The residue was diluted with
EtOAc (50 mL) and washed with water (2.times.50 mL), 0.5 M HCl
(2.times.50 mL), and brine (50 mL), and dried over MgSO.sub.4.
After solvent removal, the crude product was purified with
chromatography (hexane/EtOAc) to afford
N-(7-(benzyloxy)-9H-carbazol-2-yl)-N-methylformamide as a white
solid (110 mg, 83%). .sup.1H NMR (400 MHz, acetone-d6) .delta.
10.34 (s, 1H), 8.49 (s, 1H), 8.02 (d, J=8.4 Hz, 1H), 7.98 (d, J=8.8
Hz, 1H), 7.51 (d, J=7.2 Hz, 2H), 7.39 (m, 2H), 7.34-7.28 (m, 1H),
7.13 (d, J=2.4 Hz, 1H), 7.08 (dd, J=8.4, 2.4 Hz, 1H), 6.91 (dd,
J=8.4, 2.4 Hz, 1H), 5.19 (s, 2H), 3.31 (s, 3H); MS (ESI) m/z 331
(M+H.sup.+).
[0280] To N-(7-(benzyloxy)-9H-carbazol-2-yl)-N-methylformamide (110
mg, 0.33 mmol) in 50 mL MeOH was added Palladium on activated
carbon (50 mg). The mixture was stirred at rt under H2 atmosphere
for 15 h. Solid was filtered off and the filtrate was concentrated
to afford N-(7-hydroxy-9H-carbazol-2-yl)-N-methylformamide as a
brown solid (75 mg, 94%). This material was used directly for the
next reaction without purification. MS (ESI) m/z 241
(M+H.sup.+).
[0281] To N-(7-hydroxy-9H-carbazol-2-yl)-N-methylformamide (45 mg,
0.187 mmol) and 2-(2-(2-fluoroethoxy)ethoxy)ethyl
4-methylbenzenesulfonate (172 mg, 0.38 mmol) in 0.5 mL NMP was
added Cs.sub.2CO.sub.3 (65 mg, 0.2 mmol). The mixture was stirred
at rt for 15 h under Ar atmosphere and diluted with EtOAc (50 mL).
It was washed with water (2.times.50 mL), 0.5 M HCl (50 mL) and
brine (50 mL), and dried over MgSO.sub.4. Solvent was removed under
reduced pressure and the crude product was purified with silica
chromatography (hexane/EtOAc) to afford
2-(2-(2-(7-(N-methylformamido)-9H-carbazol-2-yloxy)ethoxy)ethoxy)ethyl
4-methylbenzenesulfonate (AD-CB-004Pa-WZ01179) as a light-brown oil
(48 mg, 48%). .sup.1H NMR (400 MHz, CDCl3) .delta. 8.52 (s, 1H),
8.45 (s, 1H), 7.95 (d, J=8.4 Hz, 1H), 7.90 (d, J=8.8 Hz, 1H),
7.80-7.77 (m, 2H), 7.30 (d, J=8.0 Hz, 2H), 7.17 (d, J=2.4 Hz, 1H),
7.02 (d, J=2.0 Hz, 1H), 7.01 (dd, J=8.0, 2.0 Hz, 1H), 6.89 (dd,
J=8.8, 2.4 Hz, 1H), 4.23 (m, 1H), 4.17 (m, 2H), 3.88 (m, 2H),
3.72-3.68 (m, 4H), 3.66-3.61 (m, 2H), 3.39 (s, 3H), 2.41 (s, 3H);
MS (ESI) m/z 527 (M+H.sup.+).
AD-CB-004Pb-WZ01191
##STR00123##
[0283] To N-(7-(benzyloxy)-9H-carbazol-2-yl)-N-methylformamide (140
mg, 0.42 mmol) in 5 mL dry THF at 0.degree. C. under Ar atmosphere
was added NaH (50 mg, 60% in oil, 1.26 mmol) in 4 portions. The
mixture was then stirred at rt for 20 min followed by the addition
of tert-butyl phenyl carbonate (244 mg, 1.26 mmol) with a syringe.
The reaction was allowed to stir at rt for 3 h and quenched onto
ice (30 g). The mixture was extracted with EtOAc (2.times.40 mL)
and the combined organic phase was dried over MgSO.sub.4. After
solvent removal, the residue was chromatographed to afford
tert-butyl
2-(benzyloxy)-7-(N-methylformamido)-9H-carbazole-9-carboxylate as a
white solid (120 mg, 66%). .sup.1H NMR (400 MHz, CDCl3) .delta.
8.56 (s, 1H), 8.15 (s, 1H), 7.98 (s, 1H), 7.86 (d, J=8.4 Hz, 1H),
7.83 (d, J=8.4 Hz, 1H), 7.50-7.49 (m, 2H), 7.43-7.39 (m., 2H),
7.37-7.32 (m, 1H), 7.13 (dd, J=8.4, 2.0 Hz, 1H), 7.05 (dd, J=8.8,
2.4 Hz, 1H), 5.18 (s, 2H), 3.41 (s, 3H), 1.75 (s, 9H); MS (ESI) m/z
431 (M+H.sup.+).
[0284] To tert-butyl
2-(benzyloxy)-7-(N-methylformamido)-9H-carbazole-9-carboxylate (120
mg, 0.28 mmol) in 50 mL MeOH was added Palladium on activated
carbon (50 mg). The mixture was stirred at rt under H2 atmosphere
for 3 h. Solid was filtered off and the filtrate was concentrated
to afford tert-butyl
2-hydroxy-7-(N-methylformamido)-9H-carbazole-9-carboxylate as a
brown solid (95 mg, 100%). This material was used directly for the
next reaction without purification. MS (ESI) m/z 341
(M+H.sup.+).
[0285] To tert-butyl
2-hydroxy-7-(N-methylformamido)-9H-carbazole-9-carboxylate (65 mg,
0.19 mmol) and 2-(2-(2-fluoroethoxy)ethoxy)ethyl
4-methylbenzenesulfonate (174 mg, 0.38 mmol) in 0.5 mL NMP was
added Cs.sub.2CO.sub.3 (68 mg, 0.21 mmol). The mixture was stirred
at rt for 15 h under Ar atmosphere and diluted with EtOAc (80 mL).
It was washed with water (3.times.50 mL), and dried over
MgSO.sub.4. Solvent was removed under reduced pressure and the
crude product was purified with silica chromatography
(hexane/EtOAc) to afford tert-butyl
2-(N-methylformamido)-7-(2-(2-(2-(tosyloxy)ethoxy)ethoxy)ethoxy)-9H-carba-
zole-9-carboxylate (AD-CB-004Pb-WZ01191) as a clear oil (75 mg,
63%). .sup.1H NMR (400 MHz, CDCl3) .delta. 8.56 (s, 1H), 8.14 (s,
1H), 7.89 (s, 1H), 7.87 (d, J=8.0 Hz, 1H), 7.83 (d, J=8.8 Hz, 1H),
7.79 (m, 2H), 7.32 (d, J=8.4 Hz, 2H), 7.15 (dd, J=8.4, 2.0 Hz, 1H),
7.00 (dd, J=8.8, 2.4 Hz, 1H), 4.23 (m, 1H), 3.89 (m, 2H), 3.88 (m,
2H), 3.73-3.68 (m, 4H), 3.66-3.63 (m, 2H), 3.41 (s, 3H), 2.42 (s,
3H), 1.76 (s, 9H); MS (ESI) m/z 527 (M+H.sup.+).
AD-CB-010S-WZ01183
##STR00124##
[0287] To 4-(benzyloxy)-1-chloro-2-nitrobenzene (394 mg, 1.5 mmol)
N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)formamide
(370 mg, 1.5 mmol) in 6 mL dioxane was added 3 mL of a 1 M
Na.sub.2CO.sub.3 (aq) solution and
Tetrakis(triphenylphosphine)palladium (52 mg, 0.045 mmol). The
suspension was heaed at reflux for 15 h under Ar atmosphere and
cooled to rt. It was added EtOAc (80 mL) and washed with brine (50
mL), water (2.times.80 mL), and dried over MgSO.sub.4. After
solvent removal, the residue was chromatographed (hexane/EtOAc) to
afford N-(4'-(benzyloxy)-2'-nitrobiphenyl-4-yl)formamide as a
yellow solid (395 mg, 75%). MS (ESI) m/z 349 (M+H.sup.+).
[0288] A suspension of
N-(4'-(benzyloxy)-2'-nitrobiphenyl-4-yl)formamide (350 mg, 1 mmol)
in 2 mL of triethyl phosphite was heated at 145 C for 15 h under Ar
atmosphere and cooled to rt. It was added 10 mL of hexane and let
sit for 10 min. Solid was collected via filtration and washed with
ether/hexane (v:v 1/1, 10 mL) and dried under high vacuum to
N-(7-(benzyloxy)-9H-carbazol-2-yl)formamide as a light-brown solid
(280 mg, 88%). MS (ESI) m/z 317 (M+H.sup.+).
[0289] To N-(7-(benzyloxy)-9H-carbazol-2-yl)formamide (250 mg, 0.79
mmol) in 50 mL MeOH was added Palladium on activated carbon (60
mg). The mixture was stirred at rt under H2 atmosphere for 15 h.
The mixture was concentrated under reduced pressure and dried under
high vacuum to afford N-(7-hydroxy-9H-carbazol-2-yl)formamide mixed
with the catalyst as a black solid (240 mg). This material was used
directly for the next reaction without purification. MS (ESI) m/z
227 (M+H.sup.+).
[0290] To N-(7-hydroxy-9H-carbazol-2-yl)formamide (30 mg) and
2-(2-(2-fluoroethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (48 mg,
0.156 mmol) in 0.3 mL of NMP was added Cs.sub.2CO.sub.3 (42 mg,
0.13 mmol). The mixture was stirred at rt for 15 h under Ar
atmosphere and diluted with EtOAc (30 mL). It was washed with water
(3.times.30 mL) and dried over MgSO.sub.4. After solvent removal,
the residue was chromatographed (hexane/EtOAc) to
N-(7-(2-fluoroethoxy)-9H-carbazol-2-yl)formamide
(AD-CB-010S-WZ01183) as a white solid (17 mg, 36%). For the major
rotomer: .sup.1H NMR (400 MHz, acetone-d6) .delta. 10.10 (s, 1H),
9.28 (s, 1H), 8.39 (d, J=1.6 Hz, 1H), 8.11 (d, J=2.0 Hz, 1H), 7.91
(s, 1H), 7.87 (d, J=8.4, Hz, 2H), 7.17 (dd, J=8.4, 2.0 Hz, 1H),
7.01 (d, J=2.0 Hz, 1H), 6.80 (dd, J=8.4, 2.0 Hz, 1H), 4.58 (m, 1H),
4.46 (m, 1H), 4.21 (m, 2H), 3.88 (m, 2H), 3.77 (m, 1H), 3.73-3.66
(m, 5H); MS (ESI) m/z 361 (M+H.sup.+).
AD-CB-012S-WZ01185
##STR00125##
[0292] Compound AD-CB-012S-WZ01185 was prepared using the same
procedure for the preparation of AD-CB-010S-WZ01183. For the major
rotomer: .sup.1H NMR (400 MHz, acetone-d6) .delta. 10.08 (s, 1H),
9.19 (s, 1H), 8.26 (d, J=1.6 Hz, 1H), 8.00 (d, J=2.0 Hz, 1H),
7.84-7.77 (m, 3H), 7.07 (dd, J=8.4, 2.0 Hz, 1H), 6.93 (d, J=2.0 Hz,
1H), 6.69 (dd, J=8.4, 2.0 Hz, 1H), 4.73 (m, 1H), 4.61 (m, 1H), 4.24
(m, 1H), 4.17 (m, 1H); MS (ESI) m/z 273 (M+H.sup.+).
AD-CB-024S-WZ02033
##STR00126##
[0294] Compound AD-CB-024S-WZ02033 was prepared using the same
procedure for the preparation of AD-CB-010S-WZ01183. For the major
rotomer: .sup.1H NMR (400 MHz, acetone-d6) .delta. 10.19 (s, 1H),
9.31 (s, 1H), 8.38 (d, J=1.6 Hz, 1H), 8.11 (d, J=2.0 Hz, 1H), 7.88
(d, J=8.2 Hz, 2H), 7.19 (dd, J=8.4, 2.0 Hz, 1H), 7.03 (d, J=2.0 Hz,
1H), 6.79 (dd, J=8.4, 2.0 Hz, 1H), 4.62 (m, 1H), 4.50 (m, 1H), 4.20
(m, 2H), 3.88 (m, 2H), 3.83 (m, 1H), 3.75 (m, 1H); MS (ESI) m/z 317
(M+H.sup.+).
AD-CB-013S-WZ-02001
##STR00127##
[0296] A mixture of palladium acetate (37 mg, 0.165 mmol) and BINAP
(154 mg, 0.248 mmol) in 5 mL dioxane was stirred for 10 min under
Ar atmosphere. To this mixture was added 1-bromo-4-nitrobenzene
(1.11 g, 5.5 mmol), 4-methoxyaniline (745 mg, 6.07 mmol),
CsCO.sub.3 (2.5 g, 7.73 mmol), and 10 mL of dioxane. The mixture
was heated at reflux for 15 h and cooled and diluted with ether (80
mL). The solid was removed through filtration and the filtrate was
concentrated. The residue was chromatographed (hexane/EtOAc) to
afford 4-methoxy-N-(4-nitrophenyl)aniline as a yellow solid (786
mg, 58%). MS (ESI) m/z 245 (M+H.sup.+).
[0297] To 4-methoxy-N-(4-nitrophenyl)aniline (785 mg, 3.2 mmol) in
5 mL of AcOH was added Pd(OAc)2 (1.43 g, 6.4 mmol). The mixture was
heated at 100.degree. C. for 15 h under air atmosphere and cooled
to rt and concentrated under reduced pressure. The residue was
taken up in EtOAc (100 mL) and washed with NaHCO.sub.3 (2.times.100
mL) and water (100 mL). After solvent removal, the crude was
purified with chromatography (hexane/EtOAc) to afford
3-methoxy-6-nitro-9H-carbazole as a orange solid (495 mg, 64%).
.sup.1H NMR (400 MHz, acetone-d6) .delta. 10.90 (s, 1H), 9.09 (d,
J=2.4 Hz, 1H), 8.27 (dd, J=9.2, 2.4 Hz, 1H), 7.96 (d, J=2.4 Hz,
1H), 7.62 (d, J=9.2 Hz, 1H), 7.53 (d, J=8.8 Hz, 1H), 7.14 (dd,
J=8.8, 2.8 Hz, 1H), 3.92 (s, 3H); MS (ESI) m/z 243 (M+H.sup.+).
[0298] To 3-methoxy-6-nitro-9H-carbazole (100 mg, 0.41 mmol) in 40
mL MeOH was added Palladium on activated carbon (50 mg). The
mixture was stirred at rt under H2 atmosphere for 5 h. Solid was
filtered off and the filtrate was concentrated to afford
6-methoxy-9H-carbazol-3-amine as a brown solid (80 mg, 92%). This
material was used directly for the next reaction without
purification. MS (ESI) m/z 213 (M+H.sup.+).
[0299] To 6-methoxy-9H-carbazol-3-amine (16 mg, 0.075 mmol) and
1-bromo-2-fluoroethane (48 mg, 0.375 mmol) in 0.3 mL of NMP was
added Cs.sub.2CO.sub.3 (30 mg, 0.09 mmol). The mixture was stirred
at rt for 72 h under Ar atmosphere and diluted with EtOAc (30 mL).
It was washed with water (3.times.30 mL) and dried over MgSO.sub.4.
After solvent removal, the residue was purified by reversed-phase
HPLC (buffer A: 0.05% aqueous TFA; buffer B: 0.05% TFA in MeCN) to
afford a light-brown wax (5 mg, 26%). .sup.1H NMR (400 MHz,
acetone-d6) .delta. 7.75 (s, 1H), 7.67 (s, 1H), 7.52 (d, J=2.4 Hz,
1H), 7.35 (t, J=9.6 Hz, 2H), 7.14 (d, J=8.0 Hz, 1H), 7.00 (dd,
J=8.8, 2.4 Hz, 1H), 4.81 (t, J=5.2 Hz, 1H), 4.69 (t, J=4.8 Hz, 1H),
3.89 (s, 3H); MS (ESI) m/z 259 (M+H.sup.+).
Synthetic Scheme of CB 14-16, 19 and 20
##STR00128##
[0300] 7-((4-fluorobutyl)(methyl)amino)-9H-carbazol-2-ol
(CB-14)
##STR00129##
[0302] To a round bottom flask containing Compound 6 (21 mg, 0.073
mmol) in DMF (1 ml), were added cesium carbonate (28.5 mg, 0.087
mmol) and 1-bromo-4-fluorobutane (56.4 mg, 0.364 mmol). The
reaction was stirred at rt for 30 min. The reaction was work-up
with EtOAc (15 mL.times.3) and water (10 mL). The organic layers
were washed with brine (10 mL), dried and concentrated in vacuo.
The residue was dissolved in MeOH (10 ml). To the reaction mixture,
was added Pd/C (22 mg). The mixture was stirred at rt overnight
under hydrogen (1 atm). The reaction was filtered through a celite
plug, concentrated in vacuo and purified on HPLC to afford CB-14
(11 mg, 0.029 mmol, 40.3% yield). .sup.1H-NMR (400 MHz, CD.sub.3OD)
.delta.: 8.74 (d, J=8.4 Hz, 1H), 7.85 (d, J=8.4 Hz, 1H), 7.53 (s,
1H), 7.25 (d, J=8.0 Hz, 1H), 6.85 (s, 1H), 6.73 (d, J=8.4 Hz, 1H),
4.44 (m, 1H), 4.32 (m, 1H), 3.70 (m, 2H), 3.35 (s, 3H), 1.74-1.67
(m, 4H); LRMS for C.sub.19H.sub.19F.sub.4N.sub.2O.sub.2+H.sup.+,
calc'd: 384.1. found: 287.2 (M+H.sup.+-TFA).
7-((2-fluoroethyl)(methyl)amino)-9H-carbazol-2-ol (CB-15)
##STR00130##
[0304] To a round bottom flask containing Compound 6 (37 mg, 0.122
mmol) in DMF (0.5 ml), were added cesium carbonate (47.8 mg, 0.147
mmol) and 1-bromo-2-fluoroethane (78 mg, 0.612 mmol). The reaction
was stirred at rt for 30 min. The reaction was work-up with EtOAc
(15 mL.times.3) and water (10 mL). The organic layers were washed
with brine (10 mL), dried and concentrated in vacuo. The residue
was dissolved in MeOH (10 ml). To the reaction mixture, was added
Pd/C (22 mg). The mixture was stirred at rt overnight under
hydrogen (1 atm). The reaction was filtered through a celite plug,
concentrated in vacuo and purified on HPLC to afford CB-15 (5 mg,
0.019 mmol, 7.3% yield). .sup.1H-NMR (400 MHz, CD.sub.3CN) .delta.:
7.96 (d, J=8.0 Hz, 1H), 7.87 (d, J=8.4 Hz, 1H), 7.31 (d, J=2.0 Hz,
1H), 7.05 (dd, J=8.0 Hz, 2.0 Hz, 1H), 6.90 (d, J=2.0 Hz, 1H), 6.76
(dd, J=8.0 Hz, 2.0 Hz, 1H), 4.86 (m, 1H), 4.74 (m, 1H), 4.60-4.52
(m, 2H), 3.28 (br, 1H), 3.03 (s, 3H); LRMS for
C.sub.17H.sub.15F.sub.4N.sub.2O.sub.2+H.sup.+, calc'd: 356.1.
found: 259.2 (M+H.sup.+-TFA).
7-(2-fluoroethylamino)-9H-carbazol-2-ol (CB-16)
##STR00131##
[0306] To a round bottom flask containing Compound 5 (21 mg, 0.073
mmol) in DMF (1 ml), were added cesium carbonate (28.5 mg, 0.087
mmol) and 1-bromo-2-fluoroethane (46 mg, 0.36 mmol). The reaction
was stirred at rt for 72 hours. The reaction was work-up with EtOAc
(15 mL.times.3) and water (10 mL). The organic layers were washed
with brine (10 mL), dried and concentrated in vacuo. The residue
was dissolved in MeOH (10 ml). To the reaction mixture, was added
Pd/C (20 mg). The mixture was stirred at rt overnight under
hydrogen (1 atm). The reaction was filtered through a celite plug,
concentrated in vacuo and purified on HPLC to afford CB-16 (5 mg,
0.015 mmol, 20% yield). .sup.1H-NMR (400 MHz, CD.sub.3CN) .delta.:
9.00 (br, 1H), 7.77-7.73 (m, 2H), 6.82 (s, 1H), 6.81 (s, 1H),
6.72-6.65 (m, 2H), 4.71 (m, 1H), 4.60 (m, 1H), 3.60-3.50 (m, 2H);
LRMS for C.sub.16H.sub.13F.sub.4N.sub.2O.sub.2.+-.H.sup.+, calc'd:
342.3. found: 245.1 (M+H.sup.+-TFA).
7-42-(2-(2-fluoroethoxy)ethoxy)ethyl)(methyl)amino)-9H-carbazol-2-ol
(CB-19)
##STR00132##
[0308] To a round bottom flask containing Compound 6 (41 mg, 0.14
mmol) in DMF (0.5 ml), were added cesium carbonate (53 mg, 0.16
mmol) and 2-(2-(2-fluoroethoxy)ethoxy)ethyl
4-methylbenzenesulfonate (125 mg, 0.407 mmol). The reaction was
stirred at rt for 4 weeks. The reaction was work-up with EtOAc (15
mL.times.3) and water (10 mL). The organic layers were washed with
brine (10 mL), dried and concentrated in vacuo. The residue was
dissolved in MeOH (10 ml). To the reaction mixture, was added Pd/C
(20 mg). The mixture was stirred at rt overnight under hydrogen
atmosphere (1 atm). The reaction was filtered through a celite
plug, concentrated in vacuo and purified on HPLC to afford CB-19 (7
mg, 0.020 mmol, 14% yield. .sup.1H-NMR (400 MHz, CD.sub.3CN)
.delta.: 9.43 (br, 1H), 8.07 ((d, J=8.4 Hz, 1H), 7.91 (d, J=8.4 Hz,
1H), 7.58 (d, J=2.4 Hz, 1H), 7.24 (dd, J=8.0 Hz, 2.0 Hz, 1H), 6.93
(d, J=2.0 Hz, 1H), 6.77 (dd, J=8.0 Hz, 2.0 Hz, 1H), 4.59 (m, 1H),
4.52 (m, 1H), 3.74-3.50 (m, 10H), 3.28 (s, 3H); LRMS for
C.sub.21H.sub.23F.sub.4N.sub.2O.sub.4+Na.sup.+, calc'd: 444.2.
found: 347.2 (M+H.sup.+-TFA).
7-(2-fluoroethoxy)-N-methyl-9H-carbazol-2-amine (CB-20)
##STR00133##
[0310] To a round bottom flask containing Compound 6 (90 mg, 0.29
mmol) in MeOH (10 ml), were added Pd/C (20 mg). The reaction was
purged with hydrogen and stirred at rt for 2 h under hydrogen
atmosphere (1 atm). The reaction was filtered through a celite plug
concentrated in vacuo to afford a dark solid (60 mg, 0.28 mmol, 95%
yield). To a round bottom flask containing the above dark solid (15
mg, 0.071 mmol) in DMF (0.5 mL), was added cesium carbonate (21 mg,
0.65 mmol) and 2-bromo-1-fluoroethane (8.1 mg, 0.065 mmol). The
reaction was stirred at rt overnight. The reaction was concentrated
in vacuo via MeCN co-evaporation. The residue was purified on HPLC
to afford CB-20 (7.0 mg, 0.027 mmol, 38% yield). .sup.1H NMR (400
MHz, CD.sub.3CN) .delta.: 9.52 (br, 1H), 7.91-7.86 (m, 2H), 7.13
(s, 1H), 7.02 (s, 1H), 6.88 (d, J=7.6 Hz, 1H), 6.82 (dd, J=7.6 Hz,
J=2.4 Hz 1H), 4.85 (m, 1H), 4.72 (m, 1H), 4.34-4.25 (m, 2H), 2.96
(s, 3H); LRMS for C.sub.17H.sub.15N.sub.2O.sub.2+H.sup.+, calc'd:
356.1. found: 259.1 (M+H.sup.+-TFA).
Synthetic Scheme of CB 25, 26
##STR00134##
[0311] 4'-(benzyloxy)-2'-nitrobiphenyl-4-ol (Compound 7)
##STR00135##
[0313] A round bottom flask charged with Compound 2 (1.96 g, 7.44
mmol), 4-Hydroxyphenylboronic acid pinacol ester (1.56 g, 7.09
mmol), terakis(triphenylphosphine) palladium (0.410 g, 0.354 mmol),
were purged with Argon. To the mixture, was added DME (10 ml) and
potassium carbonate (1.96 g, 14.2 mmol) in Water (2 ml). The
mixture was heated for 60 hours. The reaction was diluted with HCl
(1N, 10 mL) and brine (40 mL), then extracted with EtOAc (50
mL.times.3). The combined organic layer were washed with Brine (50
mL), dried (MgSO4) and concentrated in vacuo. The residue was
purified on a silica gel column (EtOAc:Hexanes=1:4) to afford
Compound 7 as a yellow solid (2 g, 6.22 mmol, 88% yield).
.sup.1H-NMR (400 MHz, CDCl.sub.3) .delta.: 7.45-7.33 (m, 7H),
7.37-7.15 (m, 3H), 6.88-6.85 (m, 2H), 5.14 (s, 2H), 5.03 (s, 1H);
LRMS for C.sub.19H.sub.15NO.sub.4+H.sup.+, calc'd: 322.1. found:
322.1 (M+H.sup.+).
7-(benzyloxy)-9H-carbazol-2-ol (Compound 8)
##STR00136##
[0315] To a pressure resistant vial, was added Compound 7 (2.00 g,
6.22 mmol and Triethyl phosphite (6.53 ml, 37.3 mmol. The mixture
was heated to 160.degree. C. overnight. The reaction mixture was
concentrated in vacuo. The residue was suspended in chloroform (20
mL), solid precipitate formed and was filtered and washed with
ether (10 mL.times.2) to afford Compound 8 (900 mg, 3.11 mmol,
50.0% yield). .sup.1H-NMR (400 MHz, DMSO) .delta.: 10.81 (br, 1H),
9.25 (br, 1H), 7.80 (d, J=8.4 Hz, 1H), 7.72 (d, J=8.4 Hz, 1H),
7.50-7.33 (m, 5H), 6.95 (s, 1H), 6-78-6.76 (m, 2H), 6.56 (dd,
J=8.4, 2.0 Hz 1H), 5.16 (s, 2H); LRMS for
C.sub.19H.sub.15NO.sub.2+H.sup.+, calc'd: 290.1. found: 290.1
(M+H.sup.+).
7-(2-fluoroethoxy)-9H-carbazol-2-ol (CB-25)
##STR00137##
[0317] To a round bottom flask containing Compound 8 (50 mg, 0.17
mmol) in DMF (1 ml), was added cesium carbonate (62 mg, 0.19 mmol)
and 1-bromo-2-fluoroethane (33 mg, 0.26 mmol). The reaction was
stirred at rt for 15 h and then diluted with water (15 mL). White
precipitate (50 mg) was collected via filtration and dried in vacu.
The solid was dissolved in MeOH (10 mL). To the reaction, was added
Pd/C (30 mg) and acetic acid (5 drops). The mixture was stirred
under hydrogen (1 atm) atmosphere for 20 h and then filtered
through a celite plug, concentrated in vacuo. The residue was
purified on HPLC to afford CB-25 (18 mg, 0.053 mmol, 31% yield).
.sup.1H NMR (400 MHz, CD.sub.3CN) .delta.: 8.99 (br, 1H), 7.72 (d,
J=8.4 Hz, 1H), 7.67 (d, J=8.4 Hz, 1H), 6.88 (d, J=2.0 Hz, 1H), 6.76
(d, J=2.0 Hz, 1H), 6.67 (dd, J=8.0 Hz, 2.0 Hz, 1H), 6.58 (dd, J=8.0
Hz, 2.0 Hz, 1H), 4.75-4.74 (m, 1H), 4.63-4.61 (m, 1H), 4.23-4.13
(m, 2H); LRMS for C.sub.16H.sub.12F.sub.4NO.sub.3+H.sup.+, calc'd:
343.1. found: 246.0 (M+H.sup.+-TFA).
7-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-9H-carbazol-2-ol (CB-26)
##STR00138##
[0319] To a round bottom flask containing Compound 8 (50 mg, 0.17
mmol) in DMF (1 ml), was added cesium carbonate (56 mg, 0.17 mmol)
and 2-(2-(2-fluoroethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (53
mg, 0.17 mmol). The reaction was stirred at rt for 15 h and then
diluted with water (15 mL). White precipitate (72 mg) was collected
via filtration and dried in vacou. The solid was dissolved in MeOH
(10 mL). To the reaction, was added Pd/C (20 mg) and acetic acid (5
drops). The mixture was stirred under hydrogen (1 atm) atmosphere
for 20 h and then filtered through a celite plug and concentrated
in vacuo. The residue was purified on HPLC to afford CB-26 (20 mg,
0.046 mmol, 27% yield). .sup.1H NMR (400 MHz, CD.sub.3CN) .delta.:
9.03 (br, 1H), 7.81-7.75 (m, 2H), 6.96 (d, J=2.4 Hz, 1H), 6.84 (d,
J=2.4 Hz, 1H), 6.76 (dd, J=7.6 Hz, 2.0 Hz, 1H), 6.67 (dd, J=7.6 Hz,
2.0 Hz, 1H), 4.59-4.57 (m, 1H), 4.47-4.45 (m, 1H), 4.17-4.15 (m,
2H), 3.83-3.63 (m, 8H); LRMS for C.sub.20H.sub.20NO.sub.5+H.sup.+,
calc'd: 431.1. found: 334.1 (M+H.sup.+-TFA).
Synthetic Scheme of CB 27
##STR00139##
[0320] tert-butyl 7-hydroxy-9H-carbazol-2-ylcarbamate (Compound
9)
##STR00140##
[0322] To a round bottom flask containing Compound 4 (1.0 g, 2.6
mmol) in MeOH (150 mL), was added palladium on charcoal (400 mg).
The flask was purged with hydrogen gas and stirred under hydrogen
atmosphere overnight. The reaction mixture was filtered through a
celite plug and concentrated to afford Compound 9 as a grey solid
(700 mg, 2.34 mmol, 90% yield). .sup.1H NMR (400 MHz,
(CD.sub.3).sub.2CO) .delta.: 9.99 (br, 1H), 8.41 (br, 1H), 8.24 (s,
1H), 7.86 (s, 1H), 7.81-7.78 (m, 2H), 7.18 (dd, J=8.4 Hz, 2.0 Hz,
1H), 6.90 (d, J=2.0 Hz, 1H), 6.70 (dd, J=8.4 Hz, 2.0 Hz, 1H), 1.51
(s, 9H).
tert-butyl 7-(4-nitrophenoxy)-9H-carbazol-2-ylcarbamate (Compound
10)
##STR00141##
[0324] To a round bottom flask containing Compound 9 (80 mg, 0.268
mmol) in DMF (2 mL) was added potassium carbonate (74.1 mg, 0.536
mmol) and 4-fluoro-nitrobenzene (41.6 mg, 0.295 mmol). The reaction
mixture was heated for 20 min at 140.degree. C. After cooling down
to rt, the mixture was diluted with water (20 mL) and extracted
with EtOAc (20 mL.times.3). The organic layers were dried,
concentrated. The residue was purified on a silica gel column
(EtOAc:Hexanes=3:7) to afford Compound 10 as a yellow solid (50 mg,
0.12 mmol, 44% yield). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta.:
8.22 (d, J=9.2 Hz, 2H), 8.10 (br, 1H), 8.00-7.90 (m, 3H), 7.12 (s,
1H), 7.06-6.90 (m, 4H), 6.70 (br, 1H), 1.56 (s, 9H); LRMS for
C.sub.23H.sub.21N.sub.3O.sub.5+H.sup.+, calc'd: 420.2. found: 420.2
(M+H.sup.+).
tert-butyl 7-(4-nitrophenoxy)-9H-carbazol-2-ylcarbamate (CB-27)
##STR00142##
[0326] To a round bottom flask containing Compound 10 (35 mg, 0.083
mmol) in MeOH (5 mL), was added palladium on charcoal (10 mg). The
flask was purged with hydrogen gas and stirred under hydrogen
atmosphere overnight. The reaction mixture was filtered through a
silica gel plug and concentrated to afford the amine intermediate
(23 mg). To a vial containing 2-fluoropropanoic acid (10.87 mg,
0.118 mmol) in DCM (1 mL), was added EDC (22.64 mg, 0.118 mmol) and
DMAP (1 mg). The mixture was stirred at rt for 5 min. The above
amine intermediate was dissolved in DCM (1 ml) and added into the
reaction vial dropwise. The reaction mixture was stirred at rt from
3 hour. The reaction mixture was then washed with water (3 mL) and
concentrated. The residue was redissolved in HCl (4.0 M in dioxane,
5 mL) and stirred overnight. The mixture was concentrated and
purified on HPLC to afford CB-27 (12 mg, 0.026 mmol, 31% yield).
.sup.1H NMR (400 MHz, CD.sub.3CN) .delta.: 9.42 (br, 1H), 8.69 (br,
1H), 7.92 (d, J=8.4 Hz, 1H), 7.87 (d, J=8.4 Hz, 1H), 7.60 (m, 2H),
7.04-7.01 (m, 4H), 6.86 (d, J=8.0 Hz, 1H), 6.84 (d, J=8.0 Hz, 1H),
5.11 (dt, J=49.2, 6.8 Hz, 1H), 1.58 (dd, J=24.8, 6.8 Hz, 3H); LRMS
for C.sub.23H.sub.18F.sub.4N.sub.3O.sub.3+H.sup.+, calc'd: 460.1.
found: 364.1 (M+H.sup.+-TFA).
Experimental Section for the Preparation of Carbazole
Derivatives
##STR00143##
[0327] 4-(Benzyloxy)-N-(4-nitrophenyl)aniline 1
[0328] To a oven dried flask was charged with Pd(OAc).sub.2 (81 mg,
0.36 mmol) and (S)-(-)-BINAP (336 mg, 0.54 mmol), followed by
toluene (10 mL). The mixture was stirred under Ar at room
temperature for 5 min. To this mixture was added 4-nitroiodobenzene
(3.0 g, 12 mmol), 4-benzyloxyaniline hydrochloride (3.39 g, 14.4
mmol), Cs.sub.2CO.sub.3 (9.8 g, 30 mmol) and toluene (40 mL). The
resulting mixture was heated under Ar at 100.degree. C. for 16 hrs,
and then cooled to room temperature and poured into H.sub.2O (100
mL). The layers were separated. The aqueous layer was extracted
with EtOAc (3.times.20 mL). The combined organic layers were washed
with brine (2.times.20 mL), dried (MgSO.sub.4) and filtered. The
filtrate was concentrated. The residue was purified via column
chromatography (silica gel, 5-40% EtOAc/hexane) to give the desired
product as an orange solid (1.2 g, 31%). .sup.1H NMR (CDCl.sub.3,
400 MHz) .delta.: 8.09 (d, J=9.2 Hz, 2H), 7.30-7.49 (m, 5H), 7.15
(d, J=9.2 Hz, 2H), 7.01 (d, J=9.2 Hz, 2H), 6.77 (d, J=8.8 Hz, 2H),
6.10 (br s, 1H), 5.09 (s, 2H). MS: m/z=321 (M+H.sup.+).sup.+.
3-(Benzyloxy)-9-nitro-9H-carbazole 2
[0329] A mixture of 4-(benzyloxy)-N-(4-nitrophenyl)aniline 1 (0.5
g, 1.56 mmol) and Pd(OAc).sub.2 (0.8 g, 3.56 mmol) in acetic acid
(20 mL) was refluxed and monitored by TLC. After refluxing for 2
hrs, TLC showed that no starting material was present. It was
concentrated in vacuo to remove acetic acid. The residue was
diluted with EtOAc (30 mL), washed with H.sub.2O (20 mL), sat.
NaHCO.sub.3 solution (2.times.20 mL), brine (20 mL), and then dried
(MgSO.sub.4) and filtered. The filtrate was concentrated in vacuo.
The residue was purified via column chromatography (silica gel,
5-40% EtOAc/hexane) to give the desired product 2 as a dark yellow
solid (100 mg, 20%). .sup.1H NMR (acetone-d.sub.6, 400 MHz)
.delta.: 10.92 (br s, 1H), 9.08 (d, J=2.0 Hz, 1H), 8.28 (dd, J=8.8,
2.4 Hz, 1H), 8.07 (d, J=2.4 Hz, 1H), 7.63 (d, J=9.2 Hz, 1H), 7.55
(d, J=8.8 Hz, 3H), 7.40 (t, J=7.2 Hz, 2H), 7.33 (t, J=7.2 Hz, 1H),
7.24 (dd, J=8.8, 2.4 Hz, 1H), 5.26 (s, 2H). MS: m/z=319
(M+H.sup.+).sup.+.
3-Amino-6-(benzyloxy)-9H-carbazole 3
[0330] To a suspension of 3-(benzyloxy)-9-nitro-9H-carbazole 2 (100
mg, 0.31 mmol) and Cu(OAc).sub.2 (57 mg, 0.31 mmol) in EtOH (20 mL)
was added NaBH.sub.4 (240 mg, 6.3 mmol). The resulting mixture was
stirred at room temperature for 3 hrs, and then concentrated in
vacuo. The residue was dissolved in H.sub.2O (30 mL), extracted
with EtOAc (2.times.30 mL). The combined organic layers were dried
(MgSO.sub.4), filtered and concentrated in vacuo to give a solid
(90 mg). It was used directly in the next step without any further
purification. .sup.1H NMR (acetone-d.sub.6, 400 MHz) .delta.: 9.67
(br s, 1H), 7.57 (d, J=2.4 Hz, 1H), 7.52 (d, J=6.8 Hz, 2H), 7.39
(t, J=6.8 Hz, 2H), 7.26-7.33 (m, 3H), 7.19 (d, J=8.8 Hz, 1H), 7.03
(dd, J=8.8, 2.4 Hz, 1H), 6.81 (dd, J=8.8, 2.4 Hz, 1H), 5.17 (s,
2H), 4.24 (br s, 2H). MS: m/z=289 (M+H.sup.+).sup.+.
6-(Benzyloxy)-N-methyl-9H-carbazol-3-amine 4
[0331] To a suspension of 3-amino-6-(benzyloxy)-9H-carbazole 3 (90
mg, 0.31 mmol) and paraformaldehyde (47 mg, 1.57 mmol) in MeOH (20
mL) was added a solution of NaOMe in MeOH (0.32 mL, 1.56 mmol). The
resulting mixture was heated at 80.degree. C. for 1 h, then
NaBH.sub.4 (59 mg, 1.55 mmol) was added. The resulting mixture was
heated at 80.degree. C. for 2 hrs, and then cooled to room
temperature. To this solution was added NaOH (1 N, 30 mL). The
mixture was then extracted with CH.sub.2Cl.sub.2 (3.times.20 mL).
The combined organic layers were dried (MgSO.sub.4), filtered. The
filtrate was concentrated in vacuo to give a brown solid (93 mg,
100%). It was used directly in the next step without any further
purification. .sup.1H NMR (acetone-d.sub.6, 400 MHz) .delta.: 9.68
(br s, 1H), 7.67 (d, J=2.4 Hz, 1H), 7.53 (d, J=7.6 Hz, 2H),
7.20-7.42 (m, 6H), 7.03 (dd, J=8.8, 2.4 Hz, 1H), 6.79 (dd, J=8.4,
2.4 Hz, 1H), 5.17 (s, 2H), 2.85 (s, 3H). MS: m/z=303
(M+H.sup.+).sup.+.
6-(Methylamino)-9H-carbazol-3-ol 5
[0332] A mixture of 6-(benzyloxy)-N-methyl-9H-carbazol-3-amine 4
(93 mg, 0.31 mmol), Pd/C (10 mg) and acetic acid (10 drops) in MeOH
(10 mL) was hydrogenated at room temperature for 1.5 hrs. It was
passed through a short Celite pad. The filtrate was concentrated in
vacuo to give the desired product 5 (66 mg). It was used directly
in the next step without any further purification. MS: m/z=213
(M+H.sup.+).sup.+.
[3-(Benzyloxy)-6-(dimethylamino)-9H-carbazol-9-yl]methanol 7
[0333] To a solution of 6-(benzyloxy)-N-methyl-9H-carbazol-3-amine
4 (110 mg, 0.38 mmol) and aqueous formaldehyde solution (37%, 1.0
mL) in acetonitrile (30 mL) was added NaB(OAc).sub.3 (323 mg, 1.52
mmol). The resulting mixture was stirred at room temperature for 6
hrs, and then concentrated. The residue was dissolved in H.sub.2O
(30 mL), extracted with CH.sub.2Cl.sub.2 (2.times.30 mL). The
combined organic layers were dried (MgSO.sub.4), filtered. The
filtrate was concentrated in vacuo to give the desired product
(0.12 g). It was used directly in the next step without any further
purification. MS: m/z=347 (M+H.sup.+).sup.+.
6-(Dimethylamino)-9-(methoxymethyl)-9H-carbazol-3-ol 8
[0334] A mixture of
[3-(benzyloxy)-6-(dimethylamino)-9H-carbazol-9-yl]methanol 7 (120
mg), Pd/C (100 mg) and acetic acid (cat. amount) in MeOH (15 mL)
was hydrogenated at room temperature for 4 hrs. It was filtered
through a short Celite pad. The filtrate was concentrated in vacuo
to give the desired product (94 mg, 100%). .sup.1H NMR
(acetone-d.sub.6, 400 MHz) .delta.: 7.38-7.50 (m, 4H), 7.05 (dd,
J=8.8, 2.4 Hz, 1H), 6.97 (dd, J=8.4, 2.4 Hz, 1H), 5.62 (s, 2H),
3.20 (s, 3H), 2.94 (s, 6H). MS: m/z=271 (M+H.sup.+).sup.+.
##STR00144##
[0335] General Procedures for the Preparation of O-Alkylated
Carbazole Derivatives
[0336] To a solution of carbazol-3-ol derivatives (1 eq.) and
Cs.sub.2CO.sub.3 (1.5 eq.) in DMF (10 mL) was added a solution of
2-(2-(2-fluoroethoxy)ethoxy)ethyl-4-methylbenzenesulfonate (1.2
eq.) in DMF (1.0 mL). The resulting mixture was stirred at room
temperature overnight, and then concentrated in vacuo. The residue
was purified via column chromatography (silica gel, 5-50%
EtOAc/hexane) to provide the desired products.
6-(2-(2-(2-Fluoroethoxy)ethoxy)ethoxy)-N-methyl-9H-carbazol-3-amine
6
[0337] (3 mg, 5%). .sup.1H NMR (acetone-d.sub.6, 400 MHz) .delta.:
7.59 (d, J=2.4 Hz, 1H), 7.28-7.33 (m, 2H), 7.26 (d, J=8.4 Hz, 1H),
6.97 (dd, J=8.8, 2.4 Hz, 1H), 6.85 (dd, J=8.8, 2.0 Hz, 1H), 4.51
(dt, J=48, 4.0 Hz, 2H), 4.19 (t, J=4.4 Hz, 2H), 3.61-3.88 (m, 8H),
3.87 (s, 3H). MS: m/z=347 (M+H.sup.+).sup.+.
6-(2-(2-(2-Fluoroethoxy)ethoxy)ethoxy)-9-(methoxymethyl)-N,N-dimethyl-9H-c-
arbazol-3-amine 9
[0338] (50 mg, 36%). .sup.1H NMR (acetone-d.sub.6, 400 MHz)
.delta.: 7.68 (d, J=2.4 Hz, 1H), 7.46-7.52 (m, 3H), 7.04-7.08 (m,
2H), 5.66 (s, 2H), 4.52 (dt, J=48.4, 4.4 Hz, 2H), 4.21 (t, J=4.8
Hz, 2H), 3.63-3.87 (m, 8H). MS: m/z=405 (M+H.sup.+).sup.+.
##STR00145##
[0339] General Procedures for the Preparation of Acylated Carbazole
Derivatives:
[0340] To a solution of
2-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-9H-carbazole (1.0 eq.) in
DMF (3.0 mL) was added NaH (excess). After stifling at room
temperature for 5 min, an acyl halide (excess) was added. The
resulting mixture was stirred at room temperature overnight, and
then concentrated in vacuo. The residue was purified via column
chromatography (silica gel, 0-40% EtOAc/hexane) to give the desired
product.
##STR00146##
1-(2-(2-(2-(2-Fluoroethoxy)ethoxy)ethoxy)-9H-carbazol-9-yl)ethanone
[0341] (4 mg, 36%). .sup.1H NMR (CDCl3, 400 MHz) .delta.: 8.21 (d,
J=8.0 Hz, 1H), 7.99-8.25 (m, 2H), 7.94 (d, J=2.4 Hz, 1H), 7.36-7.46
(m, 2H), 7.06 (dd, J=8.4, 2.4 Hz, 1H), 4.52 (dt, J=48, 4.4 Hz, 2H),
4.27 (t, J=4.4 Hz, 2H), 3.89 (t, J=8.8 Hz, 2H), 3.64-3.78 (m, 6H),
2.91 (s, 3H). MS: m/z=360 (M+H.sup.+).sup.+.
##STR00147##
1-(2-(2-(2-(2-Fluoroethoxy)ethoxy)ethoxy)-9H-carbazol-9-yl)phenylmethanon-
e
[0342] (51 mg, 78%). .sup.1H NMR (CDCl.sub.3, 400 MHz) .delta.:
7.84-7.92 (m, 2H), 7.62-7.74 (m, 3H), 7.53 (t, J=8.0 Hz, 2H),
7.27-7.33 (m, 2H), 7.17-7.23 (m, 1H), 6.99 (dd, J=8.4, 2.4 Hz, 1H),
4.57 (dt, J=47.6, 4.4 Hz, 2H), 4.06 (t, J=4.8 Hz, 2H), 3.70-3.87
(m, 8H). MS: m/z=422 (M+H.sup.+).sup.+.
Preparation of 2-(7-formamido-9H-carbazol-2-yloxy)ethyl
4-methylbenzenesulfonate: AD-CB-012P-WZ02039
##STR00148##
[0344] Compound 2-(7-formamido-9H-carbazol-2-yloxy)ethyl
4-methylbenzenesulfonate (AD-CB-012P-WZ02039) was prepared using
the same procedure for the preparation of AD-CB-012S-WZ01185) from
N-(7-hydroxy-9H-carbazol-2-yl)formamide (100 mg) and
ethane-1,2-diylbis(4-methylbenzenesulfonate) (325 mg). (white
solid, 22 mg, 12%). For the major rotomer: .sup.1H NMR (400 MHz,
acetone-d6) .delta. 10.19 (s, 1H), 9.31 (s, 1H), 8.38 (d, J=1.6 Hz,
1H), 8.11 (d, J=2.0 Hz, 1H), 7.90-7.81 (m, 4H), 7.45 (d, J=8.4 Hz,
2H), 7.19 (dd, J=8.4, 2.0 Hz, 1H), 6.95 (d, J=2.0 Hz, 1H), 6.69
(dd, J=8.4, 2.0 Hz, 1H), 4.43-4.41 (m, 2H), 4.29-4.27 (m, 2H); MS
(ESI) m/z 425 (M+H.sup.+).
Preparation of N-(7-(4-fluorobutoxy)-9H-carbazol-2-yl)formamide:
AD-CB-30S-WZ02055
##STR00149##
[0346] Compound N-(7-(4-fluorobutoxy)-9H-carbazol-2-yl)formamide
(AD-CB-30S-WZ02055) was prepared using the same procedure for the
preparation of AD-CB-012S-WZ01185) from
N-(7-hydroxy-9H-carbazol-2-yl)formamide (20 mg) and
1-bromo-4-fluorobutane (27 mg). (white solid, 11 mg, 42%). .sup.1H
NMR (400 MHz, acetone-d6) .delta. 10.18 (s, 1H), 9.31 (s, 1H), 8.39
(d, J=2.0 Hz, 1H), 8.11 (d, J=2.0 Hz, 1H), 7.95 (d, J=1.6 Hz, 2H),
7.88 (d, J=2.0 Hz, 1H), 7.20 (dd, J=8.4, 2.0 Hz, 1H), 7.03 (d,
J=2.4 Hz, 1H), 6.79 (dd, J=8.4, 2.4 Hz, 1H), 4.61 (m, 1H), 4.49 (m,
1H), 4.11 (m, 2H), 1.97-1.88 (m, 4H); MS (ESI) m/z 301
(M+H.sup.+).
Preparation of
2-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-9H-pyrido[2,3-b]indol-7-amine
hydrochloride
##STR00150##
[0347] Preparation of WZ02045
[0348] To 4-chloro-3-nitroaniline (2.5 g, 14.5 mmol) in 40 mL DCM
was added TEA (2.9 g, 29 mmol), DMAP (177 mg, 1.45 mmol), and
di-tert-butyl dicarbonate (4.7 g, 21.7 mmol). The mixture was
stirred at rt for 24 h and concentrated. The residue was diluted
with Et2O (100 mL), washed with brine (100 mL), water (100 mL), 0.5
M HCl (2.times.100 mL), and brine (100 mL), dried over MgSO.sub.4
and concentrated. The crude product was purified by silica
chromatography (EtOAc/hexane) to afford tert-butyl
4-chloro-3-nitrophenylcarbamate (WZ02045) as a yellow solid (1.5 g,
38%). MS (ESI) m/z 295 (M+Na.sup.+).
Preparation of WZ02049
[0349] A mixture of tert-butyl 4-chloro-3-nitrophenylcarbamate (818
mg, 3 mmol),
2-(benzyloxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrid-
ine (933 mg, 3 mmol),
tetrakis(triphenylphosphine)palladium (104 mg, 0.09 mmol), 10 mL of
dioxane, and 6 mL of 1 M Na.sub.2CO.sub.3 was heated at reflux for
15 h. It was diluted with 50 mL Et.sub.2O and washed with brine
(2.times.50 mL) and dried over MgSO.sub.4 and concentrated. The
crude product was purified by silica chromatography (EtOAc/hexane)
to afford tert-butyl
4-(6-(benzyloxy)pyridin-3-yl)-3-nitrophenylcarbamate (WZ02049) as a
yellow wax (1.2 g, 95%). MS (ESI) m/z 444 (M+Na.sup.+).
Preparation of WZ02057
[0350] A suspension of above compound (800 mg, 1.9 mmol) in 2 mL of
triethyl phosphite was heated at 148.degree. C. for 15 h. After
cooling, it was concentrated under reduced pressure to remove
volatiles. The crude product was purified by silica chromatography
(EtOAc/hexane) to afford tert-butyl
2-(benzyloxy)-9H-pyrido[2,3-b]indol-7-ylcarbamate (WZ02057) as a
off-white solid (400 mg, 54%). MS (ESI) m/z 390 (M+H.sup.+).
Preparation of WZ02061
[0351] To above compound (220 mg, 0.56 mmol) dissolved in 80 mL
MeOH was added Palladium on activated carbon (80 mg). The mixture
was stirred at rt under H.sub.2 atmosphere for 15 h. Solid was
filtered off and the filtrate was concentrated to afford tert-butyl
2-hydroxy-9H-pyrido[2,3-b]indol-7-ylcarbamate (WZ02061) as a white
solid (105 mg, 100%). This material was used directly for the next
reaction without purification. MS (ESI) m/z 300 (M+H.sup.+).
Preparation of WZ02063
[0352] To above compound (50 mg, 0.167 mmol) in 1 nL of NMP was
added 2-(2-(2-fluoroethoxy)ethoxy)ethyl 4-methylbenzenesulfonate
(76 mg, 0.25 mmol), and Cs.sub.2CO.sub.3 (65 mg, 0.2 mmol). The
mixture was stirred at rt for 15 h and diluted with Et2O (40 mL),
washed with water (3.times.30 mL), and dried over MgSO.sub.4 and
concentrated. The crude product was purified by silica
chromatography (EtOAc/hexane) to afford tert-butyl
2-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-9H-pyrido[2,3-b]indol-7-ylcarbamat-
e (WZ02063) as a clear wax (45 mg, 62%). MS (ESI) m/z 434
(M+H.sup.+).
Preparation of AD-CB-032S-WZ02067
[0353] The above compound (45 mg, 0.1 mmol) was treated with 2 mL
of a 4 M HCl in dioxane solution at rt for 5 h and concentrated
under reduced pressure. The residue was washed with ether (5 mL)
and dried under high vacuum to afford
2-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-9H-pyrido[2,3-b]indol-7-amine
hydrochloride (AD-CB-032S-WZ02067) as a light-yellow solid (23 mg,
62%). .sup.1H NMR (400 MHz, methanol-d4) .delta. 8.42 (d, J=8.4 Hz,
1H), 8.12 (d, J=8.4 Hz, 1H), 7.53 (d, J=2.0 Hz, 1H), 7.21 (dd,
J=8.4, 2.0 Hz, 1H), 6.77 (d, J=8.4 Hz, 1H), 4.58-4.54 (m 3H), 4.43
(m, 1H), 3.91 (m, 2H), 3.76-3.72 (m, 3H), 3.70-3.66 (m, 3H); MS
(ESI) m/z 334 (M+H.sup.+).
Preparation of
2-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-N-methyl-9H-pyrido[2,3-b]indol-7-a-
mine: AD-CB-034S-WZ02069
[0354] Compound AD-CB-034S-WZ02069 was prepared using the same
procedure for the preparation of AD-CB-004S from
2-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-9H-pyrido[2,3-b]indol-7-amine
hydrochloride (AD-CB-032S-WZ02067, 20 mg) (10 mg, 53%). .sup.1H NMR
(400 MHz, methanol-d4) .delta. 8.06 (d, J=8.0 Hz, 1H), 7.66 (d,
J=8.4 Hz, 1H), 6.65 (d, J=2.0 Hz, 1H), 6.58 (dd, J=8.4, 2.0 Hz,
1H), 6.53 (d, J=8.0 Hz, 1H), 4.58 (m 1H), 4.53-4.45 (m, 3H), 3.88
(m, 2H), 3.76 (m, 1H), 3.73-3.67 (m, 5H), 3.03 (s, 3H); MS (ESI)
m/z 348 (M+H.sup.+).
Preparation of 6-bromo-9H-carbazol-2-ol: W138
##STR00151##
[0355] Preparation of WZ02013
[0356] To 9H-carbazol-2-ol (915 mg, 5 mmol) in 10 mL DMF and 20 mL
DCM was added TEA (1.0 g, 10 mmol), followed by acetyl chloride
(589 mg, 7.5 mmol) at 0.degree. C. The reaction mixture was then
stirred at rt for 1 h and poured onto ice (50 g). The mixture was
extracted with EtOAc (2.times.60 mL) and combined organic phase was
dried over MgSO.sub.4 and concentrated. The crude product was
purified by silica chromatography to afford 9H-carbazol-2-yl
acetate (WZ02013) as an off-white solid (800 mg, 71%). MS (ESI) m/z
348 (M+H.sup.+).
Preparation of WZ02025
[0357] To a solution of 9H-carbazol-2-yl acetate (500 mg, 2.2 mmol)
in DCM (40 mL) was added a solution of NBS in 25 mL of DCM dropwise
at rt. The reaction mixture was stirred in the dark for 5 h. It was
washed with water (3.times.50 mL) and dried over MgSO.sub.4 and
concentrated. The crude product was purified by silica
chromatography (EtOAc/hexane) to afford 6-bromo-9H-carbazol-2-yl
acetate (WZ02025) as an off-white solid (250 mg, containing 17%
dibrominated product). MS (ESI) m/z 305 (M+H.sup.+).
Preparation of W138
[0358] A suspension of 6-bromo-9H-carbazol-2-yl acetate (200 mg,
0.65 mmol) in 30 mL MeOH and 4 mL of 1.0 M aqueous LiOH was stirred
for 5 h. It was neutralized with 1 M HCl and concentrated. The
crude product was purified by silica chromatography (EtOAc/hexane)
to afford 6-bromo-9H-carbazol-2-ol (W138) as an off-white solid
(125 mg, containing 15% dibrominated product). .sup.1H NMR (400
MHz, acetone-d6) .delta. 8.58 (s, 1H), 8.10 (d, J=2.0 Hz, 1H), 1H),
7.92 (d, J=8.8 Hz, 1H), 7.42 (dd, J=8.4, 2.0 Hz, 1H), 7.35 (s, 1H),
7.13 (d, J=8.4 Hz, 1H), 6.92 (d, J=2.0 Hz, 1H), 6.76 (dd, J=8.8,
2.0 Hz, 1H); MS (ESI) m/z 263 (M+H.sup.+).
Ex Vivo Competition Assay Using Amyloid (AD Patient's Brain Slice)
Autoradiography Staining
[0359] The carbazole series of AD imaging agents display
surprisingly good qualities when compared to previously established
results performed by others. Data from prior art suggests that
compounds with higher Log P values have higher amyloid affinities,
yet these same compounds can also suffer from high non-specific
binding, i.e poor brain washout (J. Molecular Neuroscience 2003,
20, 255-260). For the disclosed studies in this application, c Log
P values were used in place of Log P values.
[0360] A study was conducted to examine the grey to white matter
binding ratios for 4 different tracers: CB-001, CB-003, FDDNP and
F-PiB (FIG. 7 and FIG. 8 of U.S. Ser. No. 12/372,717). A known
carbazole containing imaging agent, 18F-fluorocarazolol, was not
examined in this study because of its relatively low c Log P value
(2.77) compared to FDDNP and PiB, and its competing specific uptake
into the beta-adrenoceptors. In addition, there is no prior art
data suggesting that 18F-fluorocarazolol binds to AD plaques. After
the human brain slices from AD patients were incubated with a given
tracer for 30 min, the slices were washed with various EtOH:water
solutions in an attempt to optimize the grey to white matter ratios
(FIG. 9 of U.S. Ser. No. 12/372,717). The results were surprising
and unexpected in view of previous work performed by other
researchers. CB-001 has a slightly higher c Log P than FDDNP (3.8
vs 3.4) and would be expected to have poorer washout than FDDNP
based on these values. However, despite the difference in c Log P
values, CB-001 has a lower non-specific binding propensity and
displays a much better grey to white matter ratio compared to FDDNP
(see section above, "original wash"). More specifically, the white
matter binding of FDDNP is several shades darker than CB-001's
white matter binding, indicating low non-specific binding of
CB-001. In contrast, F-PiB, which has a c Log P value of 3.99, also
displays reasonable, binding ratios similar to CB-001, albeit
displaying a very weak overall signal. The washing data suggests
that the carbazoles are a viable and novel target for imaging
AD-related targets due to their unique binding and washout
properties.
[0361] To expand on these results, CB-003, a tracer with a c Log P
value similar to FDDNP, was prepared and tested. Using washing
conditions that were far milder than the harsh washing conditions
(FIG. 9 of U.S. Ser. No. 12/372,717), CB-003 displayed excellent
grey to white matter binding ratios that are far superior to the
results taken from FDDNP, PiB and CB-001. These favorable and
unique results suggest that CB-003 would have a more favorable
brain washout in living systems, leading to more specific uptake
and lowered non-specific binding, leading to a clear advantage over
FDDNP and PiB imaging.
Summary of Washing Results:
TABLE-US-00007 [0362] Grey/white matter Grey/white binding ratio
matter binding using harsh ratio using FDDNP wash mild wash Name
Structure cLogP conditions* conditions** CB-001 ##STR00152## 3.789
Excellent Poor CB-003 ##STR00153## 3.4032 N/A Excellent *published
FDDNP wash conditions: 30 min incubation of CB-1 or CB-3 tracer,
PBS wash (5 mm),70% EtOH:water (1 min), 90% EtOH:water (1 min), 70%
EtOH:water (1 min), PBS (5 min). The brain slices were 20 um thick.
**mild wash conditions: 30 min incubation of CB-1 or CB-3 tracer,
PBS wash (5 min), 30% EtOH:water (2 min), 40% EtOH:water (2 min),
20% EtOH:water (2 min), PBS (5 min). The brain slices were 20 um
thick.
[0363] The results demonstrate that 1) PiB blocks [18F]-CB001
staining with increasing concentrations, suggesting the two
compounds to compete for the same amyloid binding pockets; 2) PiB
appears to block tracer binding with the same strength as cold
CB001, suggesting both to have similar binding affinities; 3) FDDNP
is much less capable of blocking [18F]-CB001 staining, due to its
lower amyloid binding affinity.
[0364] This data suggests the following order of (non-specific)
white matter binding:
FDDNP>CB001>[18F]-PiB>CB003
[0365] IC50 Determination with [18F]-PiB by Ex Vivo Competition
Assay Using Autoradiography Staining
TABLE-US-00008 Compound IC50 Average SD Code 1 2 3 4 5 6 7 8 9 10
11 12 13 IC50 SD % F-PiB 43 43 40 50 55 41 45 6 13 PiB 80 40 40 48
60 43 50 280 52 14 28 CB7 260 170 200 290 300 244 57 23 CB4 260 350
300 300 400 322 54 17 CB12 610 300 450 390 438 130 30 CB24 540 540
CB1 1000 480 740 368 50 CB10 900 900 CB3 1100 900 920 973 110
11
[0366] To further demonstrate the efficiency of employing these
CB-related tracers as AD imaging agents, CB-003 was used to clearly
differentiate between a healthy brain and an AD brain (FIG. 10 of
U.S. Ser. No. 12/372,717). More specifically, by using the mild
wash protocol, the amyloid deposits were clearly visible in the
grey matter with little white matter uptake. The results were
corroborated by both antibody IHC and thioflaving T amyloid
staining, confirming the specificity of uptake. These surprising
results demonstrate that this tracer possess the unique quality of
rapid washout from white matter and significant high uptake in grey
matter that is specific for AD plaques.
[0367] The carbazoles compete directly against 18F-PiB for the same
binding sites in human AD brains (FIG. 11 of U.S. Ser. No.
12/372,717). This surprising result could not have been predicted
given their dissimilar structures and CB-003's lack of a phenolic
OH and terminal NH-Me group, which are deemed essential for binding
to AD plaques. Despite CB-003 lacking both of these functional
groups, it still competes with 18F-PiB for binding sites in human
AD brains. Because of the simplicity of its structure, the labeling
yields of CB-001 and CB-003 are exceptionally high and better than
the labeling yields of 18F-PiB.
Surface Plasmon Resonance (SPR) Assay
[0368] An assay was developed using a Biacore instrument that
introduced the ligands over gold-surface immobilized target
proteins and measured the resultant rates of association and
disassociation in order to test various compounds that bind to
soluble AD oligomers, polymers and fibrils (FIGS. 12 to 17 of U.S.
Ser. No. 12/372,717).
[0369] The carbazole series also demonstrated a unique and
surprising ability to bind favorably and preferentially to
insoluble aggregates (9 nM) over soluble aggregates (262 nM) (FIG.
12 and FIG. 13 of U.S. Ser. No. 12/372,717). PiB also binds well to
insoluble aggregates (16 nM) but also binds essentially equally as
well to soluble aggregates (48 nM) (FIG. 14 and FIG. 15 of U.S.
Ser. No. 12/372,717). For imaging applications where it is
favorable to distinguish between a tracer's binding to insoluble
versus soluble aggregates, CB-003 provides a larger binding ratio
of 29:1, whereas PiB only provides a ratio 3:1. Thus, CB-003 may
provide more selective binding information relative to PiB. The
results indicate that 1) for soluble aggregate binding,
PIB>CB3>CB4; and 2) for insoluble aggregate binding,
PIB=CB3>CB4.
MicroPET Imaging with [18F]-CB-001 or [18F]-CB-003 in WT and App
Mice
[0370] The results demonstrate that 1) WT and App mice show
statistically significant differences in tracer retention in the
brain (FIG. 18A, FIG. 18B and FIG. 19 of U.S. Ser. No. 12/372,717);
2) App mice show up to 25% larger brain/muscle ratios compared to
WT mice (FIG. 20 and FIG. 21 of U.S. Ser. No. 12/372,717). The
carbazoles display both a surprising high uptake in mice brains
(both WT and APP) and sufficiently slow washout such that one can
distinguish WT from APP mice (FIG. 22 and FIG. 23 of U.S. Ser. No.
12/372,717). Without being bound by any theory proposed herein, we
speculate that the reason behind these results may be that CB-003
possesses a faster washout rate than 18F-PiB, which is consistent
with consistent with the staining data: 18F-PiB requires harsher
wash conditions in order to give reasonable grey to white matter
ratios. The rapid washout of CB-003 is presumably a major factor
for its low non-specific binding, yet the washout is slow enough to
distinguish WT from APP. This suggests that the carbazoles display
a unique combination of excellent washout and retention properties
in human AD brains that are not obvious from prior art data.
CB-003, being a neutral compound, would also potentially possess
greater uptake values versus zwitterionic-based imaging agents such
as methylene blue.
7-(3-Fluoropropyl)-3-methyl-5H-pyrido[3,2-b]indole*TFA: T793
##STR00154##
[0372] General experimental procedure for carbazole formation was
followed. Reaction was performed on a 8.9 mg scale of
2-(4-(3-fluoropropyl)phenyl)-5-methyl-3-nitropyridine. Isolated 3.6
mg (45%) of T793 as a white solid. .sup.1H NMR (CD.sub.3OD):
.delta. 8.48 (1H, d, J=1.6 Hz), 8.39 (1H, d, J=1.6 Hz), 8.21 (1H,
d, J=8.4 Hz), 7.55 (1H, d, J=1.6 Hz), 7.34 (1H, d, J=8.4, 1.6 Hz),
4.52 (1H, t, J=6.0 Hz), 4.40 (1H, t, J=6.0 Hz), 2.97 (2H, t, J=7.6
Hz), 2.68 (3H, s), 2.03-2.15 (2H, m); MS: 243 (M+H.sup.+).
7-(2-Fluoroethyl)-5H-pyrido[4,3-b]indole: T805
##STR00155##
[0374] General experimental procedure for carbazole formation was
followed. (Same for T794.) Reaction was performed on a 28.5 mg
scale of 3-(4-(2-fluoroethyl)phenyl)-4-nitropyridine. Isolated 13.3
mg (54%) of T805 as a white solid. .sup.1H NMR (CD.sub.3OD):
.delta. 9.14 (1H, d, J=1.2 Hz), 8.31 (1H, d, J=5.6 Hz), 8.07 (1H,
dd, J=8.0, 0.8 Hz), 7.40-7.43 (2H, m, overlapped), 7.17 (1H, dd,
J=8.0, 1.6 Hz), 4.72 (1H, t, J=6.4 Hz), 4.60 (1H, t, J=6.4 Hz),
3.17 (1H, t, J=6.4 Hz), 3.11 (1H, t, J=6.4 Hz); MS: 215
(M+H.sup.+).
7-(2-(2-(2-Fluoroethoxy)ethoxy)ethyl)-5H-pyrido[4,3-b]indole:
T813
##STR00156##
[0376] To a solution of tert-butyl
7-(2-hydroxyethyl)-5H-pyrido[4,3-b]indole-5-carboxylate (9.0 mg,
0.0288 mmol) in DMF (1.0 mL) was added NaH (60% in mineral oil, 3.6
mg, 0.09 mmol). The mixture was stirred for 15 min before
2-(2-fluoroethoxy)ethyl 4-methylbenzenesulfonate (23 mg, 0.0878
mmol) was added. The mixture was stirred at room temperature for
1.5 hours. The mixture was diluted with DCM and washed with water
twice. The DCM layer was separated and added TFA (10% TFA in DCM).
Reaction was stirred at room temperature for 1 hour. The mixture
was concentrated and purified by HPLC (acetonitrile/water) to give
4.5 mg (52%) of T813 as a white solid. .sup.1H NMR (CD.sub.3OD):
.delta. 9.46 (1H, d, J=1.6 Hz), 8.51 (1H, dd, J=6.8, 0.8 Hz), 8.28
(1H, d, J=8.8 Hz), 8.09 (1H, dd, J=6.8, 0.4 Hz), 7.76 (1H, d, J=0.8
Hz), 7.45 (1H, dd, J=8.4, 1.6 Hz), 4.79 (2H, m), 4.36 (1H, m), 4.25
(1H, m), 3.98 (2H, t, J=5.0 Hz), 3.88 (2H, t, J=6.8 Hz), 3.60 (1H,
m), 3.53 (1H, m), 3.08 (2H, t, J=6.8 Hz); MS: 303 (M+H.sup.+).
Synthesis of T757 and T758
##STR00157##
[0377] Preparation of 3-(3-nitropyridin-2-yl)phenol
[0378]
[1,1'-Bis(diphenylphosphino)ferrocnee]dichloropalladium(II),w/DCM
(0.039 g, 0.047 mmol) was added to a solution containing
3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (0.292 g,
1.325 mmol), 2-chloro-3-nitropyridine (0.15 g, 0.946 mmol),
Copper(I) iodide (0.018 g, 0.095 mmol) and Potassium carbonate
(0.946 ml, 1.892 mmol). Heated the reaction to 110.degree. C. for
15 mins. Cooled reaction to room temperature. Diluted with water
and extracted with ethyl acetate. Combined organics, dried,
filtered, concentrated and purified to afford
3-(3-nitropyridin-2-yl)phenol (0.1 g, 0.463 mmol, 48.9% yield).
Preparation of 2-(3-(2-fluoroethoxy)phenyl)-3-nitropyridine
[0379] Sodium hydride 60% (0.021 g, 0.925 mmol) was added to a
solution containing 3-(3-nitropyridin-2-yl)phenol (0.2 g, 0.925
mmol) and 1-Bromo-2-fluoroethane (0.138 ml, 1.850 mmol) in DMF
(Volume: 3.08 ml). The reaction was stirred for 2 hours. Diluted
reaction with water and extracted with ethyl acetate. Combined
organics, dried, filtered, and purified by ISCO column using 35%
ethyl acetate in hexanes to afford
2-(3-(2-fluoroethoxy)phenyl)-3-nitropyridine (0.11 g, 0.419 mmol,
45.3% yield).
Preparation of T757 and T758
[0380] 2-(3-(2-fluoroethoxy)phenyl)-3-nitropyridine (0.11 g, 0.419
mmol) in Triethyl phosphite (1.100 ml, 6.29 mmol) was heated to
125.degree. C. for 6 hours. Cooled the reaction to room
temperature, concentrated, and purified by PREP HPLC to afford T757
(0.005 g, 0.022 mmol, 5.18% yield) MS (ESI, Pos.) m/z: 231.0
[M+H].sup.+ and T758 (0.005 g, 0.022 mmol, 5.18% yield) MS (ESI,
Pos.) m/z: 231.0 [M+H].sup.+.
Synthesis of T789
##STR00158##
[0381] Preparation of
6'-fluoro-5-nitro-6-phenyl-3,3'-bipyridine
[0382]
[1,1'-Bis(diphenylphosphino)ferrocnee]dichloropalladium(II),w/DCM
(7.32 mg, 8.96 .mu.mol) was added to a solution containing
5-bromo-3-nitro-2-phenylpyridine (0.05 g, 0.179 mmol),
(6-fluoropyridin-3-yl)boronic acid (0.025 g, 0.179 mmol), Copper(I)
iodide (3.41 mg, 0.018 mmol) and Potassium carbonate (0.134 ml,
0.269 mmol) in DMF (Volume: 0.597 ml). Heated the reaction in a
microwave at 110.degree. C. for 15 minutes. Let the reaction cool
to room temperature. Diluted reaction with water, dried, filtered,
concentrated and purified with Combiflash using 0% to 25% ethyl
acetate in hexanes to afford
6'-fluoro-5-nitro-6-phenyl-3,3'-bipyridine (0.03 g, 0.102 mmol,
56.7% yield).
Preparation of T789
[0383] 6'-fluoro-5-nitro-6-phenyl-3,3'-bipyridine (0.03 g, 0.102
mmol) and Triethyl phosphite (1 ml, 5.72 mmol) was heated to
125.degree. C. for 3 hours. Let the reaction cool to room
temperature. Concentrated and purified by PREP HPLC to afford T789
(0.002 g, 7.60 .mu.mol, 7.48% yield) MS (ESI, Pos.) m/z: 264.0
[M+H]+.
Synthesis of T810
##STR00159##
[0384] Preparation of 5-(benzyloxy)-2-bromopyridine
[0385] Benzyl bromide (1.367 ml, 11.49 mmol) was added to a
solution containing 6-bromopyridin-3-ol (2 g, 11.49 mmol) and
Potassium carbonate (2.383 g, 17.24 mmol) in Acetone (Volume: 38.3
ml). Let the reaction stir for 4 hours. Concentrated and purified
by Combiflash using 15% ethyl acetate in hexanes to afford
5-(benzyloxy)-2-bromopyridine (2.5 g, 9.47 mmol, 82% yield).
Preparation of 5-(benzyloxy)-2-(2-nitrophenyl)pyridine
[0386]
[1,1'-Bis(diphenylphosphino)ferrocnee]dichloropalladium(II),w/DCM
(0.077 g, 0.095 mmol) was added to a solution containing
(2-nitrophenyl)boronic acid (0.316 g, 1.893 mmol),
5-(benzyloxy)-2-bromopyridine (0.5 g, 1.893 mmol), Copper(I) iodide
(0.036 g, 0.189 mmol) and Potassium carbonate (1.420 ml, 2.84 mmol)
in DMF (Volume: 6.31 ml). Let the reaction cool to room
temperature. Diluted reaction with water, extracted with ethyl
acetate, combined organics, dried, filtered and concentrated.
Purified with Combiflash using 15% ethyl acetate in hexanes to
afford 5-(benzyloxy)-2-(2-nitrophenyl)pyridine (0.3 g, 0.979 mmol,
51.7% yield).
Preparation of 3-(benzyloxy)-5H-pyrido[3,2-b]indole
[0387] Triethyl phosphite (3 ml, 17.15 mmol) and
5-(benzyloxy)-2-(2-nitrophenyl)pyridine (0.3 g, 0.979 mmol) were
heated to 125.degree. C. for 4 hours. Let the reaction cool to room
temperature. Concentrated and purified with Combiflash column using
ethyl acetate followed by 15% methanol in DCM to afford
3-(benzyloxy)-5H-pyrido[3,2-b]indole (0.09 g, 0.328 mmol, 33.5%
yield).
Preparation of 5H-pyrido[3,2-b]indol-3-ol
[0388] 3-(benzyloxy)-5H-pyrido[3,2-b]indole (0.09 g, 0.328 mmol)
and Palladium 10% on carbon (0.035 g, 0.033 mmol) in MeOH (Volume:
5 ml) was stirred under hydrogen for 2 hours. Filtered and
concentrated to afford 5H-pyrido[3,2-b]indol-3-ol (0.06 g, 0.326
mmol, 99% yield).
Preparation of T810
[0389] Sodium hydride 60% (0.019 g, 0.489 mmol) was added to a
solution containing 2-(2-(2-fluoroethoxy)ethoxy)ethyl
4-methylbenzenesulfonate (0.100 g, 0.326 mmol),
5H-pyrido[3,2-b]indol-3-ol (0.06 g, 0.326 mmol) in DMF (Volume:
1.086 ml). The reaction was stirred for 2 hours. Concentrated and
purified by PREP HPLC to afford T810 (0.006 g, 0.019 mmol, 5.79%
yield) MS (ESI, Pos.) m/z: 319.0 [M+H].sup.+.
##STR00160##
3-(4-(4-Nitropyridin-3-yl)phenyl)propan-1-ol
[0390] A mixture of boronic ester (524 mg, 2 mmol), bromide (406
mg, 2 mmol), Pd (0) (116 mg, 0.1 mmol), and Na2CO3 solution (1 M, 4
mL) in 8 mL of dioxane was heated at 90 C for 10 min in a microwave
reactor. After cooling to rt, the mixture was extracted with EtOAc
(3.times.20 mL) and the organic phase was dried over MgSO4 and
concentrated. The crude product was purified with silica
chromatography (EtOAc/hexane, 5% to 90%) to afford the title
compound as a yellow oil (412 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): .delta. 8.83-8.79 (m, 2H), 7.64 (dd, J=5.2, 0.8 Hz,
1H), 7.38 (d, J=8.4 Hz, 2H), 7.32 (d, J=8.4 Hz, 2H), 3.71 (t, J=6.2
Hz, 2H), 2.79 (t, J=7.6 Hz, 2H), 1.94 (m, 2H); MS (ESI) m/z
[M+H].sup.+ 259.
3-(4-(3-Fluoropropyl)phenyl)-4-nitropyridine
[0391] To 3-(4-(4-nitropyridin-3-yl)phenyl)propan-1-ol (60 mg, 0.23
mmol) in 2 mL of dry DCM at 0.degree. C. was added
(Diethylamino)sulfur trifluoride (111 mg, 0.69 mmol) dropwise. The
reaction was warmed to rt and stirred for 1 h and quenched onto ice
(20 g) in saturated Na.sub.2CO.sub.3 (20 mL). The mixture was
extracted with EtOAc (2.times.30 mL) and the organic phase was
dried over MgSO.sub.4 and concentrated. The residue was purified by
silica chromatography (EtOAc in hexane, 5% to 30%) to afford
3-(4-(3-fluoropropyl)phenyl)-4-nitropyridine as a pale-yellow oil
(12 mg, 20%). .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 8.82-8.80
(m, 2H), 7.64 (d, J=5.2, 1H), 7.33-7.27 (m, 2H), 4.55 (t, J=5.6 Hz,
1H), 4.43 (t, J=5.6 Hz, 1H), 2.82 (t, J=7.6 Hz, 2H), 2.12-1.99 (m,
2H); MS (ESI) m/z [M+H].sup.+ 261.
7-(3-Fluoropropyl)-5H-pyrido[4,3-b]indole
[0392] A solution of 3-(4-(3-fluoropropyl)phenyl)-4-nitropyridine
(12 mg, 0.046 mmol) in 0.3 mL of triethyl phosphate was heated at
125.degree. C. for 1 h. After cooling to rt, the volatiles were
removed under reduced pressure and the residue was purified by
silica chromatography (MeOH in DCM, 0% to 10%) to afford a
off-white solid. This material was then further purified by
reversed phase HPLC to yield
7-(3-fluoropropyl)-5H-pyrido[4,3-b]indole as a white solid (3 mg,
28%). .sup.1H NMR (400 MHz, methanol-d4): .delta. 9.15 (s, 1H),
8.32 (d, J=4.4, 1H), 8.07 (d, J=8.0 Hz, 1H), 7.44 (d, J=6 Hz, 1H),
7.37 (m, 1H), 7.16 (dd, J=8.0, 1.2 Hz, 1H), 4.50 (t, J=6 Hz, 1H),
4.43 (t, J=6 Hz, 1H), 2.90 (t, J=7.6 Hz, 2H), 2.12-1.99 (m, 2H); MS
(ESI) m/z [M+H].sup.+ 229.
2-(5-Fluoropent-1-yn-1-yl)benzo[4,5]imidazo[1,2-a]pyrimidine
(T806)
[0393] To 5-(benzo[4,5]imidazo[1,2-a]pyrimidin-2-yl)pent-4-yn-1-ol
(20 mg, 0.08 mmol) in 1 mL dry DCM at 0.degree. C. was added
(Diethylamino)sulfur trifluoride (64 mg, 0.4 mmol) dropwise. The
reaction was warmed to rt and stirred for 1 h and quenched onto a
mixture of ice (10 g) in saturated Na.sub.2CO.sub.3 (10 mL). The
mixture was extracted with EtOAc (2.times.10 mL) and the organic
phase was dried over MgSO.sub.4 and concentrated. The residue was
purified by silica chromatography (EtOAc in DCM, 5% to 50%) to
afford 2-(5-fluoropent-1-yn-1-yl)benzo[4,5]imidazo[1,2-a]pyrimidine
as a yellow oil (3 mg, 15%). .sup.1H NMR (400 MHz, CDCl.sub.3):
.delta. 8.65 (d, J=6.8 Hz, 1H), 8.03 (d, J=8 Hz, 1H), 7.85 (d, J=8
Hz, 1H), 7.58 (m, 1H), 7.43 (m, 1H), 6.93 (d, J=7.2 Hz, 1H), 4.69
(t, J=5.6 Hz, 1H), 4.57 (t, J=5.6 Hz, 1H), 2.70 (t, J=5.6 Hz, 2H),
2.14-2.00 (m, 2H); MS (ESI) m/z [M+H].sup.+ 254.
##STR00161##
4-(5-Bromo-3-nitropyridin-2-yl)phenol
[0394] A mixture of
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (300 mg, 1.36
mmol), 2,5-dibromo-3-nitropyridine (383 mg, 1.36 mmol),
tetrakis(triphenylphosphine)palladium (31 mg, 0.027 mmol),
Na.sub.2CO.sub.3 (4.3 mL, 2 M aqueous), 4.3 mL toluene, and 2.1 mL
EtOH was vigorously stirred at 55.degree. C. for 2 h. After cooling
to rt, the volatiles were removed under reduced pressure and the
residue was purified with silica chromatography (EtOAc in hexane,
5% to 35%) to afford 4-(5-bromo-3-nitropyridin-2-yl)phenol as a
yellow wax (285 mg, 71%). MS (ESI) m/z [M+H].sup.+ 295, 297.
5-Bromo-2-(4-(methoxymethoxy)phenyl)-3-nitropyridine
[0395] To a mixture of 4-(5-bromo-3-nitropyridin-2-yl)phenol (280
mg, 0.95 mmol) and DIPEA (360 mmg, 2.85 mmol) in 5 mL of dry DCM at
0.degree. C. was added dropwise chloro(methoxy)methane (210 mg, 1.9
mmol). The reaction was warmed to rt and stifling was continued for
3 h and the diluted with EtOAc (30 mL), washed with water
(3.times.30 mL) and dried over MgSO.sub.4. Solvent was removed
under reduced pressure and the residue was purified by silica
chromatography (EtOAc in hexane, 5% to 35%) to afford
5-bromo-2-(4-(methoxymethoxy)phenyl)-3-nitropyridine as a yellow
wax (260 mg, 80%). MS (ESI) m/z [M+H].sup.+ 339, 341.
6'-Fluoro-6-(4-(methoxymethoxy)phenyl)-5-nitro-3,3'-bipyridine
[0396] A mixture of
5-bromo-2-(4-(methoxymethoxy)phenyl)-3-nitropyridine (68 mg, 0.2
mmol),
2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
(45 mg, 0.2 mg), tetrakis(triphenylphosphine)palladium (12 mg, 0.01
mmol), Na.sub.2CO.sub.3 (0.5 mL, 1 M aqueous solution) and dioxane
(1.5 mL) was heated at 100.degree. C. for 10 min in a microwave
reactor. After cooling to rt, the reaction was diluted with EtOAc
(20 mL) and washed with brine (20 mL) and water (2.times.20 mL) and
dried over MgSO.sub.4. Solvent was removed under reduced pressure
and the residue was purified by silica chromatography (EtOAc in
hexane, 5% to 40%) to afford
6'-fluoro-6-(4-(methoxymethoxy)phenyl)-5-nitro-3,3'-bipyridine as a
yellow solid (48 mg, 67%). MS (ESI) m/z [M+H].sup.+ 356.
2-Fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
(T783)
[0397] A solution of
6'-fluoro-6-(4-(methoxymethoxy)phenyl)-5-nitro-3,3'-bipyridine (45
mg, 0.12 mmol) in 1 mL of triethyl phosphate was heated at
125.degree. C. for 4 h. After cooling to rt, volatiles was removed
under reduced pressure and the residue was purified by silica
chromatography (EtOAc in hexane, 10% to 100%) to afford
2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
(T783) as a off-white solid (8 mg, 20%). .sup.1H NMR (400 MHz,
CDCl.sub.3): .delta. 9.00 (d, J=1.6 Hz, 1H), 8.52 (d, J=1.6 Hz,
1H), 8.24 (d, J=2.4 Hz, 1H), 8.06 (td, J=8.4, 2.8 Hz, 1H),
7.59-7.56 (m, 2H), 5.22 (s, 2H), 3.51 (s, 3H); MS (ESI) m/z
[M+H].sup.+ 324.
3-(6-Fluoropyridin-3-yl)-5H-pyrido[3,2-b]indol-7-ol (T784)
[0398] A solution of
2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (7
mg, 0.02 mmol) in 0.5 mL of HCl (4 M in dioxane) was stirred at rt
for 2 h. Volatiles were removed under reduced pressure and the
residue was purified by reversed phase HPLC (water/MeCN with TFA
buffer) to afford
3-(6-fluoropyridin-3-yl)-5H-pyrido[3,2-b]indol-7-ol (T784) as a
white solid (4 mg, 71%). .sup.1H NMR (400 MHz, methanol-d4):
.delta. 8.81 (d, J=1.2 Hz, 1H), 8.66 (d, J=2.0 Hz, 1H), 8.64 (d,
J=1.2 Hz, 1H), 8.39 (td, J=8.8, 2.8 Hz, 1H), 8.17 (d, J=8.8 Hz,
1H), 7.28 (dd, J=8.8, 2.8 Hz, 1H), 7.02 (d, J=1.6 Hz, 1H), 6.98
(dd, J=8.8, 2.0 Hz, 1H); MS (ESI) m/z [M+H].sup.+ 280.
##STR00162##
7-(3-Fluoropropoxy)-3-methyl-5H-pyrido[3,2-b]indole (T773)
[0399] The title compound was synthesized using the same procedure
as for the preparation of
7-(2-fluoroethoxy)-3-methyl-5H-pyrido[3,2-b]indole (T703).
7-(3-Fluoropropoxy)-3-methyl-5H-pyrido[3,2-b]indole (T773) was
obtained as a white solid (8 mg, 15%). .sup.1H-NMR (400 MHz,
CD.sub.3OD): .delta. 8.25 (m, 1H), 8.13 (dd, J=9.2, 0.8 Hz, 1H),
7.66 (m, 1H), 7.06 (d, J=2.0 Hz, 1H), 6.91 (dd, J=8.8, 2.4 Hz, 1H),
4.74 (t, J=6.0 Hz, 1H), 4.62 (t, J=6.0 Hz, 2H), 4.22 (t, J=6.0 Hz,
1H), 2.22 (dp, J=25.2, 6.0 Hz, 1H); MS (ESI) m/z [M+H].sup.+
259.
Preparation of azacarbazole derivatives as the Tau tracers: (T660,
T686, T687, T688, T692, T703, T722, T726, T728, T731, T733, T734,
T735, T740, T741, T742, T744, T775, T779, T787, T788, T790, T803,
T804, T811)
##STR00163##
[0401] The compound was synthesized via the above scheme using the
general procedures of alkylation (or reductive amination),
boronation, Suzuki coupling and azacarbazole cyclization.
General Experimental Procedure for Boronation of Arylbromide to
Arylboronic Pinacol Ester
##STR00164##
[0403] To a microwave vial with a magnetic stir bar, was added the
arylbromide starting materials (1 equiv), Pd(dppf)Cl2 (0.05 eq),
Potassium acetate (3 eq) and Bis(pinacol)borate (1.2 eq). The solid
was dissolved in DMSO (5 vol), sealed and heated to 80.degree. C.
in an oil bath for 40-50 hours. The reaction was diluted with brine
extracted with ether/hexanes or DCM. The combine organic layers was
concentrated, the residue was purified over silica gel using
Hexanes:EtOAc or DCM:EtOAc or DCM:MeOH as the eluent to afford
boronic ester.
General Experimental Procedure for Cyclization of Aza-Carbazole
from Nitro-Substituted Biaryl Precursor
##STR00165##
[0405] To a microwave vial with a magnetic stir bar, was added the
nitro-substituted biaryl precursor aryl/heterocyclic halide (1
equiv), triethyl phosphite (4-8 eq). The suspension was heated at
120-135.degree. C. (depends on the reactivity of the starting
material and stability of the product) in an oil bath for 2 hours.
The reaction was concentrated under vacuum to remove all the
volatiles. The residue was purified over silica gel using
Hexanes:EtOAc or DCM:EtOAc or DCM:MeOH as the eluent to afford the
aza-carbazoles.
7-(2-fluoroethoxy)-1-methyl-9H-pyrido[3,4-b]indole; T660
##STR00166##
[0407] .sup.1H-NMR (400 MHz, CD.sub.3CN) .delta.: 10.77 (br, 1H),
8.24-8.16 (m, 3H), 7.15 (s, 1H), 7.08-7.05 (m, 1H), 4.89-4.88 (m,
2H), 4.44-4.35 (m, 2H), 2.95 (s, 3H); LRMS for
C.sub.14H.sub.13FN.sub.2O+H.sup.+, calc'd: 245.1. found: 245.1
(M+H.sup.+).
7-(2-fluoroethoxy)-9H-pyrido[3,4-b]indole T686
##STR00167##
[0409] .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 8.97 (s, 1H),
8.51-8.50 (m, 1H), 8.38-8.37 (m, 1H), 8.30-8.28 (m, 1H), 7.21 (s,
1H), 7.10-7.09 (m, 1H), 4.85-4.75 (m, 2H), 4.42-4.35 (m, 2H), LRMS
for C.sub.13H.sub.11FN.sub.2O+H.sup.+, calc'd: 231.1. found: 231.1
(M+H.sup.+).
N-(3-fluoropropyl)-9H-pyrido[3,4-b]indol-7-amine T687
##STR00168##
[0411] .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 8.66 (s, 1H),
8.20-8.15 (m, 2H), 7.99-7.97 (m, 1H), 6.80-6.77 (m, 1H), 6.51 (s,
1H), 4.63-4.51 (m, 2H), 3.39-3.35 (m, 2H), 2.08-2.01 (m, 2H); LRMS
for C.sub.14H.sub.14FN.sub.3+H.sup.+, calc'd: 244.1. found: 244.1
(M+H.sup.+).
7-(2-fluoroethoxy)-5H-pyrido[3,2-b]indole T688
##STR00169##
[0413] .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 8.52-8.44 (m,
2H), 8.21-8.19 (m, 1H), 7.80-7.78 (m, 1H), 7.17 (s, 1H), 7.10-7.07
(m, 1H), 4.88-4.72 (m, 2H), 4.42-4.33 (m, 2H); LRMS for
C.sub.13H.sub.11FN.sub.2O+Ft, calc'd: 231.1. found: 231.1
(M+H.sup.+).
7-(2-fluoroethoxy)-2-methoxy-5H-pyrido[3,2-b]indole T692
##STR00170##
[0415] .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 8.24-8.22 (m,
1H), 8.06-8.04 (m, 1H), 7.17-7.15 (m, 1H), 7.06 (s, 1H), 6.97-6.95
(m, 1H), 4.82-4.71 (m, 2H), 4.40-4.29 (m, 2H), 4.15 (s, 3H); LRMS
for C.sub.14H.sub.13FN.sub.2O.sub.2+H.sup.+, calc'd: 261.1. found:
261.1 (M+H.sup.+).
7-(2-fluoroethoxy)-3-methyl-5H-pyrido[3,2-b]indole T703
##STR00171##
[0417] .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 8.39 (s, 1H),
8.31 (s, 1H), 8.15 (d, J=9.2 Hz, 1H), 7.15 (s, 1H), 7.08 (d, J=9.2
Hz, 1H), 4.85-4.70 (m, 2H), 4.40-4.32 (m, 2H), 2.64 (s, 3H); LRMS
for C.sub.14H.sub.13FN.sub.2O+H.sup.+, calc'd: 245.1. found: 245.1
(M+H.sup.+).
N-(2-fluoroethyl)-N-methyl-9H-pyrido[3,4-b]indol-7-amine T722
##STR00172##
[0419] .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 8.71 (s, 1H),
8.26-8.23 (m, 2H), 8.12 (d, J=9.2 Hz, 1H), 7.02 (d, J=9.2 Hz, 1H),
6.78 (s, 1H), 4.72-4.62 (m, 2H), 3.90-3.83 (m, 2H), 3.18 (s, 3H);
LRMS for C.sub.14H.sub.14FN.sub.3+H.sup.+, calc'd: 244.1. found:
244.0 (M+H.sup.+).
N-(2-fluoroethyl)-N-methyl-5H-pyrido[3,2-b]indol-7-amine T726
##STR00173##
[0421] .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 8.29-8.22 (m,
2H), 8.06 (d, J=9.2 Hz, 1H), 7.60 (m, 1H), 7.04 (m, 1H), 6.77 (s,
1H), 4.72-4.60 (m, 2H), 3.90-3.84 (m, 2H), 3.19 (s, 3H); LRMS for
C.sub.14H.sub.14FN.sub.3+H.sup.+, calc'd: 244.1. found: 244.1
(M+H.sup.+).
N-(2-fluoroethyl)-N,3-dimethyl-5H-pyrido[3,2-b]indol-7-amine
T728
##STR00174##
[0423] .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 8.17 (s, 1H),
8.09 (s, 1H), 8.01 (d, J=9.2 Hz, 1H), 6.97 (d, J=9.2 Hz, 1H), 6.75
(s, 1H), 4.83-4.60 (m, 2H), 3.90-3.81 (m, 2H), 3.17 (s, 3H), 2.59
(s, 3H); LRMS for C.sub.15H.sub.16FN.sub.3+H.sup.+, calc'd: 258.1.
found: 258.1 (M+H.sup.+).
N-(2-fluoroethyl)-2-methoxy-N-methyl-5H-pyrido[3,2-b]indol-7-amine
T731
##STR00175##
[0425] .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 7.95 (d, J=8.8
Hz, 1H), 7.61 (d, J=8.8 Hz, 1H), 6.78-6.65 (m, 3H), 4.67-4.55 (m,
2H), 3.98 (s, 3H), 3.90-3.86 (m, 2H), 3.07 (s, 3H); LRMS for
C.sub.15H.sub.16FN.sub.3O+H.sup.+, calc'd: 274.1. found: 274.1
(M+H.sup.+).
N-(3-fluoropropyl)-5H-pyrido[3,2-b]indol-7-amine T733
##STR00176##
[0427] .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 8.28-8.19 (m,
2H), 7.95 (d, J=9.2 Hz, 1H), 7.58-7.55 (m, 1H), 6.81 (d, J=9.2 Hz,
1H), 6.61 (s, 1H), 4.66-4.52 (m, 2H), 3.42-3.38 (m, 2H), 2.10-2.03
(m, 2H); LRMS for C.sub.14H.sub.14FN.sub.3+H.sup.+, calc'd: 244.1.
found: 244.1 (M+H.sup.+).
N-(3-fluoropropyl)-3-methyl-5H-pyrido[3,2-b]indol-7-amine T734
##STR00177##
[0429] .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 8.14 (s, 1H),
8.05 (s, 1H), 7.90 (d, J=9.2 Hz, 1H), 6.76 (d, J=9.2 Hz, 1H), 6.60
(s, 1H), 4.64-4.62 (m, 2H), 3.40-3.35 (m, 2H), 2.59 (s, 3H),
2.10-2.00 (m, 2H); LRMS for C.sub.15H.sub.16FN.sub.3+H.sup.+,
calc'd: 258.1. found: 258.1 (M+H.sup.+).
N-(3-fluoropropyl)-2-methoxy-5H-pyrido[3,2-b]indol-7-amine T735
##STR00178##
[0431] .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 8.12 (d, J=8.8
Hz, 1H), 7.89 (d, J=9.2 Hz, 1H), 7.03 (d, J=8.8 Hz, 1H), 6.78 (d,
J=9.2 Hz, 1H), 6.56 (s, 1H), 4.65-4.52 (m, 2H), 4.16 (s, 3H),
3.37-3.31 (m, 2H), 2.10-2.03 (m, 2H); LRMS for
C.sub.15H.sub.16FN.sub.3O+H.sup.+, calc'd: 274.1. found: 274.1
(M+H.sup.+).
7-(2-(2-fluoroethoxy)ethoxy)-3-methyl-5H-pyrido[3,2-b]indole
T740
##STR00179##
[0433] .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 8.39 (s, 1H),
8.31 (s, 1H), 8.14 (d, J=9.2 Hz, 1H), 7.16 (s, 1H), 7.05 (d, J=9.2
Hz, 1H), 4.60-4.50 (m, 2H), 4.29-4.28 (m, 2H), 3.95-3.68 (m, 4H),
2.65 (s, 3H); LRMS for C.sub.16H.sub.17FN.sub.2O.sub.2+H.sup.+,
calc'd: 289.1. found: 289.1 (M+H.sup.+).
7-(4-(2-fluoroethoxy)phenyl)-5H-pyrido[3,2-b]indole T741
##STR00180##
[0435] .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 8.60-8.35 (m,
3H), 7.86-7.70 (m, 5H), 7.08 (d, J=8.8 Hz, 2H), 4.80-4.69 (m, 2H),
4.35-4.11 (m, 2H); LRMS for C.sub.19H.sub.1sFN.sub.2O+H.sup.+,
calc'd: 307.1. found: 307.1 (M+H.sup.+).
7-(6-fluoropyridin-3-yl)-5H-pyrido[3,2-b]indole T742
##STR00181##
[0437] .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 8.68-8.34 (m,
5H), 7.98 (s, 1H), 7.93-7.89 (m, 1H), 7.75-7.73 (m, 1H), 7.23-7.21
(m, 1H); LRMS for C.sub.16H.sub.10FN.sub.3+H.sup.+, calc'd: 264.1.
found: 264.1 (M+H.sup.+).
N-(2-fluoroethyl)-N-methyl-4-(3-methyl-5H-pyrido[3,2-b]indol-7-yl)aniline
T744
##STR00182##
[0439] .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 8.47 (s, 1H),
8.39 (s, 1H), 8.28 (d, J=8.4 Hz, 1H), 7.84 (s, 1H), 7.73-7.67 (m,
3H), 6.91 (d, J=8.4 Hz, 2H), 4.69-4.57 (m, 2H), 3.80-3.70 (m, 2H),
3.10 (s, 3H), 2.70 (s, 3H) LRMS for
C.sub.21H.sub.20FN.sub.3+H.sup.+, calc'd: 334.2. found: 334.2
(M+H.sup.+).
7-(4-fluoropiperidin-1-yl)-3-methyl-5H-pyrido[3,2-b]indole TFA
salt; T775
##STR00183##
[0441] .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 8.26 (s, 1H),
8.17 (s, 1H), 8.06 (d, J=8.8 Hz, 1H), 7.20 (d, J=9.2 Hz, 1H), 7.01
(s, 1H), 4.95-4.90 (m, 1H), 3.70-3.50 (m, 4H), 2.62 (s, 3H),
2.15-1.90 (m, 4H); LRMS for
C.sub.19H.sub.18F.sub.4N.sub.3O+H.sup.+, calc'd: 381.1. found:
284.2 (M+H-TFA.sup.+).
7-(3-fluoropropoxy)-5H-pyrido[4,3-b]indole T779
##STR00184##
[0443] .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 9.38 (s, 1H),
8.47-8.45 (m, 1H), 8.23-8.21 (m, 1H), 7.89-7.87 (m, 1H), 7.25 (s,
1H), 7.14-7.11 (m, 1H), 4.75-4.60 (m, 2H), 3.32-3.30 (m, 2H),
2.30-2.10 (m, 2H) LRMS for C.sub.14H.sub.13FN.sub.2O+H.sup.+,
calc'd: 245.1. found: 245.1 (M+H.sup.+).
4-(7-(3-fluoropropoxy)-5H-pyrido[3,2-b]indol-3-yl)aniline T787
##STR00185##
[0445] .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 8.79 (s, 1H),
8.64 (s, 1H), 8.23 (d, J=8.8 Hz, 1H), 7.85-7.82 (m, 2H), 7.31-7.28
(m, 2H), 7.21 (m, 1H), 7.11-7.09 (m, 1H), 5.48, (s, 2H), 4.87-4.61
(m, 2H), 4.31-4.29 (m, 2H), 2.30-2.04 (m, 2H); LRMS for
C.sub.20H.sub.18FN.sub.3O+H.sup.+, calc'd: 336.1. found: 336.1
(M+H.sup.+).
(E)-7-(3-fluoropropoxy)-3-(prop-1-enyl)-5H-pyrido[3,2-b]indole
T788
##STR00186##
[0447] .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 8.30 (s, 1H),
8.07 (d, J=8.8 Hz, 1H), 7.78 (s, 1H), 7.00 (s, 1H), 6.89-6.86 (m,
1H), 6.61-6.40 (m, 2H), 4.73-4.58 (m, 2H), 4.22-4.20 (m, 2H),
2.24-2.08 (m, 2H); LRMS for C.sub.17H.sub.17FN.sub.2O+H.sup.+,
calc'd: 285.1. found: 285.1 (M+H.sup.+).
3-cyclopropyl-7-(3-fluoropropoxy)-5H-pyrido[3,2-b]indole T790
##STR00187##
[0449] .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 8.20 (s, 1H),
8.08-8.06 (m, 1H), 7.43 (m, 1H), 7.00 (s, 1H), 6.88-6.86 (m, 1H),
4.74-4.61 (m, 2H), 4.22-4.19 (m, 2H), 2.24-2.18 (m, 2H), 1.30 (m,
1H), 1.10-1.07 (m, 2H), 0.82-0.80 (m, 2H); LRMS for
C.sub.17H.sub.17FN.sub.2O+H.sup.+, calc'd: 285.1. found: 285.1
(M+H.sup.+).
7-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)-5H-pyrido[4,3-b]indole
T803
##STR00188##
[0451] .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 9.35 (s, 1H),
8.45-8.43 (m, 1H), 8.20-8.18 (m, 1H), 7.86-7.84 (m, 1H), 7.22 (s,
1H), 7.12-7.09 (m, 1H), 4.54-4.42 (m, 2H), 4.26-4.25 (m, 2H),
3.92-3.90 (m, 2H), 3.74-3.70 (m, 6H); LRMS for
C.sub.17H.sub.19FN.sub.2O.sub.3+H.sup.+, calc'd: 319.4. found:
319.4 (M+H.sup.+).
7-(2-(2-fluoroethoxy)ethoxy)-5H-pyrido[4,3-b]indole T804
##STR00189##
[0453] .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 9.09 (s, 1H),
8.28-8.27 (m, 1H), 8.04-8.02 (m, 1H), 7.43-7.41 (m, 1H), 7.07 (s,
1H), 6.96-6.93 (m, 1H), 4.60-4.50 (m, 2H), 4.24-4.22 (m, 2H),
3.92-3.79 (m, 4H); LRMS for C.sub.15H.sub.1FN.sub.2O.sub.2+H.sup.+,
calc'd: 275.1. found: 275.1 (M+H.sup.+).
7-((2-(2-fluoroethoxy)ethoxy)methyl)-5H-pyrido[4,3-b]indole
T811
##STR00190##
[0455] .sup.1H-NMR (400 MHz, CD.sub.3OD) .delta.: 9.50 (s, 1H),
8.51-8.49 (m, 1H), 8.31-8.29 (m, 1H), 7.92-7.90 (m, 1H), 7.75 (s,
1H), 7.50-7.48 (m, 1H), 4.78 (s, 2H), 4.59-4.45 (m, 2H), 3.79-3.73
(m, 6H); LRMS for C.sub.16H.sub.17FN.sub.2O.sub.2+H.sup.+, calc'd:
289.1. found: 289.1 (M+H.sup.+).
7-(6-Fluoropyridine-3-yl)-5-methyl-H-pyrido[4,3-b]indole TFA salt
(AS-5357-55, T-820)
##STR00191##
[0457] T-807 0.010 g was alkylated with dimethylacetone (2 eq) in
DMF and Cs.sub.2CO.sub.3 (0.5 eq) at 160.degree. C. for 3 hrs. The
residue was purified by HPLC using ACN-H.sub.2O with 0.05% TFA.
T-820 isolated as off white solid 0.006 g (72%); .sup.1H NMR (400
MHz, CD.sub.3OD): .delta. 9.58 (s, 1H), 8.64 (d, J=2.4 Hz, 1H),
8.61 (dd, J=6.8 and 0.8 Hz), 8.49 (dd, J=8.4 and 0.8 Hz, 1H), 8.38
(qd, J=8.0 and 2.4 Hz, 1H), 8.15 (d, J=0.8 Hz, 1H), 8.11 (d, J=6.8
Hz, 1H), 7.85 (d, J=8.0 and 1.2 Hz, 1H), 7.23 (dd, J=8.4 and 2.8
Hz, 1H), 4.16 (s, 3H); MS (ESI): 278.1 [+H.sup.+, Free base].
7-(6-Fluoropyridine-3-yl)-5H-pyrido[4,3-b]indole (AS-5357-18,
T-807)
##STR00192##
[0459] General experimental procedure for Suzuki coupling (Method
A) was followed to prepare intermediate A. Reaction was performed
on a 0.6 g scale. Product eluted out in hexane-EtOAc on a
Combiflash purification system, isolated 0.600 g (72%) of
intermediate A as light yellow solid; MS (ESI): 277 and 279
(M.sup.+) and (M+2H.sup.+). Intermediate A 0.6 g was cyclized using
general method carbazole synthesis (Method CC) afforded carbazole
B. Carbazole B eluted with DCM-MeOH on a Combiflash purification
system isolated 0.21 g (40%) as light brown color solid; .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 11.9 (s, 1H), 9.36 (d, J=0.88
Hz, 1H), 8.45 (d, J=0.8 Hz, 1H), 8.20 (d, J=8.4 Hz, 1H), 7.76 (d,
J=0.8 Hz, 1H), 7.43 (d, J=2.0 Hz, 1H), 7.41 (d, J=1.6 Hz, 1H); MS
(ESI): 247 [M.sup.+] and 249 [M+2H.sup.+]. Carbazole B was further
used for Suzuki coupling (Method A). Reaction was performed on a
0.1 g scale. Product T-807 eluted with DCM-MeOH on a Combiflash
purification system, isolated 0.056 g as off white solid (56%)
which was further purified by HPLC using ACN-H.sub.2O with 0.05%
TFA; .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 11.81 (s, 1H),
9.34 (s, 1H), 8.61 (dd, J=1.6 and 0.8 Hz, 1H), 8.41-8.30 (m, 3H),
7.80 (dd, J=4.0 and 0.4 Hz, 1H), 7.57 (dd, J=8.4 and 1.6 Hz, 1H),
7.46 (dd, J=6.4 and 0.8 Hz, 1H), 7.29 (dd, J=8.4 and 2.8 Hz, 1H);
MS (ESI): 264.3 [M+H.sup.+, Free base].
8-Fluoro-7-(2fluoroethoxy)3-methyl-5H-pyrido[3,2-b]indole TFA salt
(AS-5357-14-1, T-801 and
6-fluoro-7-(2fluoroethoxy)3-methyl-5H-pyrido[3,2-b]indole TFA salt
AS-5357-14-2, T-801)
##STR00193##
[0461] General experimental procedure for Suzuki coupling (Method
A) followed by O-alkylation (Method C) was followed to prepare the
intermediate C. Reaction was performed on a 0.172 g scale.
Intermediate C eluted out in Hexane-EtOAc on a Combiflash
purification system, isolated 0.158 g (54% in two steps) as off
white solid; MS (ESI): 295.25 (M+H.sup.+). Intermediate C 0.030 g
was cyclized using general experimental process for carbazole
synthesis (Method CC) afforded carbazole mixtures. Product T-800
(0.015 g, 42%) and T-801 (0.006 g, 16%) was purified by HPLC using
ACN-H.sub.2O with 0.05% TFA; .sup.1H NMR (400 MHz, CD.sub.3OD)
(T-800): .delta. 8.44 (dd, J=1.6 and 0.8 Hz, 1H), 8.29 (br s, 1H),
7.95 (d, J=10.4 Hz, 1H), 7.32 (d, J=6.8 Hz, 1H), 4.89-4.85 (m, 1H),
4.77-4.75 (m, 1H), 4.49-4.48 (m, 1H), 4.42-4.40 (m, 1H), 2.64 (s,
3H); MS (ESI): 263.20 [M+H.sup.+, Free base].
[0462] .sup.1H NMR (400 MHz, CD.sub.3OD) T-801: .delta. 8.44 (d,
J=0.8 Hz, 1H), 8.24 (br s, 1H), 8.01 (dd, J=8.8 and 1.2 Hz, 1H),
7.25 (dd, J=8.8 and 7.2 Hz, 1H), 4.85-4.83 (m, 1H), 4.73-4.71 (m,
1H), 4.52-4.50 (m, 1H), 4.45-4.43 (m, 1H), 2.64 (s, 3H); MS (ESI):
263.20 [M+H.sup.+, Free base].
8-Fluoro-7-methoxy-3-methyl-5H-pyrido[3,2-b]indole TFA salt
(AS-5357-12, T-799)
##STR00194##
[0464] General experimental procedure for Suzuki coupling (Method
A) was followed to prepare the intermediate D. Reaction was
performed on a 0.172 g scale. Product eluted out in Hexane-EtOAc on
a Combiflash purification system, isolated 0.185 g (70%) of
intermediate D as light yellow color solid; .sup.1H NMR (400 MHz,
CDCl.sub.3): .delta. 8.63 (dd, J=1.6 and 0.8 Hz, 1H), 7.88 (dd,
J=1.6 and 0.8 Hz, 1H), 7.34 (dd, J=11.6 and 2.0 Hz, 1H), 7.23-7.21
(m, 1H), 6.99 (t, J=8.4 Hz, 1H), 3.92 (s, 3H); MS (ESI): 263.10
[M+H.sup.+]. Intermediate D 0.027 g was cyclized using general
experimental process for carbazole synthesis (Method CC) afforded
carbazole mixtures, which was purified by HPLC using ACN-H.sub.2O
with 0.05% TFA afforded T-999 as a off white solid (0.002 g, 6%);
.sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 8.19 (dd, J=1.6 and 0.8
Hz, 1H), 7.84 (d, J=10.8 Hz, 1H), 7.64 (dd, J=1.6 and 0.8 Hz, 1H),
7.12 (d, J=6.8 Hz, 1H), 3.96 (s, 3H), 2.49 (s, 3H); MS (ESI):
231.10 [M+H.sup.+, Free base].
7-Fluoro-3-methyl-5H-pyrrolo[2,3-b:4,5-b']dipyridineTert-butyl-(AS-5357-3,
T-782)
##STR00195##
[0466] General experimental procedure for Suzuki coupling (Method
A) was followed to prepare the intermediate E. Reaction was
performed on a 0.172 g scale. and intermediate E was eluted out in
DCM-EtOAc on a Combiflash purification system as a off white solid
0.180 g (77%); .sup.1H NMR (400 MHz, CDCl.sub.3) of intermediate E:
.delta. 8.70 (dd, J=1.2 and 0.8 Hz, 1H), 8.39 (m, 1H), 8.05 (dd,
J=2.0 and 0.8 Hz, 1H), 7.93 (m, 1H), 7.00 (dd, J=8.8 and 3.6 Hz,
1H), 2.50 (s, 3H); LC-MS (ESI): 234.1 [M+H.sup.+]. Intermediate E
0.048 g was cyclized using general experimental process (Method cc)
afforded solid of T-782 which was collected by filtration 0.012 g
(29%); .sup.1H NMR (400 MHz, CD.sub.3OD): .delta. 8.63 (t, J=8.0
Hz, 1H), 8.34 (m, 1H), 7.76 (dd, J=1.6 and 0.8 Hz, 1H), 6.91 (dd,
J=8.4 and 0.8 Hz, 1H), 2.53 (s, 3H); LC-MS (ESI): 202.1
[M+H.sup.+].
2-Fluoro-7-methoxy-5H-pyrido[3,2-b]indole (AS-5332-192-1,
T-781)
##STR00196##
[0468] General experimental procedure for Suzuki coupling (method
A) was followed to prepare the intermediate F. Intermediate F
eluted out in 12% EtOAc:Hexanes mixture in a gradient elution on a
Combiflash purification system. Isolated 0.048 g (36%) as light
yellow color solid; LC-MS (ESI): 249.1 [M+H.sup.+]. Intermediate F
was cyclized using general experimental procedure for carbazole
synthesis (Method cc). Reaction was performed on a 0.048 g scale.
T-781 was eluted out in 15% DCM-EtOAc on a Combiflash purification
system as a light yellow color solid (0.003 g, 5%); .sup.1H NMR
(400 MHz, CDCl.sub.3): .delta. 8.12 (dt, J=8.4 and 0.8 Hz, 1H),
8.02 (br s, 1H), 7.71 (dd, J=8.4 and 6.8 Hz, 1H), 6.92 (d, J=2.4
Hz, 1H), 6.90-6.89 (m, 1H), 6.86 (dd, J=8.8 and 2.0 Hz, 1H), 3.89
(s, 3H); LC-MS (ESI): 217.2 [M+H.sup.+].
7-(2-(2-(2-Fluoroethoxy)ethoxy)ethoxy)-3-methyl-5H-pyrrolo[2,3b:4,5-b']dip-
yridine TFA salt (AS-5357-10, T-795)
##STR00197##
[0470] General experimental procedure (Method D) for N-alkylation
of T-782 with K.sub.2CO.sub.3 as a base and MW heating at
180.degree. C. for 20 min was used. Reaction was performed on 0.020
g scale. After work-up crude residue 0.032 (90%) was used for DAST
reaction (Method). Reaction performed on 0.010 g scale. After
work-up product T-795 was purified by HPLC using ACN and H.sub.2O
with 0.05% TFA as a white solid 0.002 mg (12%); .sup.1H NMR (400
MHz, CDCl.sub.3): .delta. 8.45 (d, J=8.0 Hz, 1H), 8.45 (t, J=0.8
Hz, 1H), 8.30 (br s, 1H), 6.89 (d, J=8.8 Hz, 1H), 4.64-4.61 (m,
2H), 4.54-4.52 (m, 1H), 4.42-4.40 (m, 1H), 3.91-3.89 (m, 2H),
3.74-3.64 (m, 6H), 2.64 (s, 3H); LC-MS (ESI): 334.1 [M+H.sup.+,
Free base].
##STR00198##
3-(4-(4-Nitropyridin-3-yl)phenyl)propan-1-ol
[0471] A mixture of boronic ester (524 mg, 2 mmol), bromide (406
mg, 2 mmol), Pd (0) (116 mg, 0.1 mmol), and Na2CO3 solution (1 M, 4
mL) in 8 mL of dioxane was heated at 90 C for 10 min in a microwave
reactor. After cooling to rt, the mixture was extracted with EtOAc
(3.times.20 mL) and the organic phase was dried over MgSO4 and
concentrated. The crude product was purified with silica
chromatography (EtOAc/hexane, 5% to 90%) to afford the title
compound as a yellow oil (412 mg). .sup.1H NMR (400 MHz,
CDCl.sub.3): .delta. 8.83-8.79 (m, 2H), 7.64 (dd, J=5.2, 0.8 Hz,
1H), 7.38 (d, J=8.4 Hz, 2H), 7.32 (d, J=8.4 Hz, 2H), 3.71 (t, J=6.2
Hz, 2H), 2.79 (t, J=7.6 Hz, 2H), 1.94 (m, 2H); MS (ESI) m/z
[M+H].sup.+ 259.
3-(4-(3-Fluoropropyl)phenyl)-4-nitropyridine
[0472] To 3-(4-(4-nitropyridin-3-yl)phenyl)propan-1-ol (60 mg, 0.23
mmol) in 2 mL of dry DCM at 0.degree. C. was added
(Diethylamino)sulfur trifluoride (111 mg, 0.69 mmol) dropwise. The
reaction was warmed to rt and stirred for 1 h and quenched onto ice
(20 g) in saturated Na.sub.2CO.sub.3 (20 mL). The mixture was
extracted with EtOAc (2.times.30 mL) and the organic phase was
dried over MgSO.sub.4 and concentrated. The residue was purified by
silica chromatography (EtOAc in hexane, 5% to 30%) to afford
3-(4-(3-fluoropropyl)phenyl)-4-nitropyridine as a pale-yellow oil
(12 mg, 20%). .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 8.82-8.80
(m, 2H), 7.64 (d, J=5.2, 1H), 7.33-7.27 (m, 2H), 4.55 (t, J=5.6 Hz,
1H), 4.43 (t, J=5.6 Hz, 1H), 2.82 (t, J=7.6 Hz, 2H), 2.12-1.99 (m,
2H); MS (ESI) m/z [M+H].sup.+ 261.
7-(3-Fluoropropyl)-5H-pyrido[4,3-b]indole
[0473] A solution of 3-(4-(3-fluoropropyl)phenyl)-4-nitropyridine
(12 mg, 0.046 mmol) in 0.3 mL of triethyl phosphate was heated at
125.degree. C. for 1 h. After cooling to rt, the volatiles were
removed under reduced pressure and the residue was purified by
silica chromatography (MeOH in DCM, 0% to 10%) to afford a
off-white solid. This material was then further purified by
reversed phase HPLC to yield
7-(3-fluoropropyl)-5H-pyrido[4,3-b]indole as a white solid (3 mg,
28%). .sup.1H NMR (400 MHz, methanol-d4): .delta. 9.15 (s, 1H),
8.32 (d, J=4.4, 1H), 8.07 (d, J=8.0 Hz, 1H), 7.44 (d, J=6 Hz, 1H),
7.37 (m, 1H), 7.16 (dd, J=8.0, 1.2 Hz, 1H), 4.50 (t, J=6 Hz, 1H),
4.43 (t, J=6 Hz, 1H), 2.90 (t, J=7.6 Hz, 2H), 2.12-1.99 (m, 2H); MS
(ESI) m/z [M+H].sup.+ 229.
[0474] Having thus descried in detail advantageous embodiments of
the present invention, it is to be understood that the invention
defined by the above paragraphs is not to be limited to particular
details set forth in the above description as many apparent
variations thereof are possible without departing from the spirit
or scope of the present invention.
* * * * *